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Zusammenfassung
Mutationen entstehen in erster Linie während der Zellteilung, weshalb in somatischen
Geweben eine genetische Vielfalt besteht. Das Ausmaß dieser Heterogenität wird von der
zellulären Dynamik währendWachstum und Homöostase bestimmt, was sich imMutationsprofil
einer Gewebeprobe widerspiegelt. In der vorliegenden Arbeit werden mathematische
Methoden entwickelt, die eine Abschätzung des Wachstumsverhaltens maligner Tumore und
physiologischer Gewebe anhand von Ganzgenomsequenzierdaten erlauben.
Im ersten Teil der Arbeit wird die klonale Evolution im primären Glioblastom, einem
hochaggressiven Hirntumor, untersucht. Dazu wird zunächst ein Multinomialmodell entwickelt,
das anhand von tiefen Ganzgenomsequenzierdaten die phylogenetische Entwicklung eines
Gewebes nachvollzieht. Mithilfe dieses Modells wird anschließend die Entstehungsgeschichte
adulter Glioblastome aus 21 gepaarten Primär- und Rezidivtumorproben rekonstruiert. Trotz
ausgeprägter Heterogenität im Mutationsprofil individueller Tumore werden in allen Tumoren,
bis auf einen, frühe Kopienzahlveränderungen auf Chromosom 7 (Gewinn), Chromosom 9p
(Verlust) oder Chromosom 10 (Verlust) nachgewiesen. Dementgegen befinden sich Mutationen
in der Promoterregion des TERT -Gens, das für eine Telomerase-Untereinheit kodiert, häufig
auf subklonaler Ebene, was auf einen späteren Entstehungszeitpunkt in der Geschichte
des Tumors hindeutet. Unsere Daten legen nahe, dass Tumorrezidive typischerweise aus
mehreren Unterpopulationen des Primärtumors auswachsen und kein charakteristisches
Mutationsprofil aufweisen, sodass keine Evidenz für ein selektives Auswachsen resistenter
Unterpopulationen nach Standardtherapie besteht. Eine populationsdynamische Modellierung
des Tumorwachstums erlaubt die Abschätzung des Tumoralters auf mehrere Jahre und erklärt
die lange Entwicklungszeit mit einer hohen Zelltodrate, die erst durch Mutationen im TERT -
Promoter reduziert wird. Die hier gewonnenen Einblicke in die Entwicklungsgeschichte von
Glioblastomen können zur Entwicklung neuer Methoden zur Früherkennung eingesetzt werden.
Im zweiten Teil der vorliegenden Arbeit wird die Anhäufung von Mutationen in
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normalen Geweben betrachtet. Dazu wird zunächst die bereits bestehende Theorie zur
Mutationslast in wachsenden Geweben auf einen zweistufigen Prozess, der sich aus einer
embryonalen Wachstumsphase und anschließender Homöostase zusammensetzt, erweitert.
Mittels stochastischer Simulationen wird die Aussagekraft des Modells für selbsterneuernde
Zellpopulationen, wie besipielsweise Stammzellen, bestätigt. Das aufgrund derModellvorhersage
erwartete Mutationsprofil sich neutral entwickelnder Gewebe wird anschließend anhand von
Ganzgenomsequenzierdaten muriner Granulozyten und humaner Leukozyten geprüft und für
die Mehrheit der Proben bestätigt. Allerdings wird die unter neutraler Dynamik erwartete
Mutationslast in einigen Blutproben deutlich übertroffen. Da diese Fälle zusätzlich eine oder
mehrere mit Leukämien assoziierte Mutationen aufweisen, liegt hier die Vermutung einer
hämatopoietischen Perturbation oder einer prä-leukämischen Expansion nahe. Die vorgestellte
Analyse der Mutationslast unter normaler und gestörter Blutbildung kann zum besseren
Verständis der frühen Tumorentstehung beitragen.
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Abstract
Somaticmutations accumulate in tissues primarily through cell divisions. This observation opens
the opportunity to use somatic mutations as clonal markers for inferring the past dynamics
of cell turnover during tissue growth and homeostasis. In this thesis, I develop mathematical
approaches to the inference problems that are stimulated by deep genome sequencing data of
malignant growth and physiological tissue turnover.
In the first part of this thesis I reconstruct the evolutionary history of adult glioblastoma,
a highly aggressive brain cancer, prior to and after standard therapy. To this end, I develop a
likelihood-based multinomial model that jointly infers genetic subclones and their phylogenetic
relationships from whole genome sequencing data. Applied to 21 sample pairs from primary and
recurrent glioblastomas, the model infers a common path of early tumorigenesis characterized
by three pervasive copy number changes on chromosome 7 (gain), chromosome 9p (loss) and
chromosome 10 (loss). TERT promoter mutations are subclonal in one third of the tumor
pairs and are thus placed at a later stage of tumorigenesis. Our data indicate that recurrent
tumors typically re-grow from multiple subclones of the primary tumor with no evidence for a
‘resistance genotype’ induced by therapy. Combining the results from phylogenetic inference
with population dynamics models of tumor growth, I estimate that glioblastomas originate
several years prior to initial diagnosis but reach detectable sizes only after TERT promoter
mutations stabilized cellular survival. This project provides new insights into the evolutionary
history of glioblastoma that may ultimately aid early diagnosis.
In the second part I analyze the mutation frequency distribution in normal tissues. To
this end, I extend existing theory on mutation accumulation in exponentially growing tissues
to a two-stage situation of initial embryonic expansion and subsequent homeostasis during
adulthood. Based on stochastic simulations I show that the theoretical framework recovers
the average mutation frequency spectrum in stem cell populations. Whole genome sequencing
data from murine granulocytes and human leukocytes from subjects of different ages without
V
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diagnosed leukemia confirm the model prediction in the majority of cases but reveal an
unexpectedly high mutational burden in a smaller subgroup. These cases were associated with
one or several leukemic driver mutations, suggesting that perturbed hematopoiesis or pre-
leukemic expansions caused the deviation of the mutation frequency spectrum from neutrality.
The comprehensive analysis of the mutation frequency spectra in normal and perturbed
hematopoiesis may aid the understanding of tumor initiation in vivo.
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CHAPTER 1
Introduction
Mutations are changes of the genetic code that occur during DNA replication or are introduced
by mutagenic processes independent of replication. The former are mostly single base pair
substitutions while the latter involve more complex alterations such as base oxidation by reactive
oxygen species, DNA crosslinks by UV irradiation or tobacco-induced DNA-adducts (Chatterjee
and Walker, 2017; Fujii et al., 1999; Hecht, 2003; Kunkel, 2004). As different mutagenic processes
cause distinct patterns of single nucleotide variants in the genome, the spectrum of somatic
mutations mirrors a cell’s history of divisions and mutagenic exposure (Alexandrov et al.,
2013a).
Most mutations are functionally neutral (Kimura, 1991) but in rare cases a gene’s expression
or the structure of its encoded protein are changed in a functionally relevant way. Pathological
mutations in the germline can cause hereditary diseases, often associated with developmental
dysfunction, while mutations in somatic cells are the leading cause of cancer (Alberts et al.,
2002). Nevertheless, accumulation of mutations per se is not a hallmark of disease but may
generate phenotypic variation on which natural selection can act (Fisher, 1999).
Traditionally, the spread of a variant has been predominantly studied on the organismal level
and population genetics models have been developed for sexually and asexually reproducing
populations (reviewed, e.g. in Nei, 1975; Nowak, 2006). With the advances of next generation
sequencing, genome-wide profiling of mutations in tissues or even single cells has become
possible, and research now increasingly focuses on evolutionary processes within individual
organisms, associated with somatic mutations (Huang et al., 2018; Martincorena and Campbell,
2015; Meyerson et al., 2010). A major interest is to understand the evolutionary dynamics within
tumors, thus associating individual mutations with a selective advantage during tumorigenesis
or under therapy (Bozic et al., 2016; Martincorena et al., 2018). At the same time, more and more
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studies attempt to trace the spread of mutations in normal tissues (Blokzijl et al., 2016; Lee-Six
et al., 2018; Martincorena et al., 2015; O’Huallachain et al., 2012).
Intra-organismal ‘somatic’ evolution is experimentally and theoretically easier to tackle
than organismal evolution. In contrast to mating populations, intra-organismal evolution
is solely driven by cell division, death and mutation, which simplifies population genetics
theory. Moreover, intra-organismal evolution is rebooted at every organismal generation so
that multiple outcomes of the same evolutionary ‘experiment’ can be measured (Sidow and
Spies, 2015). In the context of cancer, this means that analyzing the mutational profile of many
cancers might reveal pervasive evolutionary pathways during tumorigenesis. Likewise, analysis
of many normal tissues is expected to provide a null model of mutation accumulation in the
absence of disease. Notably, as mutations can be interpreted as cellular labels, studying the
mutational profile of a tissue goes beyond classical attempts to link genotype and phenotype
but might reveal the dynamics of tissue growth and homeostasis.
1.1 Outline of this thesis
The two projects presented in this thesis both center around somatic mutagenesis. The first
project analyzes evolutionary dynamics in adult glioblastoma, a highly aggressive brain tumor,
while the second project focuses on somatic mutagenesis in hematopoiesis.
Chapter 1 provides general background on the mechanisms of mutation and DNA repair
and introduces cancer as a mutation-driven disease. More detailed background underlying the
individual projects is outlined in Chapter 2 and 3 prior to the respective results sections.
Chapter 2 focuses on clonal evolution in adult glioblastoma. An introductory section
summarizes clinical and biological aspects of the disease and reviews computational methods
to infer tumor heterogeneity from whole genome sequencing data. Next, a likelihood-based
multinomial model for phylogenetic reconstruction in cancer is developed and applied to
deep whole genome sequencing data from 21 pairs of primary and recurrent glioblastomas.
The inferred evolutionary trajectories are then interpreted with population dynamics models,
revealing characteristics of tumor growth and the selective advantage of mutations in the
promoter region of the telomerase gene TERT. The results are discussed in the context of the
current state of research in the concluding section of this chapter.
The dynamics of somatic mutations in normal tissues are analyzed in Chapter 3. Here,
the hematopoietic system is chosen as a model system to test the theoretical predictions.
The introductory part of this chapter provides biological background on the hematopoietic
system and mutagenesis in dynamic tissues. Subsequently, the existing theory on the spread
of mutations in growing tissues is introduced and extended to a coupled system of tissue growth
and homeostasis. The model predictions are then compared to whole genome sequencing data
of murine granulocytes and of blood samples obtained from neuro- and glioblastoma patients as
2
1.2. Mechanisms of mutation & DNA repair
controls for the genome sequencing of tumor tissue. Potentials and limitations of the presented
approach to delineate normal from pre-cancerous situations are discussed in the end of this
chapter.
In the final Chapter 4, the results of Chapters 2 and 3 are placed in a larger context and the
potential of whole genome sequencing data to probe evolutionary dynamics in somatic tissues
is discussed more generally.
Overall, this thesis covers functional and dynamical aspects of mutation accumulation
in health and disease. Deep whole genome sequencing data are analyzed with the aid of
mathematical models to delineate the growth dynamics of healthy and cancerous tissues. Beyond
specific insights into the somatic mutagenesis in glioblastomas and hematopoiesis, this thesis
highlights the potential of mutational analysis to address diverse biological questions, ranging
from cancer evolution, to tissue heterogeneity, and to early detection of pre-cancerous lesions.
1.2 Mechanisms of mutation & DNA repair
Genetic mutations are changes of the DNA sequence that are introduced by endogenous or
exogenous mutagenic processes. Endogenous mutagenic processes comprise replication errors,
spontaneous deamination and DNA damage due to reaction with naturally occurring reactants
such as reactive oxygen species (ROS). Exogenous mutagenic processes are caused by chemical
or physical agents that are not naturally occurring in the cell, but taken in through food
consumption, respiration or exposition to irradiation. Mutations vary in complexity, ranging
from single nucleotide exchanges to small insertions/deletions to chromosomal rearrangements,
aneuploidy and polyploidy (Alberts et al., 2002; Chatterjee and Walker, 2017). In the following,
I will introduce the most frequent mutagenic processes along with the DNA repair mechanisms
that have evolved in response (c.f. Fig. 1.1).
1.2.1 Replication errors
DNA replication is prerequisite for each somatic cell division. Using one parental strand as
a template, DNA polymerases catalyze the copying of the parental DNA by complementary
base pairing between the purine bases adenine and guanine, and their pyrimidine counterparts
thymine and cytosine. Since the two copies consist of one newly synthesized and one parental
DNA strand, replication is semi-conservative (Alberts et al., 2002).
Despite an energetic optimum for complementary base pairing, DNA replication is prone
to error, because the difference in free energy between matches and mismatches is low (Loeb
and Kunkel, 1982). Moreover, misalignments between the template and the newly synthesized
strand introduce small insertions and deletions, especially at replicative sites. However, intrinsic
proofreading mechanisms of the DNA polymerase together with a mismatch repair system
increase fidelity of DNA replication tremendously, yielding an error rate of approximately one
mismatch in 108 base pairs only (Kunkel, 2009).
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Replication errors DNA crosslinks (e.g., by UV & carcinogens)/
DNA adducts (e.g., by carcinogens)
Mismatch repair
Spontaneous deamination/
base oxidation (e.g., by ROS)
OH
Base excision repair
DNA double-strand break
(e.g., by ionizing radiation)
Nucleotide excision repair Homologous & non -homologous
end joining
Figure 1.1: Major mechanisms of mutation. Changes of the DNA sequence are highlighted in red;
associated major repair pathways are indicated below. Illustration based on Fig. 1 in Weeden and Asselin-
Labat, 2018.
1.2.2 Spontaneous deamination
A major source of replication-independent mutation is spontaneous deamination of adenine,
guanine, cytosine and 5-methylcytosine to hypoxanthine, xanthine, uracil and thymine,
respectively (Kow, 2002). While most deamination products are rapidly corrected by base
excision repair, thymine-guanine mismatches are less efficiently repaired, reflected in an
overrepresentation of C>T substitutions at methylated cytosine sites (Waters and Swann, 2000).
1.2.3 Mutagen-induced mutations
In addition to replication errors and spontaneous deamination, the human DNA is continuously
exposed to mutagenic chemicals and irradition. Among these are naturally occuring substances
such as reactive oxygen species (ROS) or extrinsic hazards like UV irradiation or tobacco smoke.
Exposition to mutagens causes a wide range of DNA damages. For example, reaction of the
DNA with ROS radicals has been linked with base oxidation, DNA intra-strand-crosslinks and
DNA-protein-crosslinks (Cadet and Wagner, 2013). Ionizing irradiation is mutagenic on two
accounts - indirectly, by promoting the generation of ROS and directly by introducing single-
and double-strand DNA breaks (Desouky et al., 2015). By contrast, the principal DNA-damage
that is attributed to UV-irradiation, is dimerization of adjacent pyrimidines (McGregor, 1999).
Finally, DNA can be damaged by exogenous chemicals, which introduce DNA cross-links or
DNA adducts. These chemicals are primarily alkylating agents, present for example in tobacco
smoke, fermented food products and chemotherapeutics (Fu et al., 2012).
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1.2.4 DNA repair
In response to the many sources of mutation a broad variety of cellular repair systems has
evolved. Depending on the type of lesion, the damage is either directly corrected, or a DNA
damage response is initiated by one of the cell cycle checkpoints. If DNA repair is not possible,
the cell either dies by apoptosis or incorporates the mutation (Jackson and Bartek, 2009).
Modified DNA bases, generated for example by spontaneous deamination, are directly
corrected by the ‘base excision repair’ (BER) pathway, which operates during the entire cell
cycle (Mjelle et al., 2015). In BER, glycosylases remove the faulty base and endonucleases cut
the DNA backbone causing an intermediate single strand break. Finally, DNA polymerases
resynthesize the strand and DNA ligases seal the break (Krokan and Bjørås, 2013).
Base mismatches arising from replication errors or spontaneous deamination of
methylcytosine to thymine are subjected to the mismatch repair pathway (MMR), which
is most active during S-phase (Schroering et al., 2007). In MMR, the erroneous strand is
identified and up to several hundreds of nucleotides around the mismatch are excised by
exonucleases, before the lesion is resynthesized by DNA polymerases (Kunkel and Erie, 2015).
Bulky DNA lesions, introduced by UV irradiation or alkylating agents, are removed by the
nucleotide excision repair pathway (NER). NER is active during the entire cell cycle, but the
final steps depend on enzymes active in S-phase only (Mjelle et al., 2015). NER works on a global
level but in addition can be activated during transcription by a stalled RNA polymerase. Upon
damage recognition, the vicinity of the damage is opened by DNA helicases and the damaged
site is removed by endonucleases from both sides. DNA polymerases ultimately resynthesize
the strand and ligases connect the 3’ end to the remaining DNA (Schärer, 2013).
Finally, double-strand breaks are repaired by homologous or non-homologous end joining
(abbreviated as HEJ and NHEJ, respectively). While NHEJ is active during interphase, HEJ
operates in G2- and S-phase (Hustedt and Durocher, 2017). NHEJ recruits a DNA repair
complex to the double-strand break, which prepares the breakage for ligation (Davis and Chen,
2013). By contrast, HEJ corrects the breakage by copying the missing sequence from the sister
chromosome, which may result in loss of heterozygosity due to crossing-over (Li and Heyer,
2008).
Despite the many ways of DNA repair and DNA damage response, some mutations will
remain undetected or unrepaired and are stably incorporated in the genome. In the majority
of cases this will not affect cellular survival but in rare cases, the cell will be malignantly
transformed and cancer will be initiated.
1.3 Cancer as a mutation-driven disease
The many mutagenic processes that confront the DNA on a daily basis leave their mark on
the 1013 cells in the human body (Savage, 1977). As cancer develops from mutations in proto-
oncogenes or tumor suppressor genes, mutagenesis is a constant threat to every multicellular
5
Chapter 1. Introduction
organism. Nevertheless, most mutations are phenotypically neutral. Since only 1% of the human
genome is coding for proteins (Lander et al., 2001), 99% of themutations a priori target non-coding
regions and thus do not change protein structure. Moreover, the genetic code is ‘redundant’, as
only 20 amino acids and the stop codons are encoded by the 64 possible trinucleotides in the DNA.
Approximately one third of all single base pair substitutions are therefore synonymous and do not
change the amino-acid sequence (Alberts et al., 2002). In case of a non-synonymous mutation,
the functional impact depends on the change in the protein structure, the expression level of
the gene and on the environmental context. Naturally, if the gene is not expressed, a protein
changing mutation will not have a phenotypic effect. Similarly, the functional impact of the very
same mutation might differ depending on the differentiation state of the cell, the cellular micro-
environment, or on extrinisic stressors. Thus non-neutrality of a non-synonymous mutation is
not a universal feature.
1.3.1 Somatic mutations in normal tissues and cancer
A prime example for a disease caused by non-neutral genetic mutations is cancer. Cancer is
a tissue hyperplasia that grows via uncontrolled cell divisions, invades adjacent tissues and
has the ability to metastasize to other parts of the body (Alberts et al., 2002). In addition,
self-sufficiency with respect to growth factors, the capacity to divide unlimitedly, induction of
neoangiogenesis, immune evasion and the potential to resist apoptosis have been attributed to
cancer cells (Hanahan and Weinberg, 2000, 2011). Likely, the many phenotypic properties of
cancer cells are caused by more than a single somatic mutation and, indeed, the mutational
burden in cancer is often very high. To give an example, the median mutational burden in
glioblastoma was estimated to 2.2 coding mutations per megabase, i.e. approximately 7,300
mutations per genome (Brennan et al., 2013). Although this is remarkable, most mutations
in cancer are probably functionally neutral and only few are expected to be responsible for
tumorigenesis, as discussed above. These mutations are likely targeting proto-oncogenes or
tumor suppressor genes and are commonly called driver mutations. The remaining mutations
hitchhike on the functional advantage provided by the driver mutations and are accordingly
called passenger mutations (Stratton et al., 2009).
To distinguish driver from passenger mutations, one typically compares the frequency of a
mutation among cancer samples to the theoretical expectation due to random hits (Lawrence
et al., 2013). This approach identifies genes that are targeted by a mutation more often
than expected by chance, suggesting that the mutant protein provides a selective advantage.
Alternatively, the ratio between non-synonymous and synonymous substitutions in a gene of
interest can be compared (corrected for the number of target loci). If the ratio is significantly
greater than one, the gene is likely a driver gene whose mutant form is under positive selection
(e.g., Kosakovsky Pond and Frost, 2005). Surprisingly, sequencing of 274 tissue biopsies of
sun-exposed eyelids identified that cancer-associated driver mutations are frequently found
in normal skin (Martincorena et al., 2015). Notably, re-analysis of the same dataset using
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population-dynamics models suggested that driver mutation expansions in most biopsies are
actually consistent with neutral dynamics (Simons, 2016). Thus distinction between neutral drift,
expansion of amutant due to stochastic fluctuations, and natural selection, expansion of amutant
due to a selective advantage, is not trivial.
1.3.2 Cancer initiation
The apparent contradiction between statistical and dynamical arguments used to assess positive
selection of driver mutations (Martincorena et al., 2015; Simons, 2016) may partly be explained
by sequential acquisition of multiple driver mutations prior to tumor initiation (Fig. 1.2A).
That is, single driver mutations will confer only a transient selective advantage (e.g., because
homeostatic mechanisms at the tissue level kick in; Lander et al., 2009) and further mutations
are required before the clone transforms malignantly. The hypothesis of a multistep process at
tumor initiation was originally postulated by two pioneering studies. In 1953, Carl Nordling
noticed that cancer mortality increases with the sixth power of age, an observation which he
explained with a multistep model of tumor initiation (Nordling, 1953). 18 years later, Alfred
Knudson arrived at a similar conclusion upon analysing the age distribution of patients with
hereditary and spontaneous retinoblastomas. Patients with a hereditary mutation were typically
younger than those with spontaneous tumors, which Knudson explained with a two-hit model
of tumorigenesis (Knudson, 1971). Subsequently, the multistep model of tumor initiation was
supported by data on colorectal cancer, which often develops from benign adenomas. Here, the
mutational burden in driver genes increases proportionally with the progression from adenoma
to carcinoma (Fearon and Vogelstein, 1990).
1.3.3 The clonal evolution model of cancer
It is generally thought that most cancers grow from a monoclonal origin, that is, all cancer cells
are progeny of a single somatic cell (Cheng et al., 2011). Comparison of cancer incidence across
tissues with age suggests that the cell of origin is a tissue stem cell that accumulated driver
mutations during normal replications (Tomasetti and Vogelstein, 2015). Since the acquisition
of driver mutations likely does not stop upon tumor initiation, Peter Nowell argued in 1976
that tumor progression resembles an evolutionary process during which malignancy increases
over iterative cycles of mutation and selection (Fig. 1.2B). As mutation acquisition is continuous,
each tumor cell has a unique mutational profile. In the presence of a selective pressure such as
lack of oxygen, spatial constrains or therapeutic intervention, some cells may adapt better than
others due to mutations acquired by chance. These cells will be positively selected, rendering
the tumor increasingly aggressive during the course of tumorigenesis (Nowell, 1976). Aspects of
the clonal evolution theory have been proven in a plethora of experimental studies (Greaves
and Maley, 2012), with the clearest evidence being the presence of resistant subpopulations
that are selected for by targeted therapy in some tumors (Francis et al., 2014; Turke et al.,
7
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Normal tissue cells
1st hit 2nd hit
Pre-malignant state
Tumor initiation
Clonal selection
Tumor growth +
diversification Tumor progression towards 
higher malignancy
A
B
Transient expansion
Figure 1.2: Multistep model of tumorigenesis. A According to the multistep hypothesis of tumor
initiation, multiple driver mutations are required prior to tumor initiation. B The clonal evolution model
of tumorigenesis states that tumors diversify into subpopulations through continuous mutation. Of these,
fitter subclones (yellow, darkred) are selected for, by which tumor malignancy increases.
2010). By contrast, intratumoral heterogeneity, often viewed as evidence for tumor evolution,
does not necessarily arise from non-neutral evolution towards more aggressive phenotypes.
Rather, subclonal diversification through neutral mutations is expected in any cellular expansion.
Whether additional driver mutations are acquired during tumorigenesis depends on the time
scales of tumor progression and the rate of driver mutation acquisition. Indeed, a comparative
study over 14 cancer types suggests that neutral tumor evolution is frequent across cancer entities
(Williams et al., 2016). In an extreme variant of this model, all malignant events are acquired
prior to tumor initiation (Sottoriva et al., 2015). To which extent neutral evolution guides tumor
progression is currently subject to active debate (Davis et al., 2017; Heide et al., 2018; Tarabichi
et al., 2018).
1.4 Mutational profiling with next generation sequencing
The possibility to profile whole genomes at reasonable costs has fueled research on cancer
genomics tremendously within the last ten years. High-throughput next-generation sequencing
is achieved by parallelization of the sequencing process through DNA fragmentation. In
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most technologies, the actual sequencing step is performed by synthesizing or hybridizing
complementary strands to the DNA fragments and identifying individual nucleotides by
fluorescent labeling or ionic concentration (Goodwin et al., 2016). Confidence in signal detection
is gained by PCR amplification and measurement of thousands of identical copies in parallel
(Goodwin et al., 2016). Moreover, by sequencing each DNA locus several times, the tissue fraction
harboring a specific mutation can be estimated from the fraction of reads carrying the mutation
(Strom, 2016). Thus, beyond the sole identification of mutations, next-generation sequencing
provides a probe of tissue heterogeneity. In Chapter 2 and 3 we will exploit this property to
analyze the evolutionary dynamics in glioblastoma and hematopoiesis.
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CHAPTER 2
Clonal evolution in IDH-wildtype glioblastoma
In this chapter, the clonal evolution of isocitrate dehydrogenase wildtype (IDHWT) glioblastomas
is analyzed using whole genome sequencing (WGS) data of paired primary and relapsed tumor
samples. The first part provides an overview on clinical, cellular and molecular aspects of the
disease with a special focus on intratumoral heterogeneity. This is complemented with a review
on existing computational methods to infer tumor evolution from deep sequencing data. In the
second part, we develop a likelihood-basedmultinomial model that reconstructs the phylogenetic
structure of tumor subclones from deeply sequenced sample pairs. This approach is then applied
to WGS data from 21 primary/relapsed glioblastoma sample pairs. The inferred phylogenies are
coupled with population-dynamic models of mutation acquisition and tumor growth to learn
dynamic aspects of tumor evolution in glioblastoma. Finally, the results are discussed in the
context of the current state of research.
All data shown in this chapter were collected within the scope of the ‘SysGlio’ consortium,
headed by Peter Lichter (German Cancer Research Center, Heidelberg). Bioinformatic pre-
processing (sequence alignment, variant calling and mutational signature analysis) was done by
Jing Yang from the group of Matthias Schlesner (German Cancer Research Center, Heidelberg),
while I performed all downstream analyses. Additional contributions are acknowledged in the
respective subsections. Parts of this chapter were published in Körber et al., 2019, and were
written by myself.
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2.1 Background
2.1.1 Glioblastoma
Tumors of the central nervous system are a heterogenous group of neoplasias that differ
substantially in their clinical prognosis. Approximately one third of all brain tumors are
malignant and of predominantly glial origin. These are further subdivided into slowly
progressing gliomas (∼40%) and highly aggressive glioblastomas (∼60%; Ostrom et al., 2017).
Based on histological and morphological features one distinguishes oligodendrogliomas,
astrocytomas and, less frequently, ependymomas or oligoastrocytomas among the gliomas (Louis
et al., 2016). By contrast, glioblastomas typically have an astrocytic cellular morphology and
oligodendroglial features are rare (Alexander and Cloughesy, 2017). Approximately 10% of all
glioblastomas develop from low-grade gliomas and are called secondary glioblastomas, while
the majority of glioblastomas (∼90%) arises spontaneously (primary glioblastomas; Ohgaki and
Kleihues, 2013). Primary and secondary glioblastomas are more accurately distinguished by
mutations in the IDH gene which are found in most gliomas and secondary glioblastomas but
absent in primary glioblastomas (Louis et al., 2016).
Clinical epidemiology
Glioblastoma, albeit being an infrequent diesease (incidence rate of 3.2 per 100,000), has a
strikingly poor prognosis with a 5-years survival rate of 5.5% (Ostrom et al., 2017). IDHWT
glioblastomas are primarily diagnosed in elderly people (mean age at diagnosis: 61 years) with
no anatomical predominance; IDH-mutant glioblastomas occur in younger patients (mean age
at diagnosis: 48 years) and pre-eminently develop in the frontal lobe (Lai et al., 2011; Ohgaki and
Kleihues, 2013). Characteristics of glioblastomas are pseudopalisading nuclei around a necrotic
core (Wippold et al., 2006) and a diffuse growth behavior with frequent infiltration throughout
the brain (Lefranc et al., 2005). Metastasis outside of the central nervous system is, however, rare
(Bernstein and Woodard, 1995; Schweitzer et al., 2001).
Cellular pathogenesis
Over the last decade there has been increasing evidence of a functional heterogeneity within
glioblastomas, reminiscent of normal stem cell hierarchy. Initially coined in leukemia, the term
‘cancer stem cell’ (CSC) has by now been widely accepted to describe a cancer cell subpopulation
capable of self-renewal and tumor initiation (Batlle and Clevers, 2017). Early evidence for CSCs in
glioblastoma came from two studies showing that the potential of unrestricted self-renewal and
of tumor initiation upon xenotransplantation into immunocompromisedmice is restricted to cells
expressing the neural stem cell surface marker CD133 (Singh et al., 2003, 2004). Follow-up studies
identified alternative markers for CSCs and suggested that CD133 expression is associated with
better prognosis and less aggressive tumor growth, rather than being a pre-requisite for tumor
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initiation and self-renewal (Bhat et al., 2013; Joo et al., 2008). This refined view distinguishes
CD133+ and CD133- CSCs, which due to their resemblance with fetal and adult neural stem cells,
respectively, are classified as ‘proneural’ and ‘mesenchymal’ CSCs (Lottaz et al., 2010).
The resemblance between tumor initiating cells and normal stem cells prompts the
hypothesis that glioblastomas originate from neural precursor cells. However, whether
de-differentiation of astrocytes or malignant transformation of glial stem cells initiates
tumorigenesis remains subject to debate. Most attempts at identifying the cell of origin have
relied on the introduction of oncogenic driver mutations to glial precursors and astrocytes in
mice. In 1998, Holland et al. showed that retroviral transfer of a mutant epidermal growth
factor receptor (EGFR) gene to glial lineage cells of mice with a disrupted cyclin-dependent kinase
inhibitor 2A (Cdkn2A) locus induces lesions that resemble human glioblastomas (Holland et al.,
1998). Based on the glial stem cell marker nestin and the astrocytic marker glial fibrillary acidic
protein (GFAP) the authors noticed that tumors develop more frequently from glial precursors
than from differentiated cells, indicating that glial stem cells are the likely cells of origin in
glioblastoma. These findings were corroborated by a later studywhich showed that astrocytomas
can be induced in neural progenitor cells, but not in astrocytes, upon inactivation of the tumor
suppressor genes p53, Nf1 and Pten (Llaguno et al., 2009). Moreover, a recent study identified
tumor-specific driver mutations at low levels in neural stem cells from the subventricular zone
of the same patient (Lee et al., 2018b). There is, however, also evidence that glioblastomas
may arise from de-differentiation of mature astrocytes or neurons. Lentiviral disruption of
p53 and Nf1 in cortical neurons has been shown sufficient to trigger glioblastoma induction in
mice (Friedmann-Morvinski et al., 2012). Similarly, transplantation of mature astrocytes with a
depleted Cdkn2a locus and a mutant EGFR gene induced high-grade gliomas in immunodeficient
mice (Bachoo et al., 2002). Both studies notice de-differentiation during tumor formation,
suggesting that specific molecular dysregulation can induce glioblastomas in different stages of
cellular differentiation. Whether this holds also true for glioblastomas that arise spontaneously
in vivo, remains to be elucidated.
Molecular pathogenesis
Karyotype analyzes and DNA sequencing studies have uncovered characteristic patterns of
chromosomal and genetic alterations in glioblastoma. Pioneering studies in the 1980s noticed
that gains of the entire chromosome 7, focal amplifications of the EGFR locus via double
minutes, losses of chromosome 10 and deletions or structural rearrangements of chromosome 9p
are frequent events in glioblastoma (Bigner et al., 1986, 1984, 1987). These chromosomal
alterations target prominent oncogenes — EGFR, CDK6 and MET on chromosome 7, CDKN2A/B
on chromsome 9p and PTEN on chromosome 10, to name the most striking examples (Brennan
et al., 2013) — and were confirmed to be among the most frequent events in glioblastoma overall
(Brennan et al., 2013; Dahlback et al., 2009; Vranová et al., 2007). More detailed investigation
distinguishing glioblastoma subtypes revealed frequent loss of chromosome 19q but less frequent
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loss of chromosome 10 in secondary glioblastomas, suggesting that different genetic pathways
drive primary and secondary glioblastomas (Fujisawa et al., 2000; Nakamura et al., 2000). This
hypothesis is corroborated by studies on the single-gene level, revealing that mutations in the
tumor suppressor gene PTEN are characteristic for primary glioblastomas, whereas mutations
in the metabolic enzyme IDH and the tumor suppressor gene TP53 are more frequently found in
secondary glioblastomas (Balss et al., 2008; Ohgaki et al., 2004; Tohma et al., 1998).
The most comprehensive analysis of the glioblastoma genome has been performed by The
Cancer Genome Atlas Research Network (TCGA), who analyzed the exomes of 291 glioblastoma
samples and the transcriptomes of 164 RNA samples with next generation sequencing. In
addition to identifying several new mutations (among these somatic mutations in LZTR1, SPTA1
and ATRX1), the network could link therapy-induced hypermutator phenotypes to mutations
in mismatch repair genes and define molecular core pathways in glioblastoma. Strikingly,
alterations in the RB, TP53 and RTK pathways, all involved in cell cycle progression and cell
survival, were found in approximately 80% of the patients. Moreover, the authors noticed that
activating mutations in the promoter region of the telomerase reverse transcriptase gene (TERT )
and inactivating mutations in ATRX, associated with alternative telomere lengthening, were
mutually exclusive. The authors concluded that alternative ways of telomere maintenance exist
in glioblastoma (Brennan et al., 2013; The Cancer Genome Atlas Research Network et al., 2008).
Treatment
Standard of care The standard of care for glioblastoma patients to date is surgical resection
of the tumor followed by radiation therapy and chemotherapy with the alkylating agent
temozolomide. Nevertheless, the disease progresses within 12 months after initial diagnosis in
approximately 75% of the patients (Stupp et al., 2005). To improve progression-free survival the
factors predicting treatment response and patient prognosis need to be identified. Insufficient
surgical resection due to infiltrative growth is clearly a major contributor to disease recurrence
and more gross resection has been linked to prolonged progression-free survival (Sanai et al.,
2011). Moreover, global hypermethylation on CpG sites, referred to as ‘glioma-CpG island
methylator phenotype’ (G-CIMP), is associated with better prognosis overall (Noushmehr et al.,
2010).
Temozolomide acts by linking methyl groups to the purine bases adenine and guanine in
the DNA (Drabløs et al., 2004). The primary toxic product, O6-methylguanine, mismatches with
thymine, which is directly repaired by the O-6-methylguanine-DNAmethyltransferase (MGMT).
In the absence of MGMT expression, the mismatch is recognized by the DNA mismatch repair,
which fails to correct lesions on the template strand and induces double strand breaks of which
the cell eventually dies (Zhang et al., 2012). In line with its mode of action, the response to
temozolomide treatment could be positively correlated with functional MMR and silencing of
the MGMT gene by promoter methylation (Cahill et al., 2007; Hegi et al., 2005).
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Personalized treatment based onmolecular subtyping In an attempt to capture inter-
individual heterogeneity in treatment response more accurately, Verhaak et al., 2010, developed
a molecular classification system of gene expression in glioblastoma, based on which four major
glioblastoma subtypes were identified. These subtypes were re-analyzed by Brennan et al., 2013,
collectively revealing the following characteristics:
• A ‘classical’ subtype is linked to joined high-level EGFR amplification, focal
chromosome 9p deletion and chromosome 10 loss, while TP53 mutations are typically
absent; in addition, neural stem cell markers are highly expressed in tumors classified as
of the classical subtype (Verhaak et al., 2010). Promoter methylation of theMGMT gene in
glioblastomas of the classical, but not other subtypes, is associated with better prognosis
(Brennan et al., 2013).
• A ‘mesenchymal’ subtype is primarily linked to focal NF1 deletions and the expression of
mesenchymal and astrocytic markers, among them CD44 (Verhaak et al., 2010). The MAP
kinase signaling pathway has been described as "moderately upregulated" in this subtype
(Brennan et al., 2013).
• A ‘proneural’ subtype is mainly characterized by mutations in PDGFRA, IDH1 and TP53,
absence of chromosome 7 amplification and chromosome 10 loss, and expression of
proneural development genes (Verhaak et al., 2010). Proneural glioblastomas show
increased activation of the PI3K pathway and are frequently of the G-CIMP phenotype
(Brennan et al., 2013). Overall, they have been associated with better survival and comprise
most secondary glioblastomas (Brennan et al., 2013; Phillips et al., 2006; Verhaak et al.,
2010).
• A ‘neural’ subtype is linked to the expression of neural markers and little infiltration with
non-tumor cells (Verhaak et al., 2010).
Capper and co-workers recently proposed an alternative classification approach, which focuses
on the DNA methylation status rather than gene expression and distinguishes eight subclasses
in glioblastoma. The receptor tyrosine kinase I and II and the mesenchymal subtypes are
most frequent among these and resemble the proneural, classical and mesenchymal expression
subtypes (Capper et al., 2018).
Comparison of molecular subtypes in pairs of primary and relapsed glioblastomas revealed
frequent subtype switching between primary and recurrent tumors, mostly towards the
mesenchymal or the proneural subtype (Wang et al., 2016, 2017). Interestingly, classification
of glioblastomas as mesenchymal could be linked to immune cell infiltration by primarily
macrophages and is overall associated with poorer survival (Engler et al., 2012; Wang et al.,
2017). Nevertheless, advances in robust molecular subtyping have not led to an improvement of
patient survival to date (Lee et al., 2018a).
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Personalized treatment based on mutational profiles In theory, a cancer genome
should hold key to the pathogenic mutations and precise targeting of these should exterminate
the disease. In practice, molecular targeting has proven widely disappointing in glioblastoma.
The most prominent example is precision medicine targeting mutant EGF-receptors. Tyrosine
kinase inhibitors or monoclonal antibodies against EGFR have been successful across a wide
range of cancers but have consistently failed in glioblastoma, despite the high frequency of
EGFR mutations (Westphal et al., 2017). Alternative approaches have primarily targeted neo-
vascularization and cell cycle progression with small molecule inhibitors against the endothelial
growth factor receptors KDR and FLT1 and the kinases mTOR, PKCβ and PDGFR, but turned out
to be majorily unsuccessful also (De Witt Hamer, 2010).
The reasons why precisionmedicine has been failing in glioblastoma are numerous and range
from difficulties in drug delivery, due to the blood-brain barrier, to redundancy of pathway
inactivating mutations, to intratumoral heterogeneity (Prados et al., 2015). This is especially
true for EGFR, which is frequently amplified at cell-specific levels or targeted by distinct,
often mutually exclusive mutations in different subpopulations of the tumor (Francis et al.,
2014; Snuderl et al., 2011). Understanding intratumoral heterogeneity and genetic evolution in
glioblastoma has thus become a prime interest in therapeutic development (Qazi et al., 2017).
2.1.2 Intratumoral heterogeneity and clonal evolution in glioblastoma
Intratumoral heterogeneity is considered a major cause of treatment failure in glioblastoma (Qazi
et al., 2017). As discussed in Section 2.1.1, glioblastoma cells are hierarchically organized with
a few cells having the capacity to self-renew, while most of their progeny divides transiently
and eventually dies off. Such functional heterogeneity is most likely due to transcriptional or
epigenetic differences, and, indeed, single-cell transcriptomic analysis revealed highly variable
expression of gene sets related to proliferation, immune response or hypoxia among glioblastoma
cells (Patel et al., 2014). Intratumoral heterogeneity can, however, also be studied on the genomic
level, which has been increasingly done in recent years. Two studies, which analyzed single-cell
genomes with fluorescence in situ hybridization (FISH) and single-cell sequencing, found distinct
EGFR mutations in different cells of the same tumor and, moreover, various amplification levels
of EGFR, MET or PDGFRA in a mutually exclusive way (Francis et al., 2014; Snuderl et al., 2011).
In a comprehensive study of the genetic and transcriptional heterogeneity in eleven primary
glioblastomas, Sottoriva et al., 2013 compared multiple regions per tumor and found that copy
number changes of chromosomes 7 and 9 (involving the EGFR and CDKN2A locus) were usually
present in the entire tumor, while aberrations on chromosomes 4 and 10 (involving the PDGFRA
and PTEN locus) were frequently shared by a subset of the tumor only. Moreover, the authors
noticed that several expression subtypes can co-exist within a single tumor, an observation that
was corroborated by two studies of single-cell transcriptomes in glioblastoma (Patel et al., 2014;
Wang et al., 2017).
In an attempt to link intratumoral heterogeneity with clonal evolution under standard
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therapy, recent studies have started to compare the genetic, epigenetic and transcriptional
profiles of matched pairs of primary and recurrent glioblastomas. Interestingly, whole exome
sequencing of sample pairs from initially low-grade gliomas that progressed to secondary
glioblastomas at recurrence indicated clear branching between primary and recurrent tumorwith
frequent replacement of driver mutations (Johnson et al., 2014). Moreover, approximately 50%
of the patients treated with temozolomide acquired a hypermutation genotype at recurrence,
indicating ongoing evolution under therapy (Johnson et al., 2014). A similar approach, including
primary and secondary glioblastomas, suggested highly branched evolution of both subtypes,
by which the authors argued that clonal replacements of key driver mutations between
primary and recurrent tumors are frequent (Wang et al., 2016). By contrast, comparative
whole exome sequencing of pairs with local or distant tumor recurrence suggested that clear
branching between primary and recurrent tumor occurs in the latter, but not in the former
(Kim et al., 2015). Notwithstanding the insights into the gentic architecture of glioblastomas
gained by these studies, none of them combined intra- with inter-sample heterogeneity to
obtain a comprehensive model of the phylogenetic relationships within the tumors. Moreover,
intratumoral heterogeneity has been barely used to infer the dynamics of tumor growth. Thus
further analysis is necessary to understand the evolutionary dynamics underlying glioblastoma
growth and recurrence.
2.1.3 Existing algorithms for phylogenetic inference in cancer
Phylogenetic inference of genetic subclones in cancer can be performed at various levels of
resolution. A crude analysis compares two or more tissue samples of the same tumor, treats each
as a single clone and attempts to find the phylogenetic tree that explains the mutational profile
with least error, while being maximally parsimonious. More elaborate methods take the variant
allele frequencies (VAFs) of measured mutations into account, that is the fraction of sequencing
reads reporting the mutation. Knowing the copy number state at a given locus, VAFs can be
transformed to cancer cell fractions, from which genetic heterogeneity within samples can be
inferred. Ultimately, the highest resolution can be achieved by sequencing single cells to learn
the phylogenetic relationships between these.
Irrespective of the level of resolution, methods for phylogenetic inference frequently rely on
a set of basic assumptions (Schwartz and Schäffer, 2017):
• Maximum parsimony The maximum parsimony criterion assumes that the simplest
phylogenetic tree explaining the data is the most likely solution. Phylogenetic inference
with maximum parsimony thus minimizes the number of evolutionary steps needed to
generate the data (Schwartz and Schäffer, 2017).
• Infinite sites model According to the infinite sites model the probability of a specific
mutation happening twice is negligibly small (Kimura, 1969). Conversely, the probability
for backmutation can be neglected as well.
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• Pigeonhole principle If the sum of two subclones exceeds 100%, one subclone must be
contained in the other (Beerenwinkel et al., 2014).
Phylogenetic inference from bulk sequencing data
Learning the genetic subclones and their phylogenetic relationships in a tumor sample from
bulk sequencing data is a two-dimensional inference problem. As DNA is sheared into small
pieces in next generation sequencing, information on the groups of mutations belonging to the
same subclones in the tumor is lost. Reconstructing the genetic profiles of tumor subclones
is therefore the first inference problem. On the other hand, individual subclones need to
be mapped on a phylogenetic tree, while fulfilling the pigeonhole criterion, which states the
second inference problem. Aneupoloidy, gains or losses of (parts) of chromosomes in the entire
tumor or a subset of it, further aggravates phylogenetic reconstruction. In order to address
these problems, a multitude of computational methods have been developed in the last decade.
Early attempts mostly relied on clustering of single nucleotide variants (SNVs), while assuming
that copy number variations (CNVs) are monoclonal (e.g., Roth et al., 2014). These methods
require a transformation of the VAFs to cancer cell fractions, on which the cluster analysis is
performed. Alternative approaches define subclones on the level of CNVs, while neglecting
SNVs (e.g., Oesper et al., 2013). Here, read counts at individual loci in the genome are clustered
using a multinomial model. Both approaches lack the combination of subclonal SNVs with
subclonal CNVs and many methods refrain from inferring a phylogenetic structure that relates
identified subclones to each other. In a more sophisticated approach, both SNVs and CNVs are
hence combined to jointly infer the subclonal composition and its underlying phylogenetic tree
(Deshwar et al., 2015). However, copy numbers and the subclonal fraction harboring a CNAmust
be estimated beforehand, which introduces a potential bias in the analysis.
Phylogenetic inference from single cell sequencing data
In contrast to bulk sequencing, phylogenetic inference from single cell sequencing data has the
advantage that the mutational profile of each cell is measured. Thus genetic subclones are in
principle known and it only remains to find the most likely tree explaining the phylogenetic
relationships between them. In practice, however, sequencing single cells is more prone to
sequencing artefacts so that error models incorporating false positive and false negative rates
for mutation calling are necessary. Jahn and co-workers developed a computational framework
that addresses this challenge by scanning the space of all possible trees with a Markov chain
Monte Carlo sampling scheme that simultaneously estimates the false-postive rate in mutation
calling (Jahn et al., 2016). Although single cell sequencing provides a higher resolution than
bulk sequencing, it is more prone to undersampling the tumor due to higher costs and technical
limitations. Thus single cell sequencing might become a powerful alternative to bulk sequencing
in the future but is not yet suitable for high throughput analyses to date.
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2.2 A likelihood-based multinomial model for phylogenetic
reconstruction in cancer
2.2.1 General considerations
The aim of the phylogenetic inference approach introduced below is to infer the major
phylogenetic structure within pairs of primary and recurrent tumor samples from deep whole
genome sequencing data. The methodology relies on the assumption that a tumor grows from a
monoclonal origin and that all SNVs and small insertions/deletions are unique and irreversible
events (formally known as the infinite sites model; Kimura, 1969). Copy number changes often
span larger regions so that the probability of two independent alterations in the same region is
not negligible. We address this by allowing up to two independent copy number changes at a
single locus, as described below in more detail.
In principle, a genetic subclone can be defined at arbitrary levels ranging from the entire
tumor down to single cells (Fig. 2.1). In practice, resolution is limited by the operating principle
of WGS, in which each genomic locus is sampled and sequenced multiple times. If a mutation
is uniformly present in the tissue, it is likely detected, whereas mutations present in a few
cells only might be overlooked. Although the detection limit increases with the sequencing
coverage (i.e., the average number of reads spanning each locus), the capacity to distinguish
two subclones from each other decreases inversely with the subclonal size. To see this, assume
a very high resolution, allowing the reliable detection of mutations present in as little as 1%
of the tumor cells. In this gedankenexperiment up to 100 subclones, each of approximately 1%
relative size, co-exist. Even if all subclones are of distinct sizes (thus slightly varying around
1%), the measured variant allele frequencies will all cluster around 0.5% in a diploid genome.
Therefore, the mutational profiles of very small subclones are indistinguishable even at very
high sequencing depths. Keeping these practical limitations in mind we define a subclone as a
tumor subpopulation sharing a set of passenger and driver mutations down to a resolution of
approximately 10% of the sample size. As the measured subclone sizes will vary around their
true value, accuracy increases with the number of datapoints, meaning that both driver and
passenger mutations are informative for our analysis.
2.2.2 Mathematical description of the model
Measuring a subclonal mutation in whole genome sequencing depends on two sampling steps
(Fig. 2.2). First, a tissue sample is taken from which DNA is extracted. Second, sequencing reads
are sampled from the fragmented DNA. As solid tissues are not well mixed, the frequencies
of subclonal mutations in the tissue sample may differ from the true frequencies in the tissue.
Moreover, mutations which are present in a certain region of the tissue only, may be entirely
missed by the first sampling step. The impact of tissue sampling on the measured subclonal
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Figure 2.1: Clonal evolution in tumorigenesis. Clones can be defined as the entire tumor, as cells sharing
driver mutations (marked here by different colors) or as cells sharing passenger mutations (corresponding
to single cells). The resolution of whole genome sequencing is limited to major subclonal branchings,
which can be visualized by a schematic summary tree (bottom; circle sizes scale with the relative subclonal
sizes).
distribution is exclusively controlled by the experiment itself and can only be assessed if multiple
tissue samples are taken. By contrast, the second sampling step depends entirely on the
sequencing strategy, since VAFs are measured from the sampled sequencing reads. Due to the
finite sample size, a measured VAF does not exactly correspond to the fraction of mutated DNA in
the tissue sample, but is binomially distributed around it. Thus the more sequencing reads cover
the mutated locus, i.e., the higher the sequencing coverage, the smaller the variance around the
true value. Likewise, the more mutations are characteristic for a subclone, the more reliably can
the subclonal size be inferred from the measured distribution of mutated sequencing reads.
We will now describe the second sampling step mathematically. As multiple subclones
can co-exist within a tumor sample, we model read counts as sampling from a multinomially
distributed pool, whose different categories represent the genetic subclones in the tumor. At each
genomic locus, the probability to sample reads from a distinct subclone scales with its relative
size and its copy number state. Let SCi , i = 1, ...,K denote the i-th subclone in a heterogeneous
tumor with K subclones, and µi the proportion of cells in the sample originating from the i−th
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Figure 2.2: Subclonal inference from whole genome sequencing data. Two sampling steps determine
the measured read counts at mutated loci. First, a set of tumor cells is sampled from which DNA is
extracted. Second, sequencing reads are sampled at the target coverage. While the first sampling step
is not accessible from the measured data, the second sampling step can be modeled with a multinomial
distribution. Subclonal sizes and phylogenetic structure can be inferred by fitting the model parameters
to the measured read count distribution using an expectation-maximization algorithm.
subclone. Then, at each locus l , the probability to sample a read from SCi in a Bernoulli trial can
be written as
pi,l = µi
πi,l∑K
i′=1 µi′ πi′,l
, (2.1)
where πi,l denotes the integer-valued copy number of the i−th subclone at locus l . Now, let
si,l ∈ {0, ...,πi,l } be integers that denote the number of mutated alleles at locus l in each subclone.
Accordingly, the probabilities to sample a read supporting the reference genome or a mutation,
respectively, are given by
prefi,l = pi,l
(
1 − si,l
πi,l
)
and pmuti,l = pi,l
si,l
πi,l
. (2.2)
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In bulk sequencing, the genomes from all subclones are intermingled. Consequently, r refl
reference reads and rmutl mutated reads at locus l originate from the K subclones in the sample,
such that
r refl =
K∑
i=1
r refi,l and r
mut
l =
K∑
i=1
rmuti,l . (2.3)
With this, the likelihood function for the measured numbers of reference and mutated reads at
locus l is given by
Ll (pl |r refl , rmutl ) = Pl (r refl , rmutl |pl ) =
(r refl + r
mut
l ) !∏K
i=1 r
ref
i,l ! r
mut
i,l !
K∏
i=1
(
prefi,l
)r refi,l (pmuti,l )rmuti,l , (2.4)
with the corresponding log-likelihood function ll
ll = logLl = C +
K∑
i=1
[
r refi,l log
(
prefi,l
)
+ rmuti,l log
(
pmuti,l
)]
, (2.5)
where C is a constant that solely depends on the read counts and is thus irrelevant for finding
the parameter values maximizing ll .
Solution space and phylogenetic tree design
We assume that tumors evolve from a monoclonal origin and can be visualized by a phylogenetic
tree. This restricts the solution space for subclonal inference as we will see in the following.
Invoking the infinite sites hypothesis (Kimura, 1969), we require that the combinations of
subclones carrying a mutation can be explained by a single event in the tree and are present
on one of the two parental alleles only. We thus require
0 ≤ si,l ≤ max(Bi,l ,πi,l − Bi,l ), (2.6)
where Bi,l is the number of B-alleles in subclone i at locus l .
If an SNV collocates with a CNV, si,l becomes further restricted by the following criteria:
• if the copy number change precedes the mutation in the phylogenetic tree, the mutation
can only be present on one allele,
• if the mutation precedes the copy number change, the mutation must either be present on
all A-alleles or on all B-alleles,
• if the order of the mutation and the copy number change is unclear, the mutation can be
present on any number of A- or B-alleles.
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Parameter estimation and model selection
To obtain the best tree explaining our data, we need to find the most likely tree structure along
with the relative subclone sizes. To address this two-layered problem, we successively estimate
the best parameter set for each tree template contained in a set of pre-defined candidate trees
(Fig. 2.3A). Note that by treating normal tissue as an additional subclone, we automatically
account for sample purity. Moreover, we design the candidate trees in such a way that, in general,
all subclones present in the primary sample are different from the ones in the relapse sample.
However, this also comprises solutions in which the same subclone is present in both samples
if the branches separating the two subclones are collapsed (Fig. 2.3B, two leftmost panels).
Similarly, these trees can also be collapsed into topologies of linear evolution (Fig. 2.3B, two
rightmost panels). The most likely tree among the fitted candidate trees is selected by requiring
a good fit of the tumor stem and further employing a modified Bayesian Information Criterion.
Parameter estimation with a nested expectation-maximization algorithm
The expectation-maximization algorithm (EM-algorithm) is a local optimization method for
parameter estimation with known and missing data, x and y, respectively (Held, 2008). In our
case, themodel parametersΘ are the clone sizes of genetic subclones in the primary and recurrent
tumor (µ), the available data are the number of reference and mutant sequencing reads per locus,
r refl and r
mut
l , and the missing data are the number of sequencing reads stemming from each
subclone, r refi,l and r
mut
i,l . The probability density function for the known andmissing data, f (x ,y),
is
f (x ,y) = f (y |x ) f (x ), (2.7)
and, accordingly, the log-likelihood functions read as
logL(Θ;x ,y) = logL(Θ;y |x ) + logL(Θ;x ). (2.8)
We now guess an initial value of Θ, which we call Θ0, and compute the expectation over all
possible values of the missing data y:∑
y
f (y |x ;Θ0) logL(Θ;x ,y) =
∑
y
f (y |x ;Θ0) logL(Θ;y |x )
+
∑
y
f (y |x ;Θ0) logL(Θ;x )                                                      
=log L(Θ)
(2.9)
E
[
logL(Θ;x ,y) |Θ0
]                                        
=Q (Θ;Θ0)
= E
[
logL(Θ;y |x ) |Θ0
]                                        
=C (Θ;Θ0)
+ logL(Θ;x )              
=log L(Θ)
. (2.10)
Eqn. 2.10 holds for any value of Θ and hence we can compute
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A
B
Figure 2.3: Tree templates for phylogenetic inference. A Candidate trees consisting of three primary
(P) and three recurrent subclones (R). All combinations of assigning up to three primary and recurrent
subclones each to specific tips are tested in the inference algorithm (three unique combinations are
displayed each). B By setting individual branch lengths to zero, this setting inherently accounts for
scenarios in which the same subclone is present in both tumors (two leftmost panels) and of linear
evolution (two rightmost panels). Figure modified from Körber et al., 2019.
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Q (Θ;Θ0) −Q (Θ0;Θ0) = C (Θ;Θ0) −C (Θ0;Θ0) + logL(Θ) − logL(Θ0). (2.11)
We know from Gibb’s inequality that C (Θ0;Θ0) ≥ C (Θ;Θ0). Thus if Q (Θ;Θ0) ≥ Q (Θ0;Θ0),
it follows that L(Θ) ≥ L(Θ0). This leads to the EM-algorithm with start parameter Θ0:
1. Expecation: Evaluate Q (Θ;Θ0).
2. Maximization: Maximize Q (Θ;Θ0) w.r.t. Θ, to obtain Θ1
3. Abrogate if |Θ0 −Θ1 | < ϵ (ϵ needs to be defined); else set Θ0 = Θ1 and repeat step 1 and 2.
As Θ is updated by maximization of Q (Θ;Θ0), it follows that Q (Θ1;Θ0) ≥ Q (Θ0;Θ0) and
thus the algorithm increases the log-likelihood with every iteration. However, expectation-
maximization optimizes the likelihood locally, so that the algorithmneeds to be run frommultiple
start conditions in order to find the global maximum.
In our tree inference problem, we jointly estimate the parameters of matched primary and
relapse samples at a given evolutionary tree with an expectation-maximization approach. As we
will see in the following, we slightly modify the algorithm by nesting the estimation of the copy
number state within the expectation step. We thenmaximize the likelihood and generate the new
input to the expectation step. Both steps are iteratively repeated until convergence (required as∑
(µi − µi−1)2 < 5 · 10−4, where i is the index of the iteration). In order to identify the global
maximum, optimization is repeated 100 times at random starting conditions for each candidate
tree. Expectation and maximization steps are described in detail in the following.
Expectation
The algorithm is initiated with random values of µi , which are then updated recursively.
In each expectation step, the expected counts of mutated and reference reads per subclone
are iteratively calculated for everymutated locus after inferring the copy number state as follows:
Copy numbers and B-allele frequencies. We assume that there is at most one dominating
copy number change,CNaberr,l , per locus and sample. This change does not have to be present in
all subclones, allowing for tumor heterogeneity. While we allow different copy number changes
to dominate the primary and the relapse sample at a specific locus, we assume that there is at
most one copy number change per locus within a sample.
CNaberr,l is determined from the normalized coverage ratios between tumor and blood along
with the measured B-allele frequencies, BAFl , in the tumor1. To this end, we apply the following
criteria:
1If no information on the coverage ratio is available, we assume normal ploidy (2 on autosomes and female sex
chromosomes, 1 on male sex chromosomes.). If no information on the B-allele frequency is available, we assume a
B-allele frequency of 0.5 on autosomes and female sex chromosomes and of 0 on male sex chromosomes
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• We assume that loci with coverage ratios in the interval [0.9, 1.1] and a B-allele frequency
in the interval [0.45, 0.55] (or [0, 0.05] in case of male sex chromosomes) reflect normal
copy number states, CNnorm, such that CNaberr,l = CNnorm = 2 on autosomes and female
sex chromosomes and CNaberr,l = CNnorm = 1 on male sex chromosomes. The cutoffs are
chosen based on the expected standard deviation of 8% in Poisson distributed read counts
at a coverage of 150x.
• At all other loci, we infer the copy numbers and B-allele numbers by minimizing the
squared errors between the expected and observed coverage ratios and B-allele frequencies.
To this end, we start with a single copy number whichwe iteratively increase. At each copy
number we then test different subclonal distributions f ∈ F of the copy number change,
where f is a vector f = ( f1, f2, . . . , fK ), whose elements are binary indicators of a copy
number change in the respective subclone, i.e. fi ∈ {0, 1}. The different combinations are
restricted by the candidate tree and comprise solutions in which the same or two different
copy number changes dominate the primary and the relapse sample, respectively. We
compute the expected B-allele frequency for B-allele counts, Baberr,l , in the interval [0,
CNaberr,l ] with
E[BAFl ] =
∑
i
[
fiµiBaberr,l + (1 − fi )µiBnorm]∑
i
[
fiµiCNaberr,l + (1 − fi )µiCNnorm] , (2.12)
and choose the B-allele count that minimizes the squared error between expected and
observed B-allele frequencies. Likewise, we compute the expected coverage ratio, crl , with
E[crl ] =
∑
i
[
fiµiCNaberr,l + (1 − fi )µiCNnorm]
CNnorm
. (2.13)
The algorithm is aborted once (E[BAFl ]−BAFl,obs)2+(E[crl ]−crl,obs)2 < 0.01 (the threshold
of 0.01 corresponds to the expected Poisson noise at sequencing depths of 150x)2. Bi,l and
πi,l are then determined for each i ∈ {1, 2, . . . ,K } to
Bi,l = Baberr,l fi + Bnorm (1 − fi ) (2.14)
πi,l = CNaberr,l fi +CNnorm (1 − fi ) (2.15)
2While only themost likely intratumoral distribution of a CNVs is selected here, alternative solutions are accounted
for in data presentation and analysis as discussed below.
26
2.2. A likelihood-based multinomial model for phylogenetic reconstruction in cancer
SNVs and small indels. The expected read counts for each possible combination of si,l and
πi,l
3 are computed with
E[r refi,l ] = p
′ ref
i,l r
r ef
l , p
′ ref
i,l =
prefi,l∑K
i′=1 p
ref
i′,l
, (2.16)
E[rmuti,l ] = p
′mut
i,l r
mut
l , p
′ r ef
i,l =
pmuti,l∑K
i′=1 p
mut
i′,l
, (2.17)
where p ′ refi,l and p
′mut
i,l are the conditional probabilities of a sampled reference or mutated read
originating from SCi , provided that µ, s and π are known. We then compute the corresponding
likelihood of µ, s and π :
Ll (pl |r refl , rmutl ) =
∑
(r refi,l ,r
mut
i,l )
Ll (pl |r refi,l , rmuti,l ), (2.18)
and select the solution with the highest likelihood4. Since DNA is fragmented before
amplification and mapping, the read count distributions at different loci are independent of each
other, so that the expectation step can be independently evaluated at eachmutated locus. Of note,
independence of measured coverage ratios is not guaranteed, since copy number variations can
span multiple loci. This is already accounted for during segmentation and therefore does not
affect the inference procedure.
Maximization
In the maximization step, the log-likelihood function (Eqn. 2.5) at the expected readcount
distribution (Eqn. 2.16, Eqn. 2.17) is maximized w.r.t. µ. This is approached by summing up
the log-likelihoods (Eqn. 2.5) at each locus and by introducing the constraint ∑KI=1 µi = 1 with a
Lagrange multiplier before maximization:
l˜ =
∑
l
ll + λ *,1 −
K∑
i=1
µi+- . (2.19)
After inserting Eqn. 2.2 into Eqn. 2.19, deviation with respect to µi and λ yields:
∂˜l
∂µi
=
∑
l
*, 1µi
(
r refi,l + r
mut
i,l
)
− πi,l
∑K
i′=1 r
ref
i′,l + r
mut
i′,l∑K
i′=1 µi′ πi′,l
+- − λ (2.20)
∂˜l
∂λ
= 1 −
K∑
i=1
µi . (2.21)
3Possible combinations are predefined by the candidate tree. This is explained in more detail above.
4 For data representation and analysis, alternative solutions are considered also if the best solution accounts for
less than 90% of the total likelihood.
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We find the maximum of the log-likelihood by setting Eqn. 2.20 and Eqn. 2.21 equal to zero and
solving for λ and µ:
λµi =
∑
l
*,r refi,l + rmuti,l − πi,l µi
∑K
i′=1 r
ref
i′,l + r
mut
i′,l∑K
i′=1 µi′ πi′,l
+- (2.22)
K∑
i=1
µi = 1. (2.23)
Summing up Eqn. 2.22 over all subclones yields
λ
K∑
i=1
µi =
K∑
i=1
∑
l
*,r refi,l + rmuti,l − πi,l µi
∑K
i=1 r
ref
i,l + r
mut
i,l∑K
i=1 µi πi,l
+- . (2.24)
With Eqn. 2.23 this reduces to
λ =
K∑
i=1
∑
l
*,r refi,l + rmuti,l − πi,l µi
∑K
i=1 r
ref
i,l + r
mut
i,l∑K
i=1 µi πi,l
+- , (2.25)
and consequently, by inserting Eqn. 2.25 into Eqn. 2.22, µi can be determined as
µi =
∑
l r
ref
i,l + r
mut
i,l∑
l
(
πi,l
∑K
i′=1 r
ref
i′,l+r
mut
i′,l∑K
i′=1 µi′ πi′,l
)
+ λ
, (2.26)
which reduces to
µi =
∑
l
r refi,l +r
mut
i,l
πi,l∑K
i′=1
∑
l
r refi′,l+r
mut
i′,l
πi′,l
. (2.27)
Model selection
To select the most likely tree among the candidate topologies, we first require a good fit of
the tumor trunk. This is achieved by discarding trees in which more than 50% of the clonal
(truncal) mutations are ambiguously mapped and, further, by discarding trees whose average
squared error of clonal VAFs lies outside the 10% quantile of all candidate trees. We then assess
the likelihoods of the remaining trees with a modified Bayesian Information Criterion (BIC)
(Chen and Chen, 2008). Briefly, the modified BIC incorporates increasing model complexity with
increasing numbers of parameters,
BICγ = −2 logLn +v logn + 2γ logτ , (2.28)
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where n is the number of data points, v the number of parameters and τ a parameter accounting
for increasing model complexity weighted by γ . In our case, the number of data points is the
number of readcounts (r refl + r
mut
l ), the number of parameters is the number of subclones, K , and
τ is obtained by summing up all possible values of s . We chooseγ = 0.9 to stringently incorporate
the increasing model complexity when increasing the number of parameters.
Ambiguous solutions
To avoid bias in data interpretation due to potentially ambiguous solutions, we account for three
types of ambiguity:
• CNVs. If model inference suggests two independent copy number changes in primary and
relapse tumor, respectively, but the squared error of a joined solution is less than twice the
least squared error, we account for the joined solution in data analysis and interpretation.
Likewise, if the squared error for a clonal copy number change is less than twice the error
of a subclonal copy number change, we account for the clonal solution.
• SNVs. If the location of a mutation to the phylogenetic tree is non-unique, i.e., if the best
solution carries less than 90% of the total likelihood at this locus, we sort solutions by
decreasing likelihood and account for all solutions that jointly yield at least 90% of the
total likelihood in data analysis and interpretation.
• Tree structure. We account for all solutions with BICγ ≤ min(BICγ ) + 10.
2.2.3 Method validation
To validate our phylogenetic inference algorithm we test its performance computationally and
experimentally against a known ‘ground thruth’.
Simulated data
First, we evaluate our method computationally on 100 simulated test sets of up to three primary
and recurrent subclones, respectively (Algorithm 1). Three exemplary simulations and the
matching inference results are shown in Fig. 2.4. In the example in Fig. 2.4A, the correct tree
structure was inferred and the algorithm had only minor problems in the mapping of individual
mutations to their position in the phylogenetic tree. This is expected due to the sampling noise
in the data, which renders accurate assignment of mutations to subclones ambiguous if several
subclones have similar sizes. In the two examples in Fig. 2.4B and C, the inferred tree structure is
slightly different from the true structure, butmajor branching events are recovered in the inferred
trees. Summarized over all simulated trees, the algorithm provides reliable estimates of the tumor
cell content (Fig. 2.5A) and the subclone sizes (Fig. 2.5B). The correct number of subclones is
estimated in the majority of cases, though overestimation and, more rarely, underestimation
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of the subclonal number occurs in some cases (Fig. 2.5C-E). In the vast majority of the tested
trees, clonal mutations are inferred at small false negative rates, though at the cost of higher
false positive rates (Fig. 2.5F, G). Thus, the inference algorithm is conservative towards clonal
mutations. Key characteristics of the tree structure, such as the mutational distance between
the most recent common ancestors of primary and recurrent tumors, or the mean number of
mutations per subclone, correlate well with their true counterparts, though one should be aware
of some uncertainty in these estimates (Fig. 2.5H, I).
In summary, key characteristics of tumor phylogenies can be reliably inferred from simulated
sequencing data. However, as the phylogenetic inference problem cannot be unambiguously
solved in every detail, inferred phylogenies should not be read as the true tree structure, but
rather as simplified representations of major branchings in the phylogenetic tree.
Performance on artificially mixed cell lines
In order to assess the performance of the algorithm on real data, we analyze the variant allele
frequencies in two neuroblastoma cell lines, SMS-KCN and SMS-KCNR, and in a 1:4 and a 1:10
mixture of the two cell lines (SMS-KCN : SMS-KCNR). Both cell lines were generated from
the same patient, so that the mixed samples model a genetically heterogenous tumor with a
monoclonal origin.
Sample preparation and mutation calling. Sample preparation, DNA extraction and
sequencing library preparation were performed by Selina Jansky from the group of Frank
Westermann (German Cancer Research Center, Heidelberg), and whole genome sequencing
at a target coverage of 80x was conducted by the DKFZ Genomics and Proteomics Core
Facility. Sequence alignment, variant calling and copy number estimation were done by
myself. Briefly, sequencing reads were aligned against the human reference genome hs37d5
using burrows-wheeler alignment (Li and Durbin, 2009), and duplicates were marked using
GATK Markduplicates v4.0.8.1 at default parameters (McKenna et al., 2010). Mutations were
called against a normal blood sample from a neuroblastoma patient (kindly provided by Frank
Westermann) using Strelka v2.8.4 at default parameters (Saunders et al., 2012) and annotated
using annovar (Wang et al., 2010). Low-quality variants and mutations in repeat regions
(extracted from UCSC table browser, https://genome.ucsc.edu/cgi-bin/hgTables, selecting
‘RepeatMasker’ and ‘Simple Repeats’) were filtered upon mutation calling. Finally, coverage
ratios and copy number estimates were obtained with Control-FREEC (Boeva et al., 2011; with
breakPointThreshold=0.6, maximal SubclonePresence=0.2, coefficientOfVariation=0.5 and the
normal blood sample as control).
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Algorithm 1 Simulate sequencing data from heterogenous tumors
1: Sample between one and three primary and recurrent clones (Kprim and Krec).
2: Sample the corresponding subclone sizes, µprim and µrec, at a minimal tumor cell content of
0.5.
3: Sample a random tree from Figure 2.3.
4: Sample Kprim and Krec nodes from this tree .
5: for each subclone do
6: Sample uniformly between 1 and 200 mutations for this subclone.
7: end for
8: for each sampled mutation do
9: Sample a copy number, πl according to
10: P(1 allele) = 0.1
11: P(2 alleles) = 0.75
12: P(3 alleles) = 0.1
13: P(4 to 8 alleles) = 0.05 each
14: P(0 alleles | > 8 alleles) = 0
15: end for
16: for each copy number other than 2 do
17: Sample the subclones from the tree structure that carry the copy number change and
store these in the indicator vector fi,l .
18: Sample whether the mutation was affected by the copy number change; from this
determine sl .
19: Simulate the coverage ratios according to crl =
∑
i πl fi,l µi+2(1−fi,l )µi
2 + N (µ = 0.05,σ =
10−4), thus, adding Gaussian noise to the simulated coverage ratios.
20: end for
21: for each sampled mutation do
22: Sample the read depth per locus from a Poisson distribution with λ = 150.
23: Sample the number of mutated reads from a binomial distribution with sampling
probabilities according to Eqn. 2.2.
24: end for
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Figure 2.4: Three examples of true (left panels) and inferred (right panels) phylogenetic trees based on
simulated data. Subclones present/inferred in the primary and recurrent sample are colored in yellow and
orange, respectively. Circle areas scale with the relative subclone size and vertical branch lengths with
the number of mutations.
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Figure 2.5: Phylogenetic inference on simulated data. A True and inferred tumor cell content with
Pearson’s correlation coefficient. B True and inferred clone size with Pearson’s correlation coefficient.
Shown are only cases, in which the correct number of subclones had been called. C Deviation from the
true number of subclones. D Sensitivity of detecting a subclone in dependence of the relative subclone
size. E Specificity of detecting a subclone in dependence of the relative subclone size. F, G False negative
and false positive clonal mutations if neglecting subclones ≤ 10%. H True and inferred difference
between the most recent common ancestors of primary and relapse sample, measured in mutation counts.
Pearson’s correlation coefficient is indicated in the plot. I True and inferred mean number of mutations
per subclone since the most recent common ancestor population of the tumor. Shown are the results from
100 simulations of up to three subclones per primary and relapse sample, respectively. Figure adjusted
from Körber et al., 2019.
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Variant allele frequencies of clonal and subclonal mutations. We begin by testing
whether VAFs measured with whole genome sequencing are binomially distributed around their
true value, a basic assumption of our phylogenetic inference algorithm. Mutations present in both
SMS-KCN and SMS-KCNR cells are most likely clonal mutations, comprising germline mutations
and somatic mutations acquired in the common ancestor cell of the two cell lines. As shown in
Fig. 2.6A, the measured VAF distribution of these mutations indeed conforms to the theoretical
prediction according to a binomial distribution, and thus a binomial model can be used to identify
clonal mutations. To test whether this holds also true for subclonal mutations, we next analyze
the VAF distribution of mutations that are private to either of the two cell lines. Among these,
mutations with a VAF ≥ 0.5 are likely clonal in the respective cell line, but, since they are absent
in the other cell line, were acquired after the two cell lines split from their common ancestor
cell. Analyzing the VAF distribution of these mutations in different dilutions hence reveals
whether subclonal mutations can be modeled with binomial distributions also. The selection
of high-confidence clonal mutations that are private in either of the two cell lines is shown in
Fig. 2.6B. As before, the distribution of these ‘privately clonal’ mutations agrees well with the
theoretical expectation according to a binomial distribution (Fig. 2.6B, lower panels). Moreover,
the VAFs of ‘privately clonal’ mutations remain binomially distributed upon dilution in both
mixed populations, supporting a multinomial model to analyze genetic heterogeneity in tumors
(Fig. 2.6C). Of note, average VAFs of ‘privately clonal’ mutations suggest higher fractions of SMS-
KCN cells among the cell line mixtures than experimentally mixed (Table 2.1). Nevertheless, the
estimated ratios add up to 102% in the 1:10 and to 99% in the 1:4 mixture, indicating that the
fractions of SMS-KCN and SMS-KCNR cells are accurately determined from the VAF distribution.
Next, we assess how well we can distinguish the two cell lines without prior knowledge on
the genetic heterogeneity within the samples. To this end, we subject the two mixed samples to
our phylogenetic inference algorithm, treating the 1:10 mixture as the ‘primary tumor sample’
and the 1:4 mixture as the ‘relapse tumor sample’. Tree inference is run on a subset of 595
mutations, consisting of 100 likely clonal mutations (identified from co-occurrence in pure SMS-
KCN and SMS-KCNR cells), 400 mutations randomly sampled from non-clonal mutations in the
1:10 mixture (consisting of 305 mutations that were identified in both mixtures and 95 mutations
that were identified in the 1:10 mixture only) and 95 non-clonal mutations identified in the 1:4
mixture only. Thus 500 mutations from each ‘tumor sample’ are used for tree learning.
We know from the experimental design that the ‘true tree’ consists of a common tumor
origin from which two major branches split off, yielding the cell lines SMS-KCN and SMS-KCNR.
Moreover, the two branches are present in different proportions in the two ‘tumor samples’ and
add up to 100%, respectively, as there is no contamination with normal tissue (Fig. 2.6C, left
panel). We now ask how well these key characteristics are recovered by phylogenetic inference.
The best fit (c.f. Section 2.2.2) suggests an asymmetric tree that consists of three subclones per
sample, which add up to 99% and 98%, respectively (Fig. 2.6C, right panel). Clonal mutations are
identified with 100% specificity and 91% sensitivity, and almost all mutations that are ‘privately
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Table 2.1: Experimentally mixed vs inferred cell line fractions of mixed SMS-KCN and SMS-KCNR cells.
Experimental data: Selina Jansky.
Experimentally mixed fraction Inferred fraction
SMS-KCN 0.1 0.23
SMS-KCNR 0.9 0.79
SMS-KCN 0.25 0.44
SMS-KCNR 0.75 0.55
Inferred fractions were determined by multiplying the average VAFs of ‘privately clonal’ mutations by two, thus
transforming VAFs at heterozygous loci to cell fractions.
clonal’ in SMS-KCNR cells are among the false positive clonal mutations in the joined tree.
Thus the major branching between SMS-KCN and SMS-KCNR cells is not inferred, because
‘privately clonal’ mutations in SMS-KCNR cells are wrongly assigned to the common trunk of the
phylogenetic tree. This is most likely due to the paucitiy of these mutations (2% of the mutations
used for tree inference), which reduces the statistical power to identify the branching event. By
contrast, the more frequent ‘privately clonal’ mutations in SMS-KCN cells (19% of the mutations
used for tree inference) are reliably classified as subclonal, and 88% of them are sorted to themajor
subclonal branch present in both tumor samples. The relative size of this branch is estimated to
19% in the 1:10 and to 35% in the 1:4 mixture (Fig. 2.6C, right panel); compared to the previous
estimates based on the VAF distribution only (23% SMS-KCN cells in the 1:10 mixture and 44%
SMS-KCN cells in the 1:4 mixture; c.f. Table 2.1), phylogenetic inference reliably estimates the
fraction of SMS-KCN cells in the ‘primary tumor’, while slightly underestimating it in the ‘relapse
sample’.
In summary, phylogenetic inference on artificially mixed cell lines reveals that, although
subclonal details of very small populations are blurred in bulk sequencing, clonal mutations and
major subclonal branchings can be inferred if supported by sufficiently many mutations.
2.3 Evolutionary trajectories of IDH-wildtype glioblastomas
2.3.1 Tumor samples
The data underlying this work were collected from the German Glioma Network (GGN,
www.gliomnetzwerk.de) and the database of the Central Nervous System (CNS) tumor tissue
bank at the Department of Neuropathology, Heinrich Heine University Düsseldorf, Germany. All
patients included in the study provided their written informed consent. The study was approved
by the institutional review board of the Medical Faculty, Heinrich Heine University, Düsseldorf,
Germany (study number 4940). Tumor samples were contributed by Katrin Lamszus (University
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Figure 2.6: Whole genome sequencing of mixed SMS-KCN and SMS-KCNR cells. A Variant allele
frequencies of putatively clonal mutations that were acquired prior to the split between SMS-KCN and
SMS-KCNR cells. Shown are the VAF histograms (top panels) and the cumulative distributions (bottom
panels) for 1,000 heterozygous variants, randomly sampled from loci with normal copy numbers (left, SMS-
KCN; right, SMS-KCNR). Black lines show cumulative binomial distributions with success probabilities 0.5
and sample sizes corresponding to the median sequencing depth at the displayed variants (72 and 42 for
SMS-KCN and SMS-KCNR, respectively). B Variant allele frequencies of private mutations in SMS-KCN
and SMS-KCNR cells. Among these, mutations with a VAF≥ 0.5 are clonal in the respective cell line with
high probability (‘high-confidence clonals’, colored in red). Lower panels show the cumulative distribution
of heterozygous ‘high-confidence clonal’ mutations (red lines). Black lines mark the theoretical VAF
distributions for mutations with a VAF≥ 0.5 according to binomial sampling with success probability
0.5 and sample size corresponding to the median sequencing depth at the displayed variants (71 and 40
for SMS-KCN and SMS-KCNR, respectively).
Caption continues on next page.
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Figure 2.6 (continued): C Cumulative VAF distributions of ‘privately clonal’ mutations (selected from
the ‘high-confidence clonal’ mutations in (B)) in the 1:10 (left) and the 1:4 mixture (right). Black lines,
measured distributions; red lines, binomial distributions with sampling size according to the median
sequencing depth measured at the displayed variants and success probability 0.5 × ρ, where ρ is the
inferred cell line fraction according to Table 2.1. D Phylogenetic inference if treating the 1:10 mixture as a
‘primary tumor sample’ and the 1:4 mixture as a ‘relapse tumor sample’. Left, ground truth with subclonal
sizes estimated from the distributions in (C) (c.f. Table 2.1); right, inferred tree.
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Figure 2.7: Study design. A Tumor samples were obtained after primary (treatment-naïve) and secondary
resection (exposed to treatment). B Overview of clinical parameters of the patient cohort. Figure adjusted
from Körber et al., 2019; patient data: Kerstin Kaulich, Guido Reifenberger; methylation subtyping:
Damian Stichel.
Medical Center, Hamburg-Eppendorf), Jörg-Christian Tonn (Ludwig Maximilians University,
Munich), Christel Herold-Mende (University Hospital Heidelberg), Gabriele Schackert (Technical
University Dresden), Michael Sabel (Heinrich Heine University, Düsseldorf), Bettina Hentschel
(University Leipzig) and Michael Weller (University Hospital Zürich)
The dataset comprises 21 sample triplets, consisting of matched primary and recurrent tumor
samples along with normal blood controls from patients with IDHWT glioblastomas. Primary
samples were retrieved from treatment-naïve tumors after initial surgery. With few exceptions,
recurrent tumors had been exposed to both radiation therapy and concomitant chemotherapy
with temozolomide (TMZ, Fig. 2.7). Tumor samples were histologically classified as grade IV
glioblastomas by Jörg Felsberg and Guido Reifenberger (Heinrich Heine University, Düsseldorf)
and further stratified into four DNA-methylation-based subtypes (‘Receptor tyrosine kinase I’,
‘Receptor tyrosine kinase II’, ‘Mesenchymal’ and ‘H3F3A-G34-mutant’) by Damian Stichel from
the group of Andreas von Deimling (German Cancer Research Center, Heidelberg, following the
classification scheme by Capper et al., 2018). Clinical metadata was collected by Kerstin Kaulich
from the group of Guido Reifenberger (HeinrichHeine University, Düsseldorf) and is summarized
in Table 2.2.
2.3.2 Sequencing strategy
Whole genomes of the tumor samples and the matched blood controls were sequenced at an
average coverage of 149x and 78x, respectively, and the methylation status of all tumor samples
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Table 2.2: Clinical characteristics of the glioblastoma patient cohort. Modified from Körber et al., 2019.
Data: Kerstin Kaulich, Gudio Reifenberger.
Age at diagnosis (years)
Median (range) 60 (33-73)
Gender
Male 11 (52%)
Female 10 (48%)
Tumor location
Frontal 4 (19%)
Temporal 6 (29%)
Parietal 3 (14%)
Occipital 1 (5%)
More than 1 cerebral lobe 7 (33%)
Local relapse 20 (95%)
Extent of initial surgery
Gross total resection 11 (52%)
Subtotal resection 10 (48%)
MGMT promoter methylation Primary tumor Relapse tumor
Methylated 11 (52%) 12 (57%)
Unmethylated 10 (48%) 9 (43%)
DNA methylation subgroup Primary tumor Relapse tumor
RTK I 6 (29%) 4 (19%)
RTK II 10 (48%) 9 (43%)
Mesenchymal 4 (19%) 7 (33%)
H3-G34 1 (5%) 1 (5%)
First-line therapy
Radiotherapy alone 1 (5%)
Temozolomide alone 1 (5%)
Radiotherapy plus temozolomide 19 (90%)
Survival data (days), median (range)
Interval between first and second surgery 280 (46-994)
Overall survival 580 (261-1783)
Patients alive at last follow-up 10 (48%)
Abbreviations used: RTK I, receptor tyrosine kinase I group; RTK II, receptor tyrosine kinase II group; H3-G34,
H3F3A-G34-mutant group.
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was assessed with 450k or EPIC methylation bead chip arrays (Illumina, Hayward, CA). In
addition, we sequenced the transcriptomes of 16 tumor pairs, of which sufficient RNA could be
extracted (see also Fig. 2.7B). DNA extraction and sequencing were performed by David Jones,
Bernhard Radlwimmer, Yonghe Wu and Andreas von Deimling (all German Cancer Research
Center, Heidelberg, with support from the DKFZ Genomics and Proteomics Core Facility).
Sequence alignment, tumor-specific variant calling and mutational signature analysis, as well
as detection of copy number alterations and structural variants were performed by Jing Yang,
Pankaj Barah, Daniel Hübschmann and Matthias Schlesner (all German Cancer Research Center,
Heidelberg, with support from the DKFZ Omics IT and Data Management Core Facility). All
downstream analyses, including the analysis of the mutational profiles, the selection of driver
genes, phylogenetic inference and modeling of clonal dynamics were performed by myself.
2.3.3 Mutational burden in primary and recurrent tumors
To begin with, we analyze the mutational burden of single nucleotide variants (SNVs) and small
insertions/deletions (indels) per tumor. Upon removal of putative germline mutations, detected
from comparison with the blood controls, we find tumor-specific SNVs and small indels in the
order of 104 in most tumors (median 12,800, Fig. 2.8A). Four tumors stand out with many more
mutations (> 105), which we classify as ‘hypermutated’. Notably, three of these hypermutated
tumors acquired the hypermutation genotype upon exposure to treatment, while onewas already
hypermutated at primary resection. Except for the hypermutated cases, the mutational burden
is comparable between primary and matched recurrent samples, and approximately as many
mutations are shared between a sample pair as are private to one of the sample (Fig. 2.8A-C).
While the overall mutational burden per tumor provides a rough estimate of its exposure
to mutagenic processes, more detailed information can be obtained from mutational signature
analysis. The idea behind this approach is to infer different mutagenic processes such as
replication-errors, defective DNA repair or exposure to mutagens, from the pattern of SNVs
and their sequence context by non-negative matrix factorization (Alexandrov et al., 2013b).
Estimating the contribution of previously described mutational signatures to the observed SNV
profile in non-hypermutated tumors, we find a clear dominance of mutational signature 1
(previously associated with the age at cancer diagnosis; Alexandrov et al., 2015, 2013a; Forbes
et al., 2016) among SNVs that are shared between primary and recurrent samples (Fig. 2.8D;
analysis performed by Jing Yang and Daniel Hübschmann). Among SNVs that are private to
either of the tumor samples, the contribution of signature 1 decreases at the expense of signatures
associated with DNA double-strand break-repair (signature 3), defective DNA mismatch repair
(signatures 15, 26) and one of unknown etiology (signature 5; Fig. 2.8E). Notably, the mutational
signatures between primary- and relapse-specific SNVs are majorily comparable among non-
hypermutated tumors, while there is a clear dominance of signature 11 in relapse, but not in
primary samples of hypermutated tumors. This signature has been associated with exposure
to alkylating agents (Alexandrov et al., 2013a), suggesting that the hypermutation genotype of
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Figure 2.8: Mutational burden in IDHWT glioblastomas. A Single nucleotide variants and small
insertions/deletions per tumor after correcting for germline mutations (red lines, median). B Like (A),
but distinguishing mutations shared between the samples of a tumor pair from private ones (red lines,
median). C Like (B), but relative proportions and sorted per tumor. D, E Mutational signatures among
mutations shared between the samples of a tumor pair (D) or among mutations present in the primary (E,
left panel) or the recurrent tumor (E, right panel) only. Shown are non-hypermutated tumors only. Data
are presented asmean± SEM. F Like (D, E), but for hypermutated tumors. Figure and legendmodified from
Körber et al., 2019. Whole genome sequencing: Yonghe Wu. Mutation calling and mutational signature
analysis: Jing Yang & Daniel Hübschmann.
these tumors developed under therapy.
In summary, primary and recurrent glioblastomas harbor comparable numbers and patterns
of somatic mutations, suggesting that there is little genetic evolution under therapy. Sole
exception are three tumors, which acquired a hypermutation genotype under temozolomide and
radiation therapy.
Patterns of driver mutations
The vast majority of mutations in cancer are likely passengers of no functional importance,
while only a minority drives malignancy. This raises the question, whether the pattern of driver
mutations changes between primary and recurrent tumors, despite their high similarity with
respect to the mutational burden and signatures overall. To address this question, we need
to distinguish passengers and drivers among the identified mutations. Clearly, direct evidence
for the functional impact of a mutation requires experimental proof. However, given the large
amount of mutations in cancer, we need to predict a mutation’s impact in a faster and cheaper
way. Therefore, we search for indirect evidence of driver mutations with statistical methods,
relying on the assumption that mutations are randomly acquired. If this holds true, neutral
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mutations should be evenly distributed along the genome, whereas clustering of mutations in
distinct genes is likely a footprint of selection. This approach works best with large cohorts as
the statistical power improves with the number of samples available. In the present study, we
have a limitied sample size of 21 tumor pairs and thus, in order to overcome the limitations of
our relatively small cohort, we build our set of candidate driver genes from three sources:
1. We use a list of genes that have been previously identified as likely drivers in glioblastoma.
This list has been curated by the online platform ‘intogen’ and encompasses 74 genes
(downloaded on January 24th, 2018 from www.intogen.org; Gonzalez-Perez et al., 2013).
In addition, we include mutations in the TERT promoter region as likely drivers (Barthel
et al., 2018).
2. We complement our candidate list with our own dataset, including genes in which
mutations are significantly overrepresented according to the computational framework
OncodriveFML (Mularoni et al., 2016). OncodriveFML divides the region of interest (in our
case the coding region; https://bitbucket.org/bbglab/oncodrivefml/downloads/) into short
intervals (in our case individual genes). For each interval, a functional impact score is
computed from the observed number of mutations, weighted by the specific base pair
substitution. In this way, OncodriveFML corrects for the overall frequency of specific
substitutions in the dataset. The algorithm then simulates the same number of mutations
per interval by randomly drawing individual substitutions and computes an empirical p-
value for the functional impact score per gene by comparing the observed and simulated
scores. We accept genes as putative drivers if padj ≤ 0.1, obtained by correcting the p-
values for multiple sampling with the Benjamini-Hochberg procedure. This adds another
five genes - ZNF835, CIC, FUBP1, NOTCH1 and ATM - to our driver gene list.
3. As the functional impact of mutations in non-coding regions is less well understood, we
conservatively accept non-coding RNAs as putative drivers if mutated in more than five
patients.
The most pervasively mutated driver genes in our dataset are PTEN, EGFR and CDKN2A
(Fig. 2.9A, B). These are primarily targeted by gain of chromosome 7 (including the EGFR locus),
loss of chromosome 9p (or focal deletion of the CDKN2A locus, predominantly homozygous) and
loss of chromosome 10 (predominantly hemizygous). In addition, EGFR is frequently targeted
by SNVs, high-level amplifications or structural variants (Fig. 2.9A). In seven primary and four
relapse tumors the active variant EGFRvIII is generated from deletion of exons 2-7 (Brennan
et al., 2013 and Fig. 2.9C). Similarly, hemizygous deletions of chromosome 10 frequently co-occur
with a small mutation on the second allele of PTEN. These observations agree with previous
reports of mutations in PTEN, EGFR and CDKN2A as likely drivers in glioblastoma (e.g., Brennan
et al., 2013). All three alterations may increase cell proliferation via activation of the AKT-
signaling pathway (by gain of function of EGFR and/or loss of function of PTEN ) or via cell-
cycle-checkpoint-inhibition (by loss of function of the CDKN2A transcripts p14/p16; The Cancer
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Genome Atlas Research Network et al., 2008; Wee and Wang, 2017; Fig. 2.10).
Mutations in non-coding RNAs (ncRNAs) are overall more case-specific and no ncRNA
stands out as being pervasively mutated among our cohort (Fig. 2.9A). By contrast, all but one
tumor harbor mutations in the TERT promoter region. These are predominantly one of two
‘canonical’ substitutions that have frequently been observed in glioblastoma and in cancer overall
(Barthel et al., 2018; Vinagre et al., 2013). Both mutations are G>A substitutions upstream of the
transcription start site, which generate an ETS transcription factor binding motif (Vinagre et al.,
2013). TERT promoter mutations have been associated with enhanced transcriptional activity
and improved cellular survival (Maciejowski and de Lange, 2017). Interestingly, the two tumors
without canonical TERT promoter mutations, harbor frame-shift mutations in ATRX (Fig. 2.9A),
which is associated with alternative telomere lengthening (Brosnan-Cashman et al., 2018). Our
data thus indicate that stabilization of cellular survival is a critical step in glioblastoma evolution.
In contrast to the prevalence of pervasive driver mutations that are shared between both
samples of a tumor pair, few driver mutations are recurrently acquired in the relapse tumor
(Fig. 2.9A). Moreover, primary and recurrent samples of a tumor pair harbor comparable numbers
of driver mutations if neglecting hypermutated cases. In the latter, the number of driver
mutations increases upon tumor recurrence; however, this does not necessarily reflect clonal
selection, as the mutation rate in these tumors is higher overall. This is corroborated by the
presence of mutations in the mismatch repair geneMSH6 in all hypermutated tumors, indicating
that these tumors have a defective DNA repair and are thus more likely to acquire driver
mutations by chance.
In summary, the spectrum of driver mutations in IDHWT-glioblastomas reveals a similar
pattern between primary and recurrent tumors. Mutations in PTEN, EGFR, CDKN2A and the
TERT promoter are the most frequent events and are typically present in both samples of a tumor
pair. By contrast, no stereotypical pattern of relapse-specific mutations becomes apparent.
2.3.4 Evolutionary history
To understand how clonal dynamics shape the mutational patterns in glioblastoma, we
complement our study with a phylogenetic analysis of the tumor pairs. Assuming that
glioblastomas grow from a single cell of origin, we attempt to infer which mutations lay at tumor
initiation and which were acquired later during tumor progression. As early and late mutations
will be found at clonal and subclonal levels, respectively, information on the temporal order of
mutations can be obtained from the tissue fraction in which a mutation is present. Although
we cannot directly measure tissue fractions with bulk sequencing, we can estimate them from
the combined information of the measured VAFs and the coverage ratios at each SNV and small
insertion/deletion (indel). Both metrics are readily available from the sequencing read count
distribution at mutated loci.
To get an idea about the extent of subclonality in our dataset, we will start with a simple
analysis, in which we compare the VAFs in primary and relapse samples at loci with normal
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Figure 2.9 (previous page): Driver mutations in IDHWT glioblastomas. A Mutational spectrum in
candidate driver genes. Coding genes are shown if targeted by a structural variant, SNV, small indel,
homozygous deletion or a high-level amplification in at least two patients, excluding hypermutated
samples. Mutations in MSH6 are shown due to their correlation with a hypermutation genotype. Non-
coding genes are shown if targeted by an SNV or a small indel in more than five patients. TERT promoter
mutations are shown at the bottom. Tumor samples are displayed in pairs (left, primary tumor; right,
recurrent tumor). Different types of mutations and methylation subtypes (bottom legend) are marked by
different colors. B Chromosomal gains and losses in primary (left) and recurrent glioblastomas (right).
C Structural variants in primary and relapse tumors. Intra-chromosomal variants are shown if targeting
a driver gene. Translocation partners of inter-chromosomal variants are highlighted if targeting a gene
or the vicinity of a super-enhancer (based on dbSUPER; Khan and Zhang, 2015). Numbers in brackets
indicate the number of recurrences of a structural variant (tr., inter-chromosomal translocation; ic., intra-
chromosomal variant). Figure and legend modified from Körber et al., 2019; whole genome sequencing:
Yonghe Wu; mutation calling and oncoprint: Jing Yang.
copy numbers. To this end, we first need to correct the measured VAFs for tumor cell content.
There are basically two ways to estimate the tumor cell content from whole genome sequencing
data. The first one looks at the clonal peak of the measured VAF histogram. In a pure sample of a
diploid tumor, the VAFs at heterozygous mutations are expected to peak at approximately 0.5. If
the sample is contaminated with normal tissue, the peak is shifted towards smaller VAFs. Thus
the extent of contamination with normal tissue can be estimated from the position of the clonal
VAF peak if disregarding mutations in regions with aberrant copy number (Fig. 2.11A). In an
alternative approach, the tumor cell content is estimated from the ratio between the measured
coverage in distinct genomic intervals, and the overall genomic coverage in the tumor. This
method relies on the assumption that most copy number changes are clonal and jointly adjusts
the tumor ploidy and the tumor cell content until the measured coverage ratios can be explained
by integral copy number changes (implemented e.g. in ACEseq, ‘allele-specific copy number
estimation from whole genome sequencing’; Kleinheinz et al., 2017). The phylogenetic inference
algorithm introduced in Section 2.2 combines elements from both methods, but loosens the
assumption that most copy number changes are clonal by accounting for subclonal copy number
changes also. In the following, we will use the tumor cell content estimates obtained with this
approach, but we will see later on that these estimates correlate well with the estimates based
on ACEseq.
With an estimate of the tumor cell content, ρ, at hand, we now correct the number of
sequencing reads originating from the tumor to r total,corrected = r total × ρ. Obviously, the
mutated read counts, rmut are not affected by this correction as we are considering tumor-specific
mutations only (assessed by comparison with a blood control). The corrected VAF then reads
VAFcorrected =
rmut
r total,corrected and can be used to assess whether a mutation was subclonal. To do this,
we rely on the simple assumption that the measured readcounts can be modeled by binomial
sampling (c.f. Fig. 2.6A-C). If a mutation is clonal, its true VAF is 0.5 (after correction for tumor
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Figure 2.10: Key driver mutations in IDHWT glioblastoma. A Signaling through the epidermal growth
factor receptor (EGFR) signaling pathway is frequently aberrant in glioblastoma. Ligand binding to the
receptor tyrosine kinase EGFR initiates signaling through receptor dimerization and autophosphorylation.
EGFR signaling promotes cell proliferation and inhibits cell death via cascade-activation of PI3K, AKT and
mTOR. EGFR signaling is frequently upregulated in glioblastoma either due to receptor overexpression
or due to activating mutations in EGFR, often in combination with loss-of-function mutations in its
antagonising phosphatase PTEN. Illustration based on Fig. 1 in Mellinghoff et al., 2007. B Cell cycle
progression by CDKN2A deletion. CDKN2A, frequently deleted in glioblastoma, encodes two tumor
suppressor proteins, p14 and p16. p16 inhibits G1/S-transition via activation of the E2F-inhibitor Rb, while
p14 inhibits G2/M-transition via activation of the CDK1-CyclinA/B-complex-inhibitor p53. Illustration
based on Fig. 1 in Al-Kaabi et al., 2014.
cell content) and the measured VAFs should vary around it. To detect clonal mutations at a 5%
false negative rate, we thus require
P (X ≤ rmut) =
rmut∑
k=0
(
r total,corrected
rmut
)
(0.5 · ρ)rmut (1 − 0.5 · ρ)r total,corrected−rmut < 0.05. (2.29)
If excluding hypermutated samples, 73% of all mutations are classified as subclonal in at least
one sample of a tumor pair, indicating that the majority of mutations in a tumor are subclonal
(Fig. 2.12A). Notably, the assessment of subclonality improves with a second tumor sample, as
17% of the mutations would have been erroneously classified as clonal if measuring the primary
sample only (Fig. 2.12, orange dots). Since, however, a transition from clonality to subclonality
violates a monoclonal tumor origin, these mutations must have been subclonal already in the
primary tumor, but were classified as clonal due to undersampling of the tumor (Fig. 2.12B).
Thus, we estimate the false positive rate of clonal mutations due to incomplete tumor sampling
to
P (subclonal in tumor|clonal in tumor sample) = ncPsR
ncPsR + ncPcR
= 39%, (2.30)
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Figure 2.11: Tumor cell content estimation with whole genome sequencing. A The tumor cell content is
estimated by adjusting the theoretical distribution of the clonal VAF peak to the measured data (grey line,
binomial distribution if sampling from n=150 with success probability 0.5; red line, binomial distribution
if sampling from n=150 with success probability 0.39). The measured VAF distribution shown exemplarily
here is taken from the primary tumor sample of Fig. 2.13K. B The tumor cell content is estimated by
adjusting the expected coverage ratios at integral copy number changes to the measured coverage ratio
(grey lines, expected coverage ratios at the indicated copy number changes in samples with 100% tumor
cell content; red lines, expected coverage ratios at the indicated copy number changes in samples with
50% tumor cell content; points, measured ratios).
where ncPsR is the number of mutations classified as clonal in the primary and subclonal in
the recurrent sample, and ncPcR is the number of mutations classified as clonal in both samples.
The high fraction of false positive clonal mutations emphasizes the advantage of multiple tumor
samples to reliably identify subclonal mutations.
In order to analyze subclonality in more detail, we next employ the phylogenetic inference
algorithm introduced in Section 2.2 and estimate the subclonal composition along with the
underlying phylogenetic structure in the primary/relapsed tumor pairs of our dataset5. To briefly
recapitulate the basic principle of the inference algorithm, Fig. 2.13A illustrates how SNVs and
small indels are sorted to specific positions on the phylogenetic tree based on the measured
sequencing read count distribution. In the example shown, most mutations are heterozygous
and map to the trunk of the phylogenetic tree. Two separate sets of mutations are present in
either of the two subclones only and map to the branches of the tree. In few cases, the copy
number deviates from two and therefore shifts the fraction of mutated alleles away from 0.5.
Applied to our dataset, the algorithm typically recovers two to three subclones per tumor
sample, of which one dominates the sample in size (Fig. 2.13B, C and Fig. A.1,A.2). Inherent
estimates of the tumor cell content from phylogenetic inference correlate well with estimates
by ACEseq (Pearson’s r = 0.95, Fig. 2.13D), and indicate a high sample purity for most tumors
(median tumor cell content of 0.8 in primary and 0.78 in relapse samples, respectively, Fig. 2.13E).
5The fits were performed on 500 mutated loci (including coding mutations and filled up by randomly chosen
non-coding mutations). Subsequently, all mutations were mapped on the inferred phylogenetic structure. In order
to identify large gains and losses and to adjust the solution in the case of inference problems (due to high level
amplifications or homozygous deletions) the fitting results were manually inspected.
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Figure 2.12: Variant allele frequencies measured in non-hypermutated samples. A Variant allele
frequencies of all non-hypermutated tumors, classified as clonal or subclonal according to Eqn. 2.29
(shown VAFs are corrected for tumor cell content; mutations in regions with a copy number change were
excluded. 10,000 sampled data points are shown for better visualization, whereas the indicated fractions
were computed from the entire dataset). Figure modified from Körber et al., 2019; variant calling and
copy number analysis: Jing Yang. B Incomplete tumor sampling may result in erroneous classification of
mutations as clonal.
Three exemplary trees are visualized in Fig. 2.13G-I, according to the display format outlined
in Fig. 2.13F (the inferred phylogenies of the remaining tumors are shown in Fig. 2.13K-B1).
The tumor of Fig. 2.13G lost one allele of chromosome 10 and, on the second allele, captured a
mutation in PTEN at tumor initiation. Additional driver mutations — gain of chromosome 7
and a canonical TERT promoter mutation — were acquired at subclonal levels. The relapse
tumor re-grew from both branches of the primary tumor and acquired additional putative driver
mutations in FAT1 and the noncoding RNAs KCNQ1OT1 and LINC00343. Notably, LINC00343 was
independently mutated in both branches of the relapse tumor, indicating convergent evolution.
Fig. 2.13H shows an example where no additional driver mutations were acquired upon
primary resection. This tumor, like the previous example, lost one allele of chromosome 10 in the
common trunk. However, the cell of origin accumulated many more driver mutations prior to
initial branching. These comprise additional copy number changes (gain of chromosome 7 and
loss of chromosome 9p), a small mutation in EGFR and, notably, a canonical TERT promoter
mutation. Thus TERT promoter mutations can be found at clonal or subclonal levels in
glioblastoma.
In contrast to an oligoclonal relapse origin as discussed so far, we also find one case in which
the relapse tumor re-grew from a single branch of the primary tumor (Fig. 2.13I). In this example,
the mutational distance between the two ancestor populations of primary and relapse tumor is
rather long and several new driver mutations are acquired in the recurrent tumor. Like in the
other two examples, we find copy number alterations at tumor initiation (gain of chromosome 7
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and loss of chromosome 9) along with small mutations in PTEN, the ncRNA KCNQ1OT1 and the
TERT promoter.
Note that all three examples harbor specific copy number alterations (gain of chromosome 7
and loss of chromosome 9p/10) at tumor initiation, and a TERT promoter mutation at an early
or an intermediate stage of tumorigenesis. Moreover, the three examples indicate that tumors
can re-grow from a single, or frommultiple subclones upon primary resection. To judge whether
these differences and commonalities hold true for the entire dataset, we next compare keymetrics
between all tumor phylogenies.
First, in order to analyze the structural origin of relapse tumors, we measure the mutational
distance between the most recent common ancestor (MRCA) of the primary and the recurrent
tumor, respectively. In case of an oligoclonal relapse-origin (as observed in Fig. 2.13G and H), the
MRCAs of both tumors fall together. By contrast, the twoMRCAs are distinct if the relapse tumor
re-grows from a monoclonal origin (compare Fig. 2.13I). Summarized over the entire dataset, we
find that most relapse tumors re-grew frommultiple branches of the primary tumor, reflected in a
short mutational distance between the two MRCAs (Fig. 2.14A). Our data therefore indicate that
selective re-growth of a specific subclone upon standard treatment is rare in glioblastoma. Rather,
relapsing glioblastomas typically re-grow from the intratumoral heterogeneity established prior
to primary resection.
Second, in order to identify potential commonalities at tumor initiation, we compare clonal
driver mutations between individual tumors. In all but one tumor, we find at least one of
three distinct chromosomal changes clonally (gain of chromosome 7, loss of chromosome 9p,
including the CDKN2A locus and loss of chromosome 10), indicating that large chromosomal
gains and losses on these chromosomes might be tumor initiating events (Fig. 2.14B). The single
tumor without any clonal chromosomal alteration captured a clonal mutation in PTEN before
acquiring a gain of chromosome 7 and a loss of chromosome 9p subclonally (Fig. 2.13T), which
may either reflect an alternative path to tumorigenesis or be an artefactual observation due to
an inference error. In contrast to pervasive copy number changes at tumor initiation, single
nucleotide variants and small indels are often found at subclonal levels, suggesting that small
mutations in driver genes may be later events in glioblastoma (Fig. 2.14C). Interestingly, TERT
promoter mutations, though being found in all but one of the tumor samples, are placed at a
subclonal level in at least one third of our dataset and hence might be dispensable at tumor
initiation, but selected for at a later stage in tumorigenesis.
In summary, our dataset reveals a common path of early tumorigenesis in glioblastoma that
is characterized by pervasive copy number changes on chromosome 7 (gain), 9 and 10 (losses).
By contrast, TERT promoter mutations are found at an early to intermediate stage, reflected in
frequent subclonality of these mutations. Finally, we find that relapse tumors typically re-grow
from an oligoclonal origin with little addition of new driver mutations. Relapsing glioblastomas
hence primarily mirror the heterogeneity already established in the primary tumor, and thus
there is little evidence for selective pressure exerted by standard therapy (Fig. 2.14D).
48
2.3. Evolutionary trajectories of IDH-wildtype glioblastomas
G I
A
M
ut
at
ed
 lo
ci
% Read counts Cell fraction
C
B
*   
0
# M
utations
Reference Mutated
B C
0 100 0.0 1.0
*
*
*
*
*
CNVs
A: MRCA,
most recent
common
ancestor
Subclone C
Subclone B
Subclone B
Subclone C
Normal tissue
Reference   Mutated    
A
Primary tumor
Relapse tumor
Common stem with clonal mutations
Common ancestors
of individual primary 
and relapse subclones
Subclonal mutations 
originating in primary tumor
Subclonal mutations found 
only in relapse tumor 
MRCA of all primary 
and relapse
subclones 
0
# 
M
ut
at
ion
s
12506
3649
LINC00689
TSIX
PTPN11
ZNF835
TERT promoter
KCNQ1OT1
PTEN (indel)
FZD10-AS1
# Subclones
Tu
m
or
s
0.0
0.5
1.0
Subclone index
Re
lat
ive
 si
ze
F
MRCA of primary 
subclones 
MRCA of
relapse subclones 
BRAF
TSIX FAT1
KCNQ1OT1
LINC00343*
LINC00343
TERT promoter
Chr 7 gain
PTEN
Chr 10 loss 
0
# 
M
ut
at
ion
s
6584
1774
TSIX
Chr 10 loss
H Chr 7 gain
Chr 9p loss 
B C Normal
Raw reads Subclonal structure Phylogenetic tree
0
# 
M
ut
at
ion
s
7351
5518
RP3-399L15.3
TJP1
AC108142.1
1 2 3
0
10
20 Primary
Relapse
1 2 3
Primary
Relapse
EGFR
TERT promoter
Chr10 loss
Chr9p loss
(incl. CDKN2A)
Chr7 gain (complex)
0.0
1.0
Primary Relapse
0.0 0.5 1.0
Phylogenetic inference
0.0
0.5
1.0
Ac
es
eq
CC=0.95
D
E
Tu
m
or
 ce
ll c
on
te
nt
KCNQ1OT1
RP3−399L15
Figure 2.13: Phylogenetic inference. A Overview of the inference algorithm. Read count fractions at
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Caption continues on page 51.
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Figure 2.13 (continued): B Number of inferred subclones and C, corresponding relative sizes of the 21
tumor pairs analyzed. D Comparison of the estimated tumor cell content to the estimate based on ACEseq
(performed by Jing Yang; CC, Pearson’s correlation coefficient). E Estimated tumor cell content in primary
and recurrent samples (red lines denote medians). F Display format for the phylogenetic trees. Primary
subclones are colored in yellow, recurrent subclones in orange (circle areas scale with their relative sizes).
Vertical branch lengths (green, relapse-specific branches; blue, common trunk) scale with the number
of mutations. G-I Three examples of phylogenetic trees with an oligoclonal relapse origin (G, H) and a
monoclonal origin (I; trees are designed as outlined in (F)). Putative driver mutations are indicated at their
respective positions in the phylogenetic tree (asterisk marks convergent evolution). If mutations could
not be unambiguously placed on the phylogenetic tree as clonal or subclonal, they were conservatively
counted as clonal if the probability to place them in the tumor stem was >10%. K-B2 Phylogenetic trees
of the remaining tumors of the dataset (T-W, hypermutated cases; here only the clonal driver mutations
are shown). Figure and legend modified from Körber et al., 2019; whole genome sequencing: Yonghe Wu;
bioinformatic pre-processing: Jing Yang.
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Figure 2.14: Phylogenetic metrics of the 21 glioblastoma pairs. A Origin of the recurrent tumor relative
to the origin of the primary tumor. The distance between the most recent common ancestors (MRCA)
of primary and recurrent samples is measured in mutation counts and provided as a measure for tumor
origin. B Number of tumors with a clonal and subclonal copy number change on chromosome 7, 9 and 10.
Number of tumors harboring at least one of the indicated copy number changes are displayed in darkred (if
at least one change is clonal) or white (if none of the changes is clonal) on the leftmost side. C Number of
tumors with a clonal and subclonal mutation (SNV or indel) in driver genes that were clonal in at least one
tumor. Number of tumors harboring at least one of indicated mutations are displayed in darkred (if at least
one change is clonal) or white (if none of the changes is clonal) on the leftmost side. If mutations could
not be unambiguously placed on the phylogenetic tree as clonal or subclonal, they were conservatively
counted as clonal if the probability to place them in the tumor stem was >10%. D Consensus tree over all
sample pairs. Branch widths and font sizes scale with the number of cases supporting a connection and
mutation, respectively. The median number of clonal mutations and the median of the maximal number of
mutations per subclone are indicated for primary and recurrent tumors. Driver mutations are indicated at
particular tree branches [clonal, subclonal, present in primary or recurrence only] if they are found there
in at least two tumors and are frequent overall [present at any position in at least three (coding genes)
or five (non-coding genes) among non-hypermutated tumors.] Figure and legend modified from Körber
et al., 2019; whole genome sequencing: Yonghe Wu; bioinformatic pre-processing: Jing Yang.
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2.3.5 Dynamics of tumor growth
Phylogenetic inference can be coupled with population dynamics models to analyze tumor
growth behaviour beyond the ordering of mutations to different stages of tumorigenesis. In a
simplistic view, the evolutionary dynamics during tumor growth are determined by two major
processes, proliferation and mutation (Fig. 2.15A). As most mutations are acquired during cell
divisions, and as mutations in driver genes affect proliferation, the two processes are mutually
dependent. Nevertheless, if we assume (i) that the mutation rate is constant over time and (ii) that
cells divide at a constant rate during tumorigenesis, single cells accumulate mutations according
to a Poisson process and the number of mutations per cell thus serves as amitotic clock. Denoting
the division rate with λ and the mutation rate per cell division with µ, the average number of
mutations per single cell,m(t ), reads
m(t ) = µλt . (2.31)
Accordingly, the time it takes to accumulate mˆ mutations in a single cell is
T (mˆ) =
mˆ
µλ
. (2.32)
On the other hand, the number of effective cell divisions, i.e., the number of divisions leading
to two surviving daughter cells, can be estimated from the number of tumor cells at resection.
Assuming that tumors grow exponentially from a single founder cell, the number of tumor cells
at time t , N (t ), is given by
N (t ) = eλ(1−
δ
λ )t , N (0) = 1, λ > δ , (2.33)
where λ and δ denote the cellular division and death rate, respectively. We solve again for the
time it takes to grow the tumor to a known number of cells, Nˆ :
T (Nˆ ) =
log(Nˆ )
λ
(
1 − δλ
) . (2.34)
At given estimates ofm, N and µ, we now compute the ratio between cellular death and division
rates, δ˜ = δλ :
T (mˆ)
!
= T (Nˆ ) (2.35)
δ˜ = 1 − µ
mˆ
log Nˆ . (2.36)
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From the median mutation count between the MRCA of the tumor and the founder cells of
primary subclones in the phylogenetic trees, we estimate that a single tumor cell acquired at
least mˆ = 2300 mutations during tumorigenesis (Fig. 2.15B, C, excluding hypermutated cases).
Note that this is a conservative estimate, as (i) tumor initiation might have started prior to
the MRCA and (ii) the resolution of WGS is limited, so that most likely more mutations will
be present in a single cell. Moreover, we estimate the number of tumor cells at resection to
109 cells, as previously suggested for the number of tumor cells per cubic centimeter (Del Monte,
2009; Devita Jr et al., 1975). This number agrees with a brain tumor size in the order of 20 —
80 cm3 (Goldberg-Zimring et al., 2005) and 1012 glia cells in a brain of 1500 cm3 (Drachman, 2005;
Herculano-Houzel et al., 2006; Milo et al., 2010; Pakkenberg and Gundersen, 1997). Finally, we
take the somatic mutation rate as (2.6 − 10.6) × 10−9 mutations per base pair and cell division
and account for 3.3 × 109 basepairs in the human genome. The lower bound of the mutation
rate was estimated by Milholland et al., 2017, who measured mutation accumulation in single
cell expansions; the upper bound accounts for a putative four-fold increase in the mutation rate
during tumorigenesis, since the contribution of the clock-like mutational signature 1 drops from
75% among clonal mutations to 15% among tip-specific mutation (Fig. 2.15D). At these estimates,
tumor size and mutational burden are only reconciled if the progeny generated by 69-92% of the
cell divisions eventually died (Fig. 2.15E, F). Our data thus indicate that glioblastoma growth is
accompanied by extensive cell death.
Survival advantage by TERT promoter mutations
The notion that most cell divisions during glioblastomas growth are unsuccessful emphasizes the
need for survival-stabilizing mutations during tumorigenesis. In our dataset we observed that
the vast majority of all tumors (19/21) acquired a ‘canonical’ TERT promoter mutation, which
is associated with improved cellular survival via telomere elongation (Chiba et al., 2017). The
remaining tumors had frameshift mutations in ATRX, associated with alternative lengthening of
telomeres (Amorim et al., 2016). Together, this suggests a large selective advantage of survival-
stabilizing mutations during glioblastoma growth. Moreover, as typically at least one pro-
proliferative mutation (gain of EGFR, loss of PTEN and loss of CDKN2A) was clonal, whereas
TERT promoter mutations were subclonal in a sizeable fraction of the dataset (≥ 1/3 of all
tumors), the former presumably precedes the latter. To test this idea, we first confirm whether
the inferred subclonality of TERT promoter mutations is a robust result. To do this, we compare
the measured VAFs of the TERT promoter mutations to germline variants at loci with comparable
sequencing coverage (median 123x and interquartile range [106, 140]) as a positive control for
clonality. As discussed in Section 2.3.4, the measured VAFs must be corrected for normal tissue
infiltration prior to analysis and hence, errors in the estimation of the tumor cell content are a
major source for erroneous classificiation of a mutation as subclonal. Thus, in order to gain
confidence in our estimate, we bootstrap the tumor cell content from the two independent
estimates obtained with ACEseq and with phylogenetic inference, and compute the corrected
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Figure 2.15: Dynamics of tumor growth and mutation accumulation. A Model illustration (stars,
mutations; different colors, genetic subclones). B Estimation of the mutational burden per single cell
from phylogenetic inference. A single tumor cell accumulates M2 mutations during tumor growth. The
number of mutations already present in the founder cell of the tumor, M1, is not accessible, but can be
conservatively estimated with the number of clonal mutations, Mc . With this, M2 can be estimated to
M −Mc . C Mean mutation count per primary subclone after initial branching, corresponding to M −Mc
in (B) (red line, median); hypermutated tumors are excluded. D Contribution of the clock-like mutational
signature 1 to clonal mutations and to mutations present in the tips of the phylogenetic trees (excluding
hypermutated tumors). E Extent of cell death (cellular death rate relative to cell division rate) required to
reconcile subclonal mutation counts with a tumor size of 109 cells (red line, median number of subclonal
mutations inferred from the data; shaded area, inter-quartile range). F Schematic illustration of the
interplay between cell divisions, death and mutation accumulation. The number of tumor cells scales
logarithmically with the number of cell divisions, while the number of cell divisions scales linearly with
the number of mutations per cell. The slope of the growth curve decreases with the extent of cell death
during growth and can be estimated from the combined information on the mutational burden and the
tumor size. Figure and legend modified from Körber et al., 2019; whole genome sequencing: Yonghe Wu;
bioinformatic pre-processing & mutational signature analysis: Jing Yang.
VAFs with the respective estimate. As shown in Fig. 2.16A the subclonal shoulder of the TERT
promoter-mutant VAF distribution is robustly inferred independent of the respective tumor cell
content estimate. This allows us to extend our model of glioblastoma growth to a two-step model
of tumorigenesis (Fig. 2.16B). In a first step, cells divide at rates that are only marginally larger
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than the death rate, meaning that cellular turnover is high. The growth law for this phase reads
in accordance with Eqn. 2.3.5 (and re-scaling λ to 1)
NT ERTWT (t ) = e
(1−δ˜0)t . (2.37)
TERT promotermutations can be acquired at each cell division at fixed probabilities according
to the single-basepair substitution rate, µ, and improve cellular survival, hence reaching clonal
dominance over time. The growth law for the number of cells in the tumor carrying the TERT
promoter mutation is consequently given by
NT ERT ∗ (t ) =
⎧⎪⎪⎨⎪⎪⎩
0 t < T0,T ERT ∗
e (1−δ˜T ERT ∗ ) (t−T0,T ERT ∗ ) t ≥ T0,T ERT ∗
, (2.38)
whereT0,T ERT ∗ denotes the time point at which the mutation is acquired in a single founder cell.
The probability for at least one ‘canonical’ TERT promoter mutation, P (TERT ∗), increases with
the number of division in the system, ndiv, and thus reads
P (TERT ∗) = 1 − (1 − 2µ )ndiv , (2.39)
where the scaling factor of two accounts for the two canonical TERT promoter mutations
recurrently observed in glioblastoma (chr5, 1,295,228 C>T and 1,295,250 C>T). As the number
of cell divisions per time unit scales with the population size, we can express the total number
of divisions in the system, ndiv ,as a function of time:
n˙div = λN (t ) (2.40)
ndiv =
1
1 − δ˜0
(
e (1−δ˜0)t − 1
)
. (2.41)
Inserting Eqn. 2.41 in Eqn. 2.39 then yields the probability distribution of at least one TERT
promoter mutation at time point t .
In order to assess the selective advantage provided by TERT promoter mutations, we now
need to compare the predicted distribution of the TERT promoter-mutant tumor fraction with
the observed fraction in our dataset. To do this, we employ semi-stochastic simulations of the
two-step model of glioblastoma evolution, scanning the parameter space over δ˜0 and δ˜T ERT ∗ and
requiring δ˜0 ≥ δ˜T ERT ∗ (thus assuring that the TERT promoter mutation decreases cellular death).
At each value of δ˜0, we sample 1000 instances of the time point at which the TERT promoter
mutation is acquired according to Eqn. 2.39. For each instance, we simulate the number of tumor
cells with and without TERT promoter mutation according to Eqns. 2.37 and 2.38, and abort
the simulation once the total tumor cell count equals 109 cells. We then compare the mean
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and variance of the TERT promoter-mutant tumor fraction to their observed counterparts by
computing the sum of the weighted squared residuals:
RSS =
f¯ − f¯ obs
σ 2
f¯ obs
+
Var( f ) − Var( f obs)
σ 2Var(f obs)
, (2.42)
f =
NT ERT ∗ (tres)
NT ERT ∗ (tres) + NT ERTWT (tres)
, (2.43)
where f and f obs denote the simulated and observed TERT promoter-mutant tumor fraction at
the time point of resection, tres, respectively. The standard deviation of the mean and variance
of f obs (σf¯ obs and σVar(f obs) , respectively) is assessed by bootstrapping the measured data 10,000
times. The best fit corresponds to the parameter combination that minimizes Eqn. 2.42. Fits with
an RSS ≤ RSSmin + 5.99 lie within the 95% confidence interval of the best fit, according to a
Chi-squared distribution with two degrees of freedom.
As illustrated in Fig. 2.16C, D, the exact parameter combination is not identifiable from our
data, but rather we obtain good fits for δ0 ≥ 0.87 at both normal and four-fold elevated mutation
rates. However, since we estimated that on average 69% - 92% of the cell divisions fail to produce
two surviving daughter cells (four-fold elevated and normal mutation rate, respectively; see
Section 2.3.5), and since two thirds of all tumors harbor the TERT promoter mutation clonally,
we require δ˜T ERT ∗ ≥ 0.92 at normal mutation rates and δ˜T ERT ∗ ≥ 0.69 at elevated mutation rates
(corresponding to the black lines in Fig. 2.16C, D). With this we infer that the TERT promoter
mutation reduces cell death by 6 to 26% (Fig. 2.16E), which translates to an increase in the effective
division rate by a factor of four to five,
normal mutation rate: 1 − δ˜T ERT ∗
1 − δ˜0
=
1 − 0.92
1 − 0.98 ≈ 4,
four-fold elevated mutation rate: 1 − δ˜T ERT ∗
1 − δ˜0
=
1 − 0.69
1 − 0.942 ≈ 5,
suggesting that TERT promotermutations speed up the dynamics of tumor growth tremendously.
In this view, they will eventually reach clonality in all tumors but may still be subclonal at clinical
detection.
Finally, we define the selective advantage associated with tumor cells before and after the
TERT promoter mutation, s0 and sT ERT ∗ , as the factor by which the decision between division
and death is biased towards division (Bozic et al., 2016):
δ˜0
λ + δ˜0
=
1
2 (1 − s0) (2.44)
δ˜T ERT ∗
λ + δ˜T ERT ∗
=
1
2 (1 − s0) (1 − sT ERT ∗ ). (2.45)
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Solving for s0 and sT ERT ∗ and setting λ = 1, as before, yields
s0 = 1 − 2 δ˜0
1 + δ˜0
, (2.46)
sT ERT ∗ = 1 − δ˜T ERT ∗
1 + δ˜T ERT ∗
1 + δ˜0
δ˜0
. (2.47)
According to this definition, our estimated rates of δ˜0 and δ˜T ERT ∗ suggest that TERT promoter
mutations provide a selective advantage of 0.03 - 0.16. This is very large in comparison to the
average selective advantage of driver mutations of 0.004 (Bozic et al., 2016).
Tumor age
Our estimates of the cellular death rates relative to cell division rates during glioblastoma growth
are informative on the total number of cell divisions during tumorigenesis. Finally, we attempt to
link these estimates to real time, using the time span between primary and secondary resection
to roughly estimate the cell division rate. To this end, we take the difference between the
maximal number of mutations accumulated in primary and relapse subclones, respectively, as
a proxy for the number of mutations which a single cell accumulated between the two surgeries.
Excluding hypermutated tumors and six cases in which the difference was negative, we estimate
a median of 1600 mutations and an inter-quartile range of [1000, 5400] mutations that a single
cell accumulated between the two surgeries. Dividing these numbers by the mutation rate and
the time span between the surgeries yields an estimate of the division rate in real time. We
obtain a median of 0.17 d−1 and an inter-quartile range of [0.08, 0.23] d−1 if, as before, a four-fold
increased mutation rate of 4 × 0.27 × 10−9 is assumed at tumor resection. Thus, at the lower
bound, tumor cells divide approximately once in ten days. Assuming a relative cell death rate of
0.69 ≤ λδ ≤ 0.92 and a tumor size of 109 cells, as before, we estimate an upper bound of two to
seven years of glioblastoma growth by solving
e (λ−δ )t != 109. (2.48)
Thus our data suggest that IDHWT glioblastomas evolve for several years before being clinically
detected.
2.4 Discussion
The prognosis for patients with IDHWT glioblastoma is exceptionally poor and has been
unimproved for years. As most patients succumb to the rapidly relapsing tumor within a few
months to years after diagnosis, an improved understanding of the clonal dynamics underlying
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Figure 2.16: Selective advantage by ‘canonical’ TERT promoter mutations. A Variant allele frequencies
(VAFs) of TERT promoter mutations after correction for tumor cell content (mean and 95% confidence
interval of the kernel density estimate after sampling the tumor cell contents 10,000 times from the
estimates from phylogenetic inference and ACEseq; tumors with non-neutral copy number at the TERT
promoter were excluded) and of germline mutations from loci with read coverage within the inter-
quartile-range of the coverage at the TERT promoter (IQR=[106,140], down-sampled to 1,000 loci for
better visualization). B Two-step model of tumorigenesis with an initial phase of rapid turnover and
reduced cellular death after random acquisition of the TERT promoter mutation. C, D Residual sum of
squares when comparing themean and variance ofmeasured and simulated TERT promoter-mutant tumor
fractions at different values of δ˜0 and δ˜T ERT ∗ (grey dashed lines, bisetrices). For each point the simulated
mean and variance of 1000 simulations were compared to the measurement. Shown are the results for
the somatic mutation rate (C) and the four-fold somatic mutation rate (D). Estimates lying within the
95% confidence interval of the best fit are shaded in dark red. Horizontal black lines mark the minimal
cell death rate (relative to cell divisions), required to reconcile tumor sizes of 109 cells with mutation
accumulation during glioblastoma growth (c.f. Fig. 2.15). E Measured (black) and simulated (red) TERT
promoter mutant tumor fractions at the best-fit parameters. Figure and legendmodified from Körber et al.,
2019; whole genome sequencing: Yonghe Wu; bioinformatic pre-processing: Jing Yang.
glioblastoma growth and recurrence is needed to guide the development of novel treatment
approaches. The objective of this work was therefore to characterize the genomic evolution
of IDHWT glioblastomas before and after standard therapy. To this end, a likelihood-based
multinomial model for phylogenetic reconstruction from deep whole genome sequencing data
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resection, ∆T , and the number of mutations acquired during this time span, ∆M . Note that ∆M measures
the number of mutations acquired in a single cell.
was developed and applied to primary and relapse sample pairs from 21 glioblastoma patients.
This revealed a common path of early tumorigenesis and case specific tumor recurrence from
an oligoclonal origin. Moreover, coupling mutation counts and tumor size with population
dynamics models allowed an estimation of the tumor age and a characterization of the clonal
dynamics during glioblastoma evolution.
In Section 2.2, we developed a likelihood-basedmultinomialmodel for phylogenetic inference
from whole genome sequencing data. The model attempts to infer major subclonal branchings
from the combined information of variant allele frequencies and coverage ratios at SNVs and
small indels. In contrast to most existing frameworks for phylogenetic inference (e.g., Deshwar
et al., 2015; Oesper et al., 2013; Roth et al., 2014), the here introduced model accounts for
both subclonality of SNVs and CNVs without prior information other than the readcounts and
the coverage ratios. This provides a high level of control over the assumptions flowing into
phylogenetic inference, as no additional computational tools are required to run the anaylsis.
Trained and evaluated on simulated data and a cell line mixture experiment, the strenghts
and weaknesses of this approach become apparent. The power of the methodology lies in
the inference of major subclonal branching, reliable estimation of the tumor cell content and
solid identification of clonal mutations, without prior assumptions on the growth behaviour of
the tumor. The performance improves with the subclonal size and the number of mutations
supporting a subclone, whereas subclones that are characterized by few mutations are likely
missed, as our model selection criterion favours parsimonious solutions. Likewise, mutations
with small VAFs cannot be unambiguously assigned to subclones. This is due to the very
nature of bulk whole genome sequencing, as mutual information between two variants is
lost when shearing the DNA into short pieces. Therefore, accurate resolution of very small
subclones cannot be achieved by bulk sequencing and requires a single cell sequencing approach.
Nevertheless, most fine-grained subclonal diversification is due to neutral mutations that are
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of no interest for the current project, in which we primarily ask how major drivers shape the
evolutionary trajectory of a tumor and how this trajectory is affected by standard therapy.
Thus phylogenetic inference from bulk whole genome sequencing data with the here presented
likelihood-based model provides the resolution required for our purpose.
In Section 2.3, we applied the inference algorithm to deep whole genome sequencing data
from 21 pairs of primary and relapsed glioblastomas and typically found that (locally) re-growing
tumors recover the genetic heterogeneity of the primary tumor. This was reflected in an
oligoclonal origin of the recurrent tumor and little acquisition of driver mutations upon primary
resection, contrasting with two previous studies that suggested highly branched evolution
between primary and relapsed glioblastomas (Kim et al., 2015; Wang et al., 2016). The different
conclusions drawn by these studies might be partially due to the characteristics of the patient
cohort, as Kim et al. linked branched evolution to a distant tumor relapse, whereas our cohort
was biased towards locally re-growing tumors (95%). Moreover, apparent subclonal branching
between primary and recurrent tumors may in fact represent two subsamples of the same
subclone that differ solely by neutral mutations, consistent with the idea of predominantly
"neutral tumor evolution across cancer types" (Williams et al., 2016). Nevertheless, proof or
disproof for selection under standard therapy is difficult as, in theory, each tumor may find its
own way of adaptation. If this is the case, common trajectories of mutations associated with
resistance to treatment will become apparent in very large datasets only. Overall, however, such
a scenario is unlikely as most mutations are of little functional relevance (Bozic et al., 2016).
Moreover, our observation that tumors typically re-grow from all branches of the primary tumor
argues against directed selection under therapy.
In contrast to a paucity of driver mutations that were recurrently acquired after primary
resection, we found highly recurrent driver mutations at tumor initiation; all but one tumor
pair harbored gains of chromosome 7 or losses of chromosome 9p or 10 clonally, suggesting
that these alterations might be tumor initiating events. This finding is supported by the high
prevalence of these copy number changes among glioblastomas overall (Brennan et al., 2013;
Gerstung et al., 2017) and by two studies that sequenced multiple samples within a single tumor
and from matched primary/relapsed pairs (Brastianos et al., 2017; Sottoriva et al., 2013). As
opposed to this, small mutations were overall more diverse and frequently found at subclonal
levels. This included prominent driver mutations such as mutations in PTEN, EGFR and TP53,
in good agreement with previous reports (Francis et al., 2014; Ozawa et al., 2014; Spiteri et al.,
2018; Wang et al., 2016). TERT promoter mutations, despite being found in all tumors, were also
subclonal in one third of the tumor pairs, suggesting that these mutations may be acquired later
during tumorigenesis. This is a surprising finding, since TERT promoter mutations are discussed
as tumor initiating events in glioblastoma (Barthel et al., 2018). However, subclonal levels of
TERT promoter mutations have also been reported in thyroid cancer and meningioma (Juratli
et al., 2017; Landa et al., 2016), and few studies have assessed the clonality of TERT promoter
mutations based on variant allele frequencies, which is necessary to account for intratumoral
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heterogeneity. Indeed, a recent study that analyzed the VAF distribution of driver mutations in
glioblastoma suggested that TERT promoter mutations can also be subclonal in glioblastoma
(Brastianos et al., 2017), supporting the temporal order of early copy number changes and
subsequent TERT promoter mutations as suggested by our dataset.
In Section 2.3.5, we employed population dynamics models to combine the inferred
evolutionary trajectories with tumor growth. We showed that mutation accumulation serves
as a mitotic clock that can be used to date back the tumor origin if calibrated with the time
span between primary and secondary resection. Unexpectedly, the combined information
on glioblastoma size, mutational burden and division rate suggested that glioblastomas have
been growing for years before they were clinically detected. This contrasts with reports of
glioblastoma or high-grade glioma patients who had negative MRI scans when presenting with
seizures several months prior to initial diagnosis (e.g., Landy et al., 2000; Nishi et al., 2009).
However, our population dynamics model suggests that glioblastomas grow below the clinical
detection limit for years, since only a minority of cell divisions contributes to tumor growth. In
this view, glioblastoma is initiated by mutations in cell cycle genes that accelerate cell divisions,
but fail to stabilize the survival of the daughter cells. The three pervasive copy number changes
identified at tumor initiation in our dataset (gain of chromosome 7, loss of chromsome 9p or 10)
are attractive candidates for thesemutations as all of them target pivotal cell cycle genes (EGFR on
chromosome 7, CDKN2A on chromosome 9p and PTEN on chromosome 10). Despite extensive
cell death during this initial phase, the rapid turnover of the tumor cell population increases
the probability to capture a survival stabilizing mutation in the TERT promoter by chance. As
the TERT promoter mutant tumor fraction grows faster than the founder population, it will
eventually reach clonality, but, depending on the time it had to expand, may still be subclonal at
resection.
Our population dynamics model indicates that the TERT promoter mutant tumor fraction
should by tendency increase between primary and secondary resection. However, we found no
such trend in our dataset and, in fact, only two of the seven caseswith a subclonal VAF of the TERT
promoter mutation progressed to clonality under treatment. Two recent studies have associated
TERT promoter mutations with better prognosis in MGMT promoter methylated glioblastomas
(Arita et al., 2016; Nguyen et al., 2016), raising the question of how the selective advantage
associated with TERT promoter mutations changes under therapy. As TERT promoter mutations
have been shown to support the survival of differentiated cells, but not of stem cells (Chiba
et al., 2015), it will be interesting to stratify the fate of TERT promoter mutant cells based on
transcriptional and epigenetic heterogeneity. Indeed, the large extent of cell death during tumor
growth predicted by our population dynamics model supports the idea of a cellular hierarchy
in glioblastoma. In this view, tumor growth is driven by self-renewing divisions in a stem
cell-like compartment, while transiently amplifying cells in more downstream compartments
survive for a limited time span. A recent study on the clonal dynamics of glioblastoma xenografts
corroborates this interpretation by estimating approximately 10-15% symmetric divisions among
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stem cell-like glioblastoma cells (Lan et al., 2017). Together, these findings call for a combined
analysis of genetic evolution and cellular hierarchies to unravel treatment failure in glioblastoma.
In summary, the presented project provides a comprehensive analysis on the genomic
evolution of IDHWT glioblastomas. Linking genomic data with population dynamics models,
a common path of early tumorigenesis was reconstructed that happens years ahead of diagnosis
and is characterized by large chromosomal changes on chromosome 7 (gains), 9p or 10 (losses).
This common early path is accompanied by rapid cellular turnover, followed by the acquisition of
TERT promoter mutations that stabilize cellular survival and eventually reach clonal dominance.
Upon primary resection and standard therapy, glioblastomas re-grow oligoclonally from residual
cancer cells, with no evidence for a directed evolution. These findings are of clinical relevance as
they suggest that treatment resistance of relapsing glioblastomas might be due to transcriptional
or epigenetic heterogeneity rather than genomic evolution. Moreover, the long phase of
glioblastoma evolution prior to clinical presentation may open up new opportunities for early
detection and treatment design.
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CHAPTER 3
Mutation accumulation in growing and homeostatic tissues
While mouse models have played a pivotal role in cancer research they have been of very
limited utility in understanding how cancer arises initially, without the artificial introduction
of oncogenes by the experiments. It is therefore of particular interest to understand how tumors
arise de novo and how this knowledge can be used to guide early diagnosis. Mutational profiling
with whole genome sequencing provides a minimally invasive way to study clonal dynamics
in human tissues and may aid this understanding. However, accurate classification of clonal
expansions as pre-cancerous requires reliable distinction from expansions expected under neutral
drift, and thus a thorough understanding of the clonal dynamics in normal tissues.
In this chapter, we will develop a theoretical expectation of the mutation frequency
distribution in growing and homeostatic tissues, exemplified by adult hematopoiesis. In the
first part, biological and theoretical background on hematopoiesis and mutation acquisition is
provided. Next, existing theory on mutational dynamics in exponentially growing tissues is
reviewed. We extend this model to a two-stage situation of initial tissue expansion, followed
by a phase of homeostatic turnover. The theoretical expectation is then compared to deep
whole genome sequencing data of granulocytes from healthy mice, and of leukocytes from
neuroblastoma and glioblastoma patients. Finally, the potentials and limitations of this approach
to identify pre-leukemic states in peripheral blood are discussed.
The data used in this chapter were provided by different collaborators. All murine data were
generated by Ruzhica Bogeska and bioinformatically pre-processed by Megan Druce, both from
the group of Michael Milsom (German Cancer Research Center, Heidelberg). Human data were
obtained from neuroblastoma and glioblastoma patients, whose blood samples were originally
sequenced as normal controls for tumor sequencing. The glioblastoma data were collected and
sequenced by the SysGlio Consortium, headed by Peter Lichter (German Cancer Research Center,
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Heidelberg). The neuroblastoma data were collected and sequenced by Frank Westermann,
Moritz Gartlgruber and Sabine Hartlieb (German Cancer Research Center, Heidelberg). All
human sequencing data had already been mapped to the human genome, while I performed
all downstream bioinformatic analyses.
3.1 Background
3.1.1 Brief introduction to the hematopoietic system
The formation of blood and immune cells is a hierarchically organized process termed
hematopoiesis. Hematopoietic stem cells (HSCs) reside at the apex of the hematopoietic system
and are capable of self-renewal and multi-lineage output of all cell types of the blood (Fig. 3.1;
Dick et al., 1985; Ford et al., 1956; Keller et al., 1985; Pei et al., 2017). Lineage differentiation runs
through multiple intermediate states of increasing proliferative activity and decreasing capacity
to self-renew (Busch et al., 2015). Myeloid and lymphoid lineages split from a multipotent
progenitor state (MPP; Akashi et al., 2000; Kondo et al., 1997).
During embryogenesis, hematopoiesis develops in two waves. The first hematopoietic
progenitors are produced in the yolk sac at day E7.5 of murine embryogenesis and give rise
to primitive erythrocytes and myeloid cells (Golub and Cumano, 2013), while the second wave of
embryonic hematopoiesis is initiated in the aortic-gonado-mesonephros at day E9.5. From there,
hematopoietic progenitors migrate to the fetal liver, where the definitive hematopoiesis takes
place (Medvinsky et al., 1993; Samokhvalov et al., 2007; Zovein et al., 2008). Starting from day
E17.5, hematopoietic stem cells colonize the bonemarrow and fully establish adult hematopoiesis
by week three after birth (Bowie et al., 2007; Christensen et al., 2004).
3.1.2 Clonal hematopoiesis
A prominent example of a pre-cancerous lesion that may progress to malignancy is ‘clonal
hematopoiesis’ in the elderly. Clonal hematopoiesis refers to large expansions of single
hematopoietic stem cells (typically ≥ 20%; Jaiswal et al., 2014) and has been reported for >50%
of subjects older than 85 years (Zink et al., 2017). Clonal hematopoiesis was first detected
from skewed X-inactivation in the blood of elderly females (Busque et al., 1996) and later
confirmed with next generation sequencing of larger cohorts (e.g., Genovese et al., 2014; Jaiswal
et al., 2014). These studies identified known leukemic driver mutations, primarily in the DNA
(de-)methylation genes DNMT3A and TET2 and the chromatin remodeling gene ASXL1, at high
frequencies in the blood of elderly people. Follow up studies revealed an elevated risk for initially
asymptomatic persons with clonal hematopoiesis to develop hematological cancers and also
coronary heart disease and stroke (Genovese et al., 2014; Jaiswal et al., 2014). Surprisingly, a
recent study showed that a substantial fraction of individuals with clonal hematopoiesis does
not harbor any known driver muation, but nevertheless has a higher overall mortality risk (Zink
66
3.1. Background
HSC
MPP
CLP
pro-T pro-B
CMP
MEP GMP
Erythro-
cytes
Mega-
karyocytes
Mono-
cytes
Granulo-
cytes
CD4+ 
T lympho-
cytes
CD8+ 
T lympho-
cytes
B lympho-
cytes
Myeloid lineage Lymphoid lineage
Se
lf r
en
ew
al
Pr
oli
fe
ra
tio
n
Figure 3.1: Hematopoietic lineage tree. Hematopoietic stem cells (HSC) reside at the top of
the hematopoietic tree. Myeloid and lymphoid lineages split after differentiation of multipotent
progenitors (MPP) into common myeloid progenitors (CMP) or common lymphoid progenitors (CLP).
MEP, megakaryocyte-erythrocyte progenitor; GMP, granulocyte-monocyte progenitor; pro-B, pro-B cells;
pro-T, pro T cells. Illustration based on Figure 1 in Graf, 2008.
et al., 2017). Whether clonal hematopoiesis in these individuals was due to neutral drift or due
to a selective advantage provided by unknown driver mutations remains unknown, in particular,
because the mutation dynamics in undisturbed hematopoiesis are not well understood (Lee-Six
et al., 2018).
3.1.3 Mutagenesis in dynamic tissues
In the absence of external mutagens, most mutations are acquired during replication or from
spontaneous deamination of methylated cytosines to thymidines. As replication is linked to cell
division, accumulation of replication errors can be interpreted as a mitotic clock. By contrast,
accumulation of mismatches due to spontaneous deamination is independent of cell divisions
and thus represents a chronological rather than a mitotic clock (Gao et al., 2016). If, however,
division rates are (approximately) constant over time, a detailed distinction of both contributions
will not be needed and both processes can be added up to obtain an effective mutation rate per
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cell division.
Estimates of the somatic mutation rate in human somatic tissues range from 0.27 × 10−9
(Lynch, 2010) to 2.66 × 10−9 (Milholland et al., 2017) mutations per nucleotide and cell division.
This translates to one to ten mutations per cell division in the human genome of approximately
3.3 × 109 basepairs. Thus mutations are frequent enough to label most cell divisions and rare
enough to be unique cellular markers (Kimura, 1969).
In an exponentially growing tissue of monoclonal origin, mutations present in the founder
cell will be inherited to its entire progeny. In every subsequent division, new mutations will be
acquired, but these will be present in a sub-tree of the total division tree only (Fig. 3.2A). On
average, the tissue fraction sharing a newly acquired mutation halves with every generation,
while the number of newly acquired mutations doubles with every generation. However,
deviations from average are possible due to neutral drift or selection of a favourable mutation.
Thus the dynamics of cell division and death imprint on the mutation frequency distribution of
the tissue.
A straightforward approach to measure the mutation frequency distribution of a tissue
sample is bulk whole genome sequencing (WGS). WGS identifies mutations present in a
substantial fraction of the sample, albeit single cell information is lost. In addition, WGS reports
the fraction of sequencing reads harboring a specific mutation, which provides a direct estimate
of the variant allele frequency (VAF), the relative frequency of a mutation in the tissue. In diploid
genomes, mutations are typically present on one of the two alleles only, so that the fraction
of cells carrying a heterozygous mutation scales 2:1 with the VAF. Therefore, a typical VAF
histogram measured in a monoclonal, diploid cell population consists of a clonal peak at 50%
and a subclonal tail at small VAFs, as shown schematically in Fig. 3.2B.
3.2 Experimental motivation: Mutation frequency distribution
in normal blood samples
We start with a qualitative analysis of the mutation frequency distribution in peripheral blood
cells sampled from mice and humans of different age groups (Fig. 3.3). The data comprise WGS
data of murine granulocytes from one eight-week-old and one two-year-old mouse as well as
WGS data of unsorted human leukocytes from 68 children diagnosed with neuroblastoma and
39 adults diagnosed with glioblastoma.
3.2.1 Sequencing and mutation calling
Murine samples
Sample preparation and mutation calling of the murine samples were performed by Ruzhica
Bogeska (experimental part) and Megan Druce (sequence alignment and mutation calling), both
from the group of Michael Milsom (German Cancer Research Center, Heidelberg). Briefly,
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Figure 3.2: Accumulation of replication-coupled mutations in an exponentially growing tissue. A
Mutation acquisition at a constant rate per cell division (barcodes represent DNA loci; black, mutated;
white, wildtype). Percentages indicate the fraction of alleles harboring a specific mutational profile. B
Variant allele frequency histogram of the example shown in (A; barcodes illustrate the mutations being
present at a specific VAF).
CD11b+ Gr1+ granulocytes were sorted from the peripheral blood of one eight-week-old and one
two-year-old C57/BL6 mouse, sequenced at 140x coverage and aligned to the murine reference
genome mm10. Somatic mutations were called against control samples obtained from analogous
preparation of tail cells of the same individuals.
Human samples
The human blood samples were taken from 68 neuroblastoma patients (median age = 4 ys,
IQR=[2 ys, 6 ys]) and 39 glioblastoma patients (median age = 54 ys, IQR = [43 ys, 63 ys]), and
originally served as germline controls when sequencing whole genomes of the tumors. Except
for one glioblastoma patient, the samples were taken prior to treatment with chemoradiation
therapy. The samples consisted of unsorted leukocytes, were sequenced at a target coverage
of 80x and were aligned to the human reference genomes hg19 or hs37d5 by the DKFZ Omics
IT and Data Management Core Facility. Somatic mutations were called with Strelka v2.8.4
(Saunders et al., 2012) at default parameters, using the corresponding tumor as a gemline
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control, and annotated using annovar (Wang et al., 2010). Low-quality variants and mutations
in repeat regions1 were filtered upon mutation calling. Moreover, mutations at loci with copy
number changes in the tumor (as determined with ACEseq; Kleinheinz et al., 2017; analysis
performed by Jing Yang and Umut Toprak, German Cancer Research Center, Heidelberg) were
excluded, since germline mutations on these loci may have been lost in the tumor. To achieve
comparability between individual patients, the mutation counts were extrapolated from the
analyzed genome fraction to the entire genome.
3.2.2 Mutation frequency distributions
Fig. 3.4A shows the mutation frequency distributions in murine granulocytes of the eight-week-
old and the two-year-old mouse. Both histograms are consistent with a tissue expansion from a
monoclonal origin, reflected in few clonal mutations at VAFs around 0.5 and increasing numbers
of mutations at subclonal levels. Notably, the overall mutational burden approximately doubles
from 235 mutations in the young mouse to 555 mutations in the old mouse. By contrast, the
number of subclonal mutations (VAF < 0.25) in human samples is overall higher in children
(median 342) than in adults (median 269), despite a high degree of inter-individual variability
(Fig. 3.4B; p=0.017,Wilcoxon rank sum test with continuity correction). While these observations
appear contradictory at a first glance, theymaywell be due to differences between the organisms,
inter-individual heterogeneity and the type of data, as we will see later on. Without pre-empting
the discussion, let us briefly summarize the available data basis:
• In mice, the mutational burden of granulocytes doubles with age. Murine data is under
better control than human data, as both mice are of the same inbred strain and were kept in
controlled environmental conditions. However, the data suffers from the lack of replicates.
• In humans, an increase in the mutational burden with age is not evident. Human data
are available for more patients and have therefore more statistical power than the murine
data. On the other hand, we can expect a higher variability among human samples as
humans do not live in controlled environments, the blood samples were obtained from
cancer patients (and the matching cancer samples were used to distinguish germline and
somatic mutations), and the samples were obtained from unsorted leukocytes, so that a
mixed cell population was analyzed.
1extracted from UCSC table browser, https://genome.ucsc.edu/cgi-bin/hgTables, selecting ‘RepeatMasker’ and
‘Simple Repeats’; downloaded on December 5th, 2018.
70
3.3. Neutral mutation accumulation in growing and homeostatic tissues
n=1 n=1
n=68 n=39
8 weeks 2 years
2-6 years ~40-70 years
Unsorted leukocytes Unsorted leukocytes
Granulocytes
Granulocytes
Neuroblastoma
Glioblastoma
Normal tail
Normal tail
Figure 3.3: Whole genome sequencing of normal blood. Whole genomes of sorted granulocytes and
unsorted leukocytes were sequenced from two mice (140x target sequencing coverage) and 107 humans
(80x target sequencing coverage), respectively. For the murine samples, tail was sequenced as a germline
control. The human blood samples were originally sequenced as germline controls for neuro- and
glioblastomas. To call somatic variants in the blood, the samples were switched, i.e., the tumor was used
as a germline control for the blood. Illustrations are modified from Vecteezy (www.vecteezy.com).
3.3 Neutral mutation accumulation in growing and homeostatic
tissues
3.3.1 Exponential growth
To begin with, we recapitulate existing theory for an exponentially growing tissue with
continuous accumulation of neutral mutations (Ohtsuki and Innan, 2017; Williams et al., 2016).
Both approaches trace the fate of mutations that are acquired during cell divisions in a clonal
expansion (Fig. 3.2). In the framework provided by Williams et al., 2016, cell death is neglected
and all newly acquired mutations expand deterministically in the population. Ohtsuki and Innan
refined this approach by accounting for the stochasticity in the clone size distributions. We will
show that this refinement is necessary if cell loss during tissue expansion is not negligible.
Exponential growth with deterministic clonal expansions
We model tissue expansion from a single cell and assume that this expansion follows an
exponential growth law at rate β = λ − δ , where λ is the cellular division rate and δ the cellular
death rate, with λ > δ . Following Williams et al., 2016, we assume that all newly acquired
mutations expand deterministically at rate β . The number of cells at time t , N (t ), then obeys
N (t ) = eβt . (3.1)
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Figure 3.4: Mutation frequency distribution in the peripheral blood of mice and humans. A Variant
allele frequencies of single nucleotide variants detected in peripheral granulocytes of an eight-week-old
(left panel) and a two-year-old mouse (right panel). Mutations supported by less than five sequencing
reads were excluded. B Subclonal mutation counts in unsorted leukocytes of human children and adults
(requiring at least three reads supporting the variant and 0.05 < VAF < 0.25; values are extrapolated
from the analyzed genome fraction to the entire genome). Mouse data: Ruzhica Bogeska and Megan
Druce; human data: Frank Westermann (children) and Peter Lichter & ‘SysGlio’ Consortium (adults).
We now assume that mutations are acquired at a constant rate per cell division, µ. The total
number of mutations,M , is thus determined by
dM
dt = µλN (t ), (3.2)
which can be solved by integration to give
M (t ) =
∫ t
0
µλN (t ′)dt ′ (3.3)
=
µλ
β
(N (t ) − 1) . (3.4)
As cells are assumed to divide deterministically, the tissue fraction containing a specific mutation
will be constant over time. We introduce the tissue fraction of a single cell f = 1N (t ) and find the
number of mutations with fraction f or larger:
M ( f ) =
µλ
β
(
1
f
− 1
)
. (3.5)
Thus the number of mutations present in a tissue fraction of f or larger grows linearly with 1/f
(Fig. 3.5A, B).
We expect that treating all cells as proliferating exponentially in a deterministic setting
has limitations. Therefore, we compare the theoretical prediction to stochastic simulations of
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Figure 3.5: Predicted mutation accumulation in exponentially growing tissues following Williams et al.,
2016. A Predicted mutation frequency histogram. B Predicted number of mutations present in at least
the indicated tissue fraction (the slope of the curve scales with the mutation rate). The mutation rate was
taken as 2 mutations per effective cell division (one per daughter cell).
mutation accumulation in a growing population at different death rates (recall that β = λ − δ ).
To this end, we simulate the expansion of a single cell stochastically (Fig. 3.6A). The simulation
works by tracking the mutational profiles of dividing cells in an agent-based fashion and is
initiated with a single cell. At each time step, the cell to divide is randomly selected and inherits
its mutational profile to both daughter cells. New mutations, acquired at division, are sampled
from a binomial distribution for both daughter cells (using a sample size of 3×109, corresponding
to the number of basepairs in the human genome, and a per-base substitution rate of 0.33× 10−9
per division, corresponding to an average mutation rate of one mutation per daughter cell and
division). The simulation is terminated once the population size reaches 1,000 cells.
In the absence of cell death, the theoretical prediction matches the simulated mutation
frequency distribution accurately (Fig. 3.6B, black curve and red shading). However, with
increasing cellular death rates, the simulated curve bends down from the theoretical prediction
(Fig. 3.6B, orange shadings). Thus the linear prediction between the cumulative number of
mutations and the inverse of the mutated tissue fraction will be accurate for neutral mutation
accumulation only if cell death is negligible. By contrast, in tissues with high cellular turnover
— due to death of or differentiation — a more refined approach is needed that properly accounts
for the stochasticity of small cell numbers.
Exponential growth with stochastic clonal expansions
To account for neutral drift in mutation accumulation, we employ the theoretical framework
developed by Ohtsuki and Innan, 2017. Ohtsuki and Innan extended the theoretical setting by
Williams et al. to account for the stochasticity of clonal expansions. Like Williams et al., Ohtsuki
and Innan model the growth of the total cell population deterministically:
N (t ) = e (λ−δ )t with λ > δ , (3.6)
73
Chapter 3. Mutation accumulation in growing and homeostatic tissues
Mutations
Cell division: λ Cell death: δ
Replication-coupled mutation: μ
Ce
lls 1
2
3
A B C D
0
0 500 1000
1/Mutated tissue fraction (1/f)
Analytical prediction
No cell death
50% Cell death
B
90% Cell death
103
Cu
m
ula
tiv
e 
m
ut
at
ion
 co
un
t (
M
)
A
Figure 3.6: Stochastic simulation of mutation accumulation. A Simulation design. Cells either divide (rate
λ) or die (rate δ ). At cell divisions, a randomly selected cell inherits its mutational profile to both daughter
cells. Newly acquired mutations are sampled according to the mutation rate µ. The mutational profile
of each cell is stored in a mutation table. B Cumulative number of mutations according to the analytical
prediction (black line; c.f. Fig. 3.5) and from stochastic simulations without cell death (darkred) and with
δ = 0.5λ (darkorange) and δ = 0.9λ (orange). Shown are the 95% confidence bands of 100 simulations
each. All simulations were terminated once a population size of 1,000 cells was reached; the mutation rate
was taken as 2 mutations per effective cell division (one per daughter cell).
and rely on a deterministic description of mutation acquisition, as before:
dM
dt = µλN (t ). (3.7)
However, in contrast to Williams et al., Ohtsuki and Innan model clonal expansions of newly
acquiredmutations stochastically, using the transition probabilities of a supercritical linear birth-
death process (i.e., λ > δ ). At constant birth and death rates, the probability that a mutation
acquired at time t ′ will be present in a clone of size i at time t is given as (Bailey, 1964)
Pexp,i (t , t
′ |λ,δ ) =
⎧⎪⎪⎨⎪⎪⎩
x (t − t ′) if i = 0
(1 − x (t − t ′))) (1 − y (t − t ′))y (t − t ′)i−1 if i ≥ 1 , (3.8)
with
x (t ) =
δe (λ−δ )t − δ
λe (λ−δ )t − δ (3.9)
y (t ) =
λe (λ−δ )t − λ
λe (λ−δ )t − δ . (3.10)
Integration over time yields the total number of mutations present in i cells at time t , in the
following denoted as Si (t |µ, λ,δ ):
Si (t , |µ, λ,δ ) =
∫ t
0
Neutral drift during expansion                          
Pexp,i (t , t
′ |λ,δ ) × µλN (t ′)      
Number of mutations acquired at t ′
dt ′. (3.11)
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Figure 3.7: Predicted cumulative number of mutations (present in at least the indicated tissue fraction)
if accounting for stochastic clonal expansions (following Ohtsuki and Innan, 2017). Shown are the
theoretical predictions (lines) for expanding populations without cell death (darkred) and with δ = 0.5λ
(darkorange) and δ = 0.9λ (orange), along with the 95% confidence bands of corresponding stochastic
simulations (shaded areas, 100 simulations each). Simulations are the same as shown in Fig. 3.5 (terminated
at a population size of 1,000 cells; µ =2 mutations per effective cell division).
Finally, expressing the tissue fractions harboring individual mutations as f (t ) = iN (t ) , we obtain
the number of mutations,M ( f ), present in a tissue fraction of at least f at time t :
M ( f , t |µ, λ,δ ) =
N (t )∑
i=f N (t )
∫ t
0
Pexp,i (t , t
′ |λ,δ )µλN (t ′)dt ′, (3.12)
where f = 0N (t ) ,
1
N (t ) , ..., 1. Note that, in contrast to the theoretical framework proposed by
Williams et al., 2016, the mutation frequency-distribution is time-dependent, which is due to
stochastic drift.
When comparing the analytical prediction of Ohtsuki and Innan to stochastic simulations of
mutation accumulation in growing cell populations (c.f. Section 3.3.1), we note that Eqn. 3.12
provides accurate predictions for scenarios with and without cellular death (Fig. 3.7). We
note that this agreement of the theory with stochastic simulations was achieved by describing
stochastic clonal drift while retaining a deterministic picture of mutation accumulation.
3.3.2 Homeostatic turnover
While the theoretical frameworks by Williams et al., 2016, and Ohtsuki and Innan, 2017, model
the dynamics of mutation accumulation in exponential tissue expansions as occuring during
embryogenesis or carcinogenesis, homeostatic turnover in adult tissues translates to a balanced
birth-death process that yields a constant population size over time. Therefore, in order to predict
the mutation frequency distribution in adult hematopoietic tissues, we will now couple an early
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Figure 3.8: Two-stage tissue dynamics with an exponential expansion phase that is followed by a phase
of homeostatic turnover. Piecharts represent clone size distributions if following the progeny of labeled
cells over time. Due to neutral drift dynamics, the proportion of individual clones may change during
homeostatic turnover.
exponential growth phase, translating to embryonic tissue expansion, to a subsequent steady-
state phase, translating to homeostatic turnover in the adult (Fig. 3.8). To achieve this, we will
first analyze neutral drift under balanced division and death rates and eventually link this to a
preceding phase of exponential growth.
To model the clonal dynamics of mutations during homeostatic tissue turnover, we assume
that cells divide at rate λ and die or differentiate at rate δ = λ. We further assume a constant
population size, Nss, over time, which is a valid assumption if N is large. Analogous to
Section 3.3.1, we model clonal expansions using the transition probabilities of a linear birth-
death process. However, we now need to find the transition probabilities of a critical birth-death
process, that is λ = δ . An explicit solution for the probability that a cells at time t ′ transition
into b cells at time t is obtained by expanding the probability generating function of the linear
birth-death process (see Appendix B), which yields:
Pss,a,b (t
′, t |λ) =
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
0 a = 0,b , 0,
pa b = 0,∑b
k=1
k
b
(
a
k
)
pa−k (1 − p)k
(
b
k
)
pb−k (1 − p)k a , 0,b , 0,
(3.13)
p =
λ(t − t ′)
1 + λ(t − t ′) . (3.14)
In analogy to Eqn. 3.11, we can now determine the total number of mutations that were acquired
during adulthood and are present in i cells at time t to
Si (t |µ, λ,Nss,Tss) = µλNss
∫ t
Tss
Pss,1,i (t
′, t |λ)dt ′, (3.15)
where Tss marks the beginning of the steady-state phase. Finally, in order to obtain the
mutation frequency distribution of the two-stage system, we couple the expansion phase during
embryogenesis with the steady-state phase during adulthood. Cells acquiring a mutation during
embryogenesis may have grown to clones of any size between 0 and Nss at the transition to
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adulthood, and eventually reached their final clone size due to neutral drift in the homeostatic
tissue. Labeling the parameters of the expansion phase with ‘exp’ and those of the steady-state
phase with ‘ss’ we obtain the mutation frequency distribution of the coupled system:
Si (t |µ, λexp,δexp, λss,Nss,Tss) = (3.16)∫ Tss
0
Nss∑
k=1
Neutral drift during expansion                                
Pexp,k (t
′ |Tss, λ,δ ) µλe (λexp−δexp)t ′ ×
Neutral drift during steady-state                            
Pss,k,i (Tss, t |λss) dt ′                                                                                                                                                                                                      
Mutations acquired during expansion
+
+
∫ t
Tss
Pss,1,i (t
′, t |λss)µλNssdt ′                                                            
Mutations acquired during steady-state
, t ≥ Tss.
As before, we obtain the number of mutations present in a tissue fraction of at least f by setting
f = iN :
M ( f , t |µ, λexp,δexp, λss ,Nss,Tss) =
N (t )∑
i=f N (t )
Si (t |µ, λexp,δexp, λss,Nss,Tss). (3.17)
Again, we assess the accuracy of our analytical prediction with stochastic simulations. To this
end, we first simulate clonal expansions until the population size reaches 1,000 cells, using the
agent-based simulation approach, as before (c.f. Section 3.3.1). Keeping in mind our ultimate
goal to model embryonic and adult hematopoiesis, we simulate the expansion phase with a
cellular death rate of δexp = 0.5λexp, thus assuming fast expansion while accounting for some
cell death or differentiation. Subsequently, we assume that the cell population remains constant,
i.e., division and death rates are balanced. Following previous estimates of cell division rates
in murine hematopoietic stem cells, we choose λss = δss = 0.009 d−1 (Busch et al., 2015).
To assess the accuracy of our theoretical prediction at different time points, we report the
simulation result five weeks, two years and four years after the steady-state was reached (the
five-weeks time point corresponds roughly to eight-week-old mice, as hematopoietic stem cells
transition to an adult proliferation phenotype three weeks after birth; Bowie et al., 2007). We find
that the analytical prediction slightly overestimates the average from stochastic simulations at
all timepoints (Fig. 3.9), which may, in part, be due to random fluctuations of the population
size in the simulations and rare outliers that were not captured by the simulation. This is
corroborated by the large variance that is suggested by the stochastic simulations. Interestingly,
the model predicts that the overall mutational burden increases with age, and that mutations
drift to high tissue fractions with time (red arrows in Fig. 3.9). Thus neutral drift dynamics in
homeostatic tissues changes the mutation frequency distribution distinctly from exponentially
growing tissues.
Taken together, our theoretical considerations show that different tissue dynamics, such as
growth versus homeostasis, but also the degree of cellular turnover, affect mutation accumulation
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in distinct ways. This provides a theoretical framework based on which deviations from
neutrality, as expected during tumor initiation, may become identifiable.
3.4 Model applications: Mutation accumulation in the
hematopoietic system
Having a theoretical expectation of the mutation frequency distribution at hand, we now
exemplify potential applications of our approach by revisiting the mutational burden in murine
and human blood samples. To this end, we need to ensure that mutation accumulation
in hematopoietic stem cells and peripheral blood cells correlate sufficiently well. This is a
necessary prerequisite, since our theoretical framework describes mutation acquisition and
clonal expansions in an influx-free population, comparable to stem cells. However, additional
cell divisions during differentiation likely contribute to the mutation frequency distribution
in downstream compartments. Accurate prediction of mutation accumulation in granulocytes
therefore requires the coupling of clonal drift dynamics within granulocytes with stochastic
influx from upstream compartments. However, this becomes computationally cumbersome,
as the cell counts in downstream compartments are large. Yet, mutation accumulation in the
measurable range (VAFs>1%, irrespective of the read coverage; Alioto et al., 2015) correlates
sufficiently well between stem cells and downstream compartments, as we will see in the
following. Thus mutation accumulation in peripheral granulocytes can be approximated by an
influx-free cell population.
3.4.1 Mutation spectrum in peripheral granulocytes as a readout for
hematopoietic stem cell dynamics
To show that the measurable mutation frequency distribution is only marginally affected by
cell divisions during progressive differentiation, we analyze the clonal dynamics between long-
term hematopoietic stem cells (LT-HSCs), short-term hematopoietic stem cells (ST-HSCs) and
multipotent progenitors (MPPs), corresonding to the three most upstream compartments in
the hematopoietic system as defined by Busch et al., 2015 (Fig. 3.10A). Hierarchical tissue
organization may affect the mutation frequency distribution in downstream compartments by
(i) acquisition of new mutations during divisions in transiently amplifying compartments and
(ii) neutral drift of mutations acquired in LT-HSCS (Fig. 3.10B). However, our WGS data reports
mutations only if present in at least 10% of the sample, and hence the relevant question for
our purpose is not, whether hierarchical tissue organization changes the mutation frequency
distribution at all, but whether it does so within the measurable window.
Previous studies estimated a total number of 500×106 bone marrow cells (Colvin et al., 2004)
and a LT-HSC frequency of 3 × 10−5 cells (Höfer and Rodewald, 2016), yielding approximately
10,000 LT-HSCs in the mouse. MPPs are about ten times more frequent than LT-HSCs (Busch
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Figure 3.9: Predicted mutation frequency distribution if coupling an exponential expansion phase to
a phase of homeostatic turnover. Shown are the theoretical predictions of the mutation frequency
distribution at different time points post steady-state (left) and the corresponding cumulative number of
mutations (right, dashed lines; shown is the number of mutations present in at least the indicated tissue
fraction). The cumulative distribution is compared to the result of analogous stochastic simulations (solid
lines, means; shaded areas, 95% confidence intervals from 100 simulations each). Simulations were run
with δexp = 0.5λexp and λexp = 1 d−1 until a population size of 1,000 cells was reached, and then continued
with λss = δss = 0.009 d−1 for the indicated time. Mutation rate in all predictions/simulations was taken
as six mutations per cell division (three per daughter cell).
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et al., 2015), corresponding to roughly 100,000 cells per mouse. Thus a mutation acquired in a
downstream compartment becomes detectable with WGS only if the cell of origin expands to a
clone size of several thousand cells.
To assess the clone size distribution of expanding LT-HSCs, ST-HSCs and MPPs, we
simulate the three most upstream compartments stochastically, adopting themodel structure and
parametrization from Busch et al., 2015. Briefly, we assume a linear differentiation path between
LT-HSCs, ST-HSCs and MPPs, as shown in Fig. 3.10A. Moreover, we assume that cells divide and
differentiate at constant rates λ and α , and neglect cellular loss due to death. Indexing LT-HSCs,
ST-HSCs and MPPs with 0, 1, and 2, respectively, we define the state vector n = (n0,n1,n2) and
formulate the Master equation that describes the temporal evolution of the state probabilities in
the linear differentiation path:
dPn (t )
dt =
2∑
i=1
⎡⎢⎢⎢⎢⎢⎢⎣
Division of cell type i                                  
λi (ni − 1)Pn−ei (t ) +
Differentiation of cell type i into cell type i + 1                                              
αi (ni + 1)Pn+ei−ei+1 (t )                                                                                                                                        
Stochastic processes running into state n
−λiniPn (t ) − αiniPn (t )                                                
Sochastic processes running out of state n
⎤⎥⎥⎥⎥⎥⎥⎦ , (3.18)
where ei is the (i + 1)-th unit vector and e3 is set to (0, 0, 0) by convenience.
From the Master equation one can extract the stochastic moments (Appendix C.1), allowing
us to simulate the temporal evolution of the mean and the variance of single cell expansions
starting in different compartments (cf. Eqns. C.11 and C.12 in the Appendix). With the
parametrization by Busch et al., 2015 (c.f. Table 3.1), the capacity of robust clonal expansion
declines with progressive differentiation, consistent with a decreasing capacity to self-renew
(Fig. 3.10C). While a single LT-HSC can produce long-term surviving progeny, ST-HSCs may
only transiently expand and MPPs become rapidly extinct. Accordingly, LT-HSCs can produce
the largest clones, consisting of up to 50 LT-HSCs, 100 ST-HSCs and 1000 MPPs after two
years (Fig. 3.10D; assessed with stochastic simulations of the reactions shown in Fig. 3.10A
and using the steady-state parametrization listed in Table 3.1; c.f. Appendix C.2). Since we
estimate the number of MPPs per mouse to approximately 105 (Table 3.1), measurable mutations
must be present in at least 1,000 MPPs and are thus most likely acquired in the stem cell
compartment. Moreover, as large stem cell clones are rare (Fig. 3.10D), most measurable
mutations will be acquired during embryogenesis. Thus it is very unlikely that mutations
acquired during adulthood contribute significantly to the measurable range of the mutation
frequency distribution in granulocytes.
Next, we show that neutral drift dynamics downstream of ST-HSCs do not measurably
alter the mutation frequency distribution in granulocytes either. To this end, we once again
employ stochastic simulations of murine hematopoiesis. As we are now interested in the fate
of individual mutations, we simulate mutation frequencies with an agent-based model (Fig. 3.11
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Table 3.1: Parameters used to simulate the mutation frequency distributions in LT-HSCs, ST-HSCs and
MPPs.
Parameter Value Comment
Expansion phase
λS,0 (d−1) 1 chosen to reflect a high proliferation rate in the fetus
λA,0 (d−1) 0.6 chosen according to the model fit in Section 3.4.2
λS,1 (d−1) 0.7940611 tailored to obtain ∼ 29,000 ST-HSCs
λA,1 (d−1) 0.6
λS,2 (d−1) 0 MPP expansion is not modeled
λA,2 (d−1) 0
Steady-state phase
λS,0 (d−1) 0.009
from Busch et al., 2015
α0 (d−1) 0.009
λS,1 (d−1) 0.042
α1 (d−1) 0.045
λS,1 (d−1) 4
αS,2 (d−1) 4.014
Population size at
steady-state
NLT−HSC 10,000 from Colvin et al., 2004; Höfer and Rodewald, 2016
NST−HSC : NLT−HSC 2.9 from Busch et al., 2015
NMPP : NLT−HSC 9
Abbreviations used: λS,0, rate of symmetric LT-HSC division; λA,0, rate of asymmetric LT-HSC division; λS,1, rate of
symmetric ST-HSC division; λA,1, rate of asymmetric ST-HSC division; λS,2, rate of symmetric MPP division; λA,2,
rate of asymmetric MPP division; αS,0, rate of LT-HSC differentiation; αS,1, rate of ST-HSC differentiation; αS,2, rate
of MPP differentiation; µ, mutation rate; NLT−HSC, number of LT-HSCs at steady state; NST−HSC, number of ST-HSCs
at steady state; NMPP, number of MPPs at steady state.
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and Appendix C.3). Briefly, the model simulates the embryonic expansion of a single LT-HSC
on the macroscopic scale, and mutation acquisition and inheritance during cell divisions on the
microscopic scale. Embryonic expansion is run until the population size of LT-HSCs reaches
10,000 cells, corresponding to the stem cell population size at homeostasis. Subsequently, the
simulation is approximated by sampling the cellular fate of each LT-HSC and ST-HSC from
the simulated clone size distributions after two years (c.f. Fig. 3.10D and Appendix C.2). This
approximation accelerates the simulation by neglecting any mutations newly acquired during
adulthood. Importantly, this does not impair the model prediction within the measurable
window, since adult mutations are unlikely to drift to measurable frequencies, as discussed
above (c.f. Fig. 3.10C, D).
Simulations of the agent-based model suggest that the variance of the mutation frequency
distribution indeed increases downstream of LT-HSCs (Fig. 3.12A). However, this is primarily due
to the relatively slow proliferating ST-HSCs, while the fast turnover of MPPs barely changes the
distribution (Fig. 3.12B). As the potential to self-renew decreases with progressive differentiation
in the hematopoietic system (Busch et al., 2015), compartments downstream ofMPPs are unlikely
to affect the mutation frequency distribution beyond the impact of MPPs. Thus mutation
accumulation in ST-HSCs approximately models mutation accumulation in more downstream
states within the measurable window.
3.4.2 Mutation frequency distribution in murine granulocytes
With a setup to simulate mutation accumulation in undisturbed hematopoiesis at hand, we now
test whether neutral drift explains the measured increase in the mutational burden of murine
granulocytes during ageing (c.f. Fig. 3.4). To begin with, we treat the measurement in peripheral
granulocytes as a direct readout of the mutational profile in LT-HSCs, following the discussion
of Section 3.4.1. This reduces our system to a single, self-sustaining compartment, for which
the theory of Section 3.3.2 applies. To compare theory and data, we fit the free parameters of
Eqn. 3.17 to the measured mutation frequency distribution in granulocytes of the eight-week-old
mouse. Using the calibrated model, we then predict the mutation frequency distribution after
two years and compare it to the measured data in the two-year-old mouse.
In principle, Eqn. 3.17 has six free parameters: the cell division and loss rate during expansion,
λexp and δexp, the cell division rate during steady-state, λss, the number of stem cells at steady-
state, Nss, the time point at which expansion is completed, Tss, and the mutation rate per cell
division, µ. Adopting previous estimates from the literature, we reduce the parameter estimation
to two unknown parameters:
• We fix Nss to 10,000 LT-HSCs and λss to 0.009 d−1, as before (Table 3.11).
• As hematopoietic stem cells have been shown to switch from an embryonic to an adult
proliferation phenotype within the first three weeks of newborn mice, we fix Tss to three
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Figure 3.10 (previous page): Single cell expansions of LT-HSCs, ST-HSCs and MPPs. A Model scheme
and parametrization of adult hematopoiesis according to Busch et al., 2015. Cells divide at rate λ and
differentiate at rate α . B The mutation frequency distribution may change over the course of progressive
differentiation due to newly acquired mutations and neutral drift. C Mean (solid lines) and variance
(shaded areas) of clonal expansions of a single LT-HSC (three upmost panels), a single ST-HSC (middle
panels) or a single MPP (bottom panel) over two years. Mean and variance were computed from the
master equation of the stochastic system shown in (A). D Clone size distributions of LT-HSCs (three
leftmost panels, 10,000 simulations), ST-HSCs (middle panels, 29,000 simulations) and MPPs (right panel,
90,000 simulations) after two years assessed with stochastic simulations (c.f. Appendix C.2). Insets
show the clone size distribution of surviving cells only. The number of simulations was scaled with
the relative compartment sizes according to Busch et al., 2015 and assuming 10,000 LT-HSCs per mouse.
Parametrization for all simulations was taken according to Table 3.1, ‘Steady-state phase’.
weeks after birth (Bowie et al., 2007). Thus we assume that the blood sample of the eight-
week-old mouse was taken five weeks after the steady-state was reached.
• We arbitrarily fix λexp = 1 d−1, since the absolute duration of the the expansion phase
(consisting of embryogenesis and the first three weeks after birth) is irrelevant for our
analysis.
This leaves the extent of cellular loss, δexp, and the division-coupled mutation rate, µ, to
be determined. To do this, we perform a uniform scan over the range 1 ≤ µ ≤ 10 and
0 d−1 ≤ δexp ≤ 0.9 d−1 (10 values each) and compute the residual sum of squares between
the measured and predicted mutation frequency distribution in the blood of the eight-week-old
mouse. We find the best fit at a mutation rate of seven mutations per cell division and a relative
loss rate (due to death or differentiation) of δexp/λexp = 0.6, indicating that approximately every
second stem cell division during embryogenesis is a symmetric division (Fig. 3.13A). With this
parametrization we capture the mutation frequency distribution in the granulocytes of the eight-
week-old mouse accurately (Fig. 3.13B, left panel).
Next, we analyze the mutation frequency distribution in the granulocytes of the two-
year-old mouse, and find that the number of mutations shared by large tissue fractions is
comparable to the young mouse, whereas the number of mutations shared by small tissue
fractions is elevated (Fig. 3.13B, blue points in right panel). This observation resembles the
mutation frequency distribution predicted under neutral dynamics in ageing mice qualitatively
(c.f. Fig. 3.9). Quantitatively, however, an increase in the mutational burden is not expected
within themeasurable window if using the same parametrization as before (Fig. 3.13B). Moreover,
simulations accounting for additional divisions of ST-HSCs do not fill the gap between theory
and data (assessed with the agent-based model introduced in Section 3.4.1; Fig. 3.13C). This raises
the question of whether (i) the experimental observation is due to non-neutral dynamics, (ii)
additional parameters need to be adjusted to reconcile the measured data with the theoretical
prediction of neutral drift or (iii) the observation represents a rare outlier.
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Figure 3.11: Agent-based simulation of mutation accumulation in adult hematopoiesis. The expansion
phase is simulatedwith symmetric and asymmetric divisions on themacroscopic scale. On themicroscopic
scale, the model simulates acquisition and inheritance of mutations during divisions. The steady-state
phase is approximated by sampling the mutational profiles of individual cells from the mutation frequency
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in Appendix C.3.
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based model. A Mean (solid lines) and 95% confidence interval of 100 simulated mutation frequency
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LT-HSCs (left), and between MPPs and ST-HSCs (right) for the 100 simulations shown in (A; red lines,
bisetrices). All simulations were performed with the agent-based model illustrated in Fig. 3.11, using the
parameters of Table 3.1.
As non-neutral dynamics can be caused by driver mutations, we screen themutational profile
of the two-year-old mouse for exonic mutations. Interestingly, we find a single exonic mutation
only, which is a non-synonymous substitution in exon 13 of the Janus kinase 3 gene (Jak3),
generating the constitutively active mutant Jak3A568V that is homologous to the human variant
JAK3A572V (Fig. 3.13D; Walters et al., 2006). This mutation is found at a variant allele frequency
of 0.09 and has previously been associated with T-cell lymphoma (Koo et al., 2012). Consistent
with the role of JAK3 in promoting lymphopoiesis (Springuel et al., 2015), activating mutants in
Jak3 have been shown to induce lymphoproliferative syndromes in bone marrow transplantation
models (Cornejo et al., 2009). Moreover, hyperproliferative T lymphocytes with the Jak3A568V
mutation colonize the bone marrow upon expansion in the periphery (Rivera-Munoz et al., 2018).
A possible effect of the acquired Jak3A568V mutation in the two-year-old mouse could hence
involve a reduction of the stem cell pool due to competition with invading CD8+ T lymphocytes.
Since blood counts of myeloid cells remain unaffected in a Jak3A568V mouse model (Cornejo et al.,
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2009), LT-HSCs would need to compensate their reduced cell counts by increased proliferation.
Indeed, decreasing the pool of LT-HSCs from 10,000 to 1,000, while increasing the division
rate during homeostasis from 0.009 d−1 to 0.05 d−1 improves model predictions at two years
(Fig. 3.13E). Thus the unexpectedly high mutational burden in the two-year-old mouse may have
been induced by the Jak3A568V mutation and hence may mirror a pathological rather than a
normal situation. However, as the data lack a replicate, additional sequencing is necessary to
conclusively disentangle the dynamics of undisturbed hematopoiesis in ageing mice.
3.4.3 Mutation frequency distribution in human leukocytes
A potential application of our theoretical framework is the identification of pre-cancerous
lesions due to deviations from the mutation frequency distribution expected under neutral tissue
dynamics. As an outlook, we therefore anecdotally revisit themutation frequency distributions in
human leukocytes introduced at the beginning of this chapter. As these patients were diagnosed
with neuro- or glioblastoma, but not with a hematological disorder, we expect that themutational
burden conforms to the theoretical expectation under neutral stem cell dynamics. To test this
hypothesis quantitatively with model simulations, we would need to simulate a larger stem cell
pool than inmice, as a recent study estimated that humans have approximately ten times asmany
LT-HSCs as mice, while the rate of stem cell turnover is comparable (105 LT-HSCs that divide
at most once in two months; Lee-Six et al., 2018). However, simulations of large stem cell pools
become computationally costly, wherefore we compare the experimental data to simulations of
a smaller pool of 104 cells, as before. As changes in the mutation frequency distribution become
measurable earlier if the stem cell pool is small, this simplification may wrongly classify non-
neutral dynamics as neutral, but not vice versa.
As shown in Fig. 3.14A and B, the mutation frequency distributions in the blood of most
children conform to the expectation under neutral dynamics, whereas approximately 40% of
the samples have more mutations than expected (Fig. 3.14A, C, D). Deviation from neutrality
is primarily evident at small VAFs and of a mild extent in some samples (Fig. 3.14C), while
striking in others (Fig. 3.14D). The unexpectedly high mutational burden in the latter raises
the question whether oncogenic mutations drove a pre-leukemic phenotype in these patients.
To address this question, we scan the mutational profiles for driver mutations associated with
clonal hematopoiesis (Steensma et al., 2015) and leukemia (www.intogen.org; Gonzalez-Perez
et al., 2013). Note that the true number of driver mutations in the blood samples might be higher,
since loci with a copy number change in the matching tumor sample (which was used as a
germline control) had to be excluded from mutation calling. In line with the conjunction that
the hypermutation genotypes may have evolved non-neutrally, mutations in leukemic driver
genes, such as NOTCH1, JAK3 or RUNX1, are frequent in hypermutated samples, while rare in
the rest (Fig. 3.14 and Fig. 3.15). Moreover, in two, but not all of the hypermutated samples, we
find non-synonymous and stop-gain mutations in the mismatch repair genes MSH5 and MLH3,
respectively. Thus the strong deviation of some blood samples from the theoretical expectation
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Figure 3.13: Mutation accumulation in undisturbed hematopoiesis. A Parameter scan over the mutation
rate per cell division, µ, and the differentiation/death rate, δexp, during expansion of the hematopoietic
system in the murine embryo. Shown are the residual sums of squares when comparing the theoretical
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square.
Caption continues on next page.
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Figure 3.13 (continued): B, C Expected mutation frequency distribution in murine LT-HSCs (B), ST-
HSCs and MPPs (C) of eight-week-old and two-year-old mice along with measured data in peripheral
granulocytes. Theoretical predictions are based on Eqn. 3.17 (B, lines) and 100 stochastic simulations
with the agent-based model outlined in Section 3.4.1 (B, C, shaded areas). The parametrization is based
on the best fit marked in (A) (see also Table 3.1; lines represent the analytical prediction according to
Eqn. 3.17; shaded areas represent 95% confidence intervals of the stochastic simulations; red arrows
indicate the measured tissue fraction of the Jak3A568V mutation in the two-year-old mouse). D Genomic
locus of the Jak3 gene with A568V mutation in exon 13. E Expected mutation frequency distribution in
murine LT-HSCs if assuming a compartment size of 1,000 LT-HSCs, a division rate 0.05 d−1 during adult
hematopoiesis and all other parameters as in (B, C) (lines, theoretical prediction according to Eqn. 3.17).
Tissue fractions were obtained from the measured mutation frequency distribution by multiplying variant
allele frequencies at heterozygous loci by two, thus accounting for diploid genomes. Mutations with
VAFs<0.05 and VAFs>0.25, as well as mutations supported by less than five sequencing reads were
excluded. Experimental data: Ruzhica Bogeska. Bioinformatic pre-processing: Megan Druce.
under neutral tissue dynamics may indeed be due to pre-cancerous lesions.
Finally, we analyze the adult blood samples and ask whether putatively pre-cancerous lesions
are also present in the glioblastoma patients. In contrast to the neuroblastoma patients, the
mutation frequency distributions in the peripheral leukocytes of all glioblastoma patients look
qualitatively similar, and all individuals have subclonal mutations in the same order of magnitude
(100 - 1000; Fig. 3.16A). Moreover, leukemic driver mutations are rarely found in the adult blood
samples, indicating that the mutation frequency distributions were predominantly shaped by
neutral stem cell dynamics (Fig. 3.15). To test whether a single model of mutation accumulation
captures the measured mutation frequency distributions of all adult blood samples, we simulate
adult hematopoiesis as before, but extend the simulation over 50 years. We find that a single
model of mutation accumulation explains the data of approximately 60% of the patients only
(Fig. 3.16B-D), suggesting that the dynamics of mutation acquisition and stem cell turnover is not
homogenous among individuals. Interestingly, comparison of the measured mutation frequency
distribution in children and adults with the model predictions suggests that the mutation rate
in children is approximately twice as high as the rate in adults (14 versus six mutations per cell
division in children and adults, respectively; Fig. 3.14, 3.16). However, further measurements
will be needed in order to assess whether this observation is true or due to differences in sample
acquisition and processing.
In summary, unsorted blood samples of cancer patients with no diagnosed leukemias
suggest that undisturbed hematopoiesis and putatively pre-cancerous lesions shape the mutation
frequency distribution in peripheral blood cells distinctly. Moreover, the shape of the mutation
frequency distribution in non-hypermutated samples matches our theoretical expectation
qualitatively. Thus our theoretical framework may facilitate the interpretation of deep whole
genome sequencing data. Nevertheless, a better understanding of the dynamics and the inter-
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individual heterogeneity in the human hematopoietic system will be necessary to exploit the
predictive potential of our theoretical framework in a more quantitative way.
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Figure 3.14: Cumulative mutation frequency distributions measured in blood samples from children
diagnosed with neuroblastoma (shown are mutations supported by at least three sequencing reads,
excluding mutations with VAFs≤0.05 and VAFs≥0.25; values are extrapolated from the analyzed genome
fraction to the entire genome). A Ten exemplary samples, corresponding to the deciles of the measured
subclonal mutation count among the cohort of in total 68 samples. Leukemic driver mutations are
indicated in red. B-DMean (lines) and 95% confidence intervals (shaded areas) of 100 simulated mutation
frequency distributions in ST-HSCs. Simulations are the same as shown in Fig. 3.13C (middle panel)
and as described in Section 3.4.1, but mutation counts were multiplied by two to account for the steeper
curve measured in human samples (thus, yielding a mutation rate of 14 mutations per cell division). The
measured mean and 95% confidence intervals of the samples corresponding to the lower six deciles (B), the
seventh and the eigth deciles (C) and the ninth and tenth deciles (D) are shown alongside and are colored
in black (mutated tissue fractions were obtained by multiplying the measured VAFs of heterozygous
mutations with two to account for diploid genomes). Experimental data: Frank Westermann.
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Figure 3.16: Cumulative mutation frequency distributions measured in blood samples from adults
diagnosedwith glioblastoma (shown aremutations supported by at least three sequencing reads, excluding
mutations with VAFs≤0.05 and VAFs≥0.25; values are extrapolated from the analyzed genome fraction to
the entire genome). A Ten exemplary samples, corresponding to the deciles of the measured subclonal
mutation count among the cohort of in total 39 samples. Leukemic driver mutations are indicated in
red. B-D Mean (lines) and 95% confidence intervals (shaded areas) of 100 simulated mutation frequency
distributions in ST-HSCs. Simulations were done as in Fig. 3.13C (middle panel) and as described in
Section 3.4.1, but for 50 years and at a mutation rate of six mutations per cell division (all other parameters
were taken as before, Table 3.1). The measured mean and 95% confidence intervals of the samples
corresponding to the lower six deciles (B), the seventh and the eigth deciles (C) and the ninth and tenth
deciles (D) are shown alongside and are colored in black (mutated tissue fractions were obtained by
multiplying the measured VAFs of heterozygous mutations with two to account for diploid genomes).
Experimental data: Peter Lichter & ‘SysGlio’ Consortium.
93
Chapter 3. Mutation accumulation in growing and homeostatic tissues
3.5 Discussion
The transition of normal tissues to pre-cancerous lesions is of particular interest to understand
the cellular processes governing tumor initiation and to guide early diagnosis. In the current
chapter, we analyzed how clonal dynamics in normal tissues imprint on the mutation frequency
distribution measured with whole genome sequencing and how this knowledge may be used to
differentiate between normal and pre-cancerous situations.
The purpose of this chapter is two-fold. On the one hand, we developed a theoretical
framework to describe mutation accumulation in neutrally evolving somatic tissues. On the
other hand, we analyzed how this framework may be used to identify pre-leukemic lesions with
whole genome sequencing. To this end, we first assessed the validity of existing theory on
mutation accumulation in exponentially growing tissues by comparing the model predictions
to stochastic simulations. This revealed that a deterministic view on mutation accumulation, as
suggested by Williams et al., 2016, relies on simplifying assumptions that are valid in the limit
of negligible cell loss only. By contrast, we showed that, in general, reliable predictions of the
mutation frequency distribution are only obtained if accounting for the stochasticity of clonal
drift, as suggested by Ohtsuki and Innan, 2017. It is noteworthy that cell loss, due to death or
differentiation, is non-negligible in many physiological, but also pathological tissue expansions.
For example, embryonic expansion of the hematopoietic stem cell compartment is accompanied
by the production of mature blood cells via differentiation of early hematopoietic stem cells
(Golub and Cumano, 2013). Likewise, many tumors retain a functional hierarchy, in which only
a minor fraction of the daughter cells produced by ‘cancer stem cell’ divisions survives lastingly
and contributes to tumor growth, while most of the daughter cells eventually die. To give an
example, we showed in Chapter 2 that high cell death rates are a characteristic of glioblastoma
growth, which may be due to functional heterogeneity (see also Lan et al., 2017) or other growth
impediments. Thus a deterministic view on mutation accumulation in expanding tissues likely
oversimplifies the mutational dynamics in many cases.
While existing theory on mutation accumulation in somatic tissues has primarily focused on
exponentially growing cell populations, such as tumors, physiological tissues typically undergo
homeostatic turnover upon embryonic expansion to their definite size. Thus, in order to predict
mutation accumulation in adult tissues over time, we extended the model by Ohtsuki and Innan,
2017, to a two-stage system of initial expansion and subsequent homeostasis. This extension
is necessary to understand the expected mutation frequency distribution in normal somatic
tissues and thus to distinguish neutral mutation accumulation from pre-cancerous situations.
Moreover, coupling an expansion phase with subsequent homeostasis may also be useful when
sequencing tumors that grow according to the Gompertzian law and have approached the
carrying capacity. We validated our theoretical framework with stochastic simulations and
showed that the analytical solution is on average accurate and may hence aid a mechanistic
interpretation of bulk whole genome sequencing data. However, stochastic simulations of
the analogous process showed that individual measurements may deviate from the average
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prediction as the mutation frequeny distribution varies according to the stochasticity of mutation
accumulation. Whether an analytical prediction of the variance inherent to the stochastic process
can be found analytically is subject to future work. Until then model predictions should ideally
be complemented with stochastic simulations and compared to an ensemble of measurements.
The advantage of stochastic simulations to validate our model predictions becomes especially
evident when measuring mutations in a downstream compartment of a hierarchical system as
discussed in Section 3.4.1. Here, a complete analytical description of the clonal drift dynamics
would become computationally cumbersome as multiple summation and integration steps are
required. Nevertheless, using the example of murine hematopoiesis, we showed that divisions
during progressive differentiation affect the measurable mutation frequency distribution only if
the downstream compartments have a high capacity to self-renew (e.g., ST-HSCs). By contrast,
transiently amplifying compartments that rapidly turn over (e.g., MPPs) do not change the
mutation frequencies in the mesaurable window. Thus WGS of downstream compartments can
serve as a reliable readout for the mutation frequency distribution in the stem cell compartment,
but this needs to be examined for each tissue individually.
A future application of our theoretical framework could lie in the identification of pre-
cancerous lesions with deep whole genome sequencing. The idea behind this approach is that
non-neutral growth dynamics associated with tumor initiation cause deviations of the mutation
frequency distribution from the neutral expectation. Thus, in order to develop this approach
in the future, it is necessary to understand how whole genome sequencing data of normal
and pre-cancerous tissue samples conform to our model predictions. As an outlook to this
application, we analyzed available sequencing data of undisturbed hematopoiesis in the second
part of this chapter. First, we used whole genome sequencing data from granulocytes of two
healthy mice of different ages. Unexpectedly, we observed that the mutational burden at small
variant allele frequencies is markedly increased in the granulocytes of the two-year-old mouse
as compared to the eight-week-old counterpart, and that this increase is not expected under the
current understanding of the size and the dynamics of the hematopoietic system in mice (Bowie
et al., 2007; Busch et al., 2015; Colvin et al., 2004; Höfer and Rodewald, 2016). However, model
predictions can be tailored to match the experimental observation if decreasing the number of
stem cells, while increasing the rate of cellular turnover. If this is true, it either implies a different
parametrization of the hematopoietic system than currently agreed on, or suggests that non-
neutral dynamics affected the mutational burden in the two-year-old mouse. Indeed, we found
a mutation in the Jak3 gene that may account for the observed increase in the mutation count
by altering the dynamics of the hematopoietic system (Cornejo et al., 2009; Rivera-Munoz et al.,
2018). However, as the current dataset lacks replicates, robust conclusions on the hematopoietic
dynamics during ageing cannot be drawn at this stage. It is hence unclear whether the present
observation reflected a rare outlier, a pathological situation or normal hematopoietic dynamics
during ageing. The presented data should thus be seen as a motivating example for further
sequencing studies on normal blood.
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The advantage of inferring clonal dynamics with next generation sequencing, as compared
to fate mapping or cellular barcoding, lies in the minimally invasive character of data acquisition
by which the system can be studied in an unperturbed way. Moreover, this approach can be
easily applied to humans, for whom the dynamics of tissue maintenance are known in much
less detail. To illustrate this potential, we analyzed the mutation frequency distribution in
blood samples from children and adults with diagnosed neuro- or glioblastoma, but without
diagnosed leukemia. The human dataset, in contrast to the murine dataset, had the advantage
of a large sample size, which increases the statistical power. On the downside, however, a
mixed cell population of unsorted leukocytes was sequenced, and much less is known on the
dynamics of human hematopoiesis than on murine hematopoiesis. As expected for human
data, the mutational burden varied between individual patients, which may in part be due
to stochastic drift, but also due to differences in the tissue dynamics, the individual disease
history and genetic predisposition. Nevertheless, a subgroup of the neuroblastoma patients
stood out by having many more mutations than the rest, reminiscent of a ‘hypermutation
genotype’. Patients of this subgroup accumulated several leukemic driver mutations associated
with both myeloid and lymphoid leukemias and in two cases also mutations in mismatch repair
genes. Interestingly, the blood samples of these patients had been taken prior to chemoradiation
therapy, so that a therapy-induced hypermutation genotype is unlikely. Although the cause of
these hypermutation genotypes remains unknown, this observation indicates that pathological
states may be identifiable in the mutation frequency distribution measured with whole genome
sequencing.
Apart from the hypermutated cases, the majority of human blood samples were qualitatively
reconciled with the theoretical expectation of neutral mutation accumulation. Interestingly,
the mutation rate appeared to be higher among children (approximately fourteen base pair
substitutions per division) than among adults (approximately six base pair substitutions per
division). This difference might be due to the different lengths of the genomic regions that could
be used for mutation calling (on average 2.2×109 basepairs in glioblastoma patients and 1.8×109
basepairs in neuroblastoma patients). Although we attempted to account for this difference by
extrapolating the mutation count to the entire genome, more robust results are expected with
a proper germline control, consisting of a pure sample of normal non-hematopoietic tissue.
Moreover, measuring mutations in sorted granulocytes may provide more accurate insights in
the dynamics of mutation acquisition than measuring a mixed population of leukocytes whose
composition varies both between individuals and between children and adults.
Interestingly, our estimate of six to fourteen mutations per cell division contradicts two
previous studies that analyzed themutation frequency distribution in normal blood samples from
241 adults (Ju et al., 2017) and in single cell expansions of hematopoietic stem cells from a single
individual with whole genome sequencing (Lee-Six et al., 2018). These studies estimated that the
mutation rate during early embryogenesis is at most three base pair substitutions per division.
A possible reason for this difference may be the lower sequencing coverage used in these studies
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(15x and 30x) compared to our data (80x), as well as the different algorithms used to call somatic
variants. Here, a re-analysis of our data with different variant callers would be instructive, but
goes beyond the scope of this thesis.
In summary, the project presented in this chapter highlights the potentials and limitations of
whole genome sequencing studies to analyze clonal dynamics in tissues in vivo. We learned from
theoretical considerations how different clonal dynamics manifest on the measurable mutation
frequency distribution in stem cells and more downstream compartments. These thought
experiments showed that— putting aside themutation rate— the relevant parameters influencing
the measured distribution are the compartment size, the degree of self renewal and the speed of
cellular turnover. Comparison of the model predictions with exploratory datasets qualitatively
confirmed our theoretical predictions in most cases, but revealed unexpected phenotypes in a
smaller subset. Thus combining our theoretical framework with sequencing data of defined cell
populations may contribute to the development of new tools for early cancer diagnosis, and also
to a better understanding of human tissue dynamics in vivo. It will be interesting how these
questions can be tackled within the emerging field of next generation sequencing in the future.
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CHAPTER 4
Final discussion & conclusions
According to the ‘cancer evolution hypothesis’ (Nowell, 1976), tumors progress towards more
malignant stages by iterative cycles of mutation and selection. In this view, genetic evolution
and tumor growth are mutually dependent, since the rate of cell divisions is determined by the
genotype, and, conversely, the acquisition of genetic mutations is driven by cell divisions. Next
generation sequencing has facilitated the measurement of genetic heterogeneity within tissue
samples, providing a glimpse on the somatic evolution in normal tissues and cancer.
In this thesis, I analyzed the evolutionary dynamics during glioblastoma growth and
hematopoiesis. Both projects relied on whole genome sequencing data and thus reveal the
potentials and limitations of deep sequencing to understand tissue dynamics in health and
disease. In homeostatic tissues, such as the blood or the skin, cells are continuously replaced
by influx from a stem cell compartment, and constant population sizes are achieved by a
detailed balance between cell divisions and death. Thus in the absence of functional mutations,
one may assume that the probabilities for cell division, death and mutation are homogenous
among all cells of a particular differentiation stage. We saw in Chapter 3 that full analytical
predictions for the mutation frequency distribution in normal tissues can be obtained with few
simplifying assumptions, and that these predictions depend on the cellular turnover rate, the
mutation rate and the size of the tissue. Moreover, a measured deviation from the expected
mutation frequency distribution may serve to identify pre-cancerous lesions. Thus sequencing
normal tissues may indeed reveal characteristics of tissue homeostasis and tumor initiation,
although prior knowledge on the architecture and the dynamics of the specific tissue facilitates
data interpretation. With decreasing costs of high-throughput sequencing studies, it will be
interesting to trace the mutational profiles in the blood of large patient cohorts longitudinally.
As some patients may eventually progress to leukemia, studies of this kind have the potential to
99
Chapter 4. Final discussion & conclusions
not only identify early markers of tumor initiation, but also the time scale over which the tumor
develops. Eventually, this may help to develop new tools for early diagnosis, the most promising
approach to combat cancer.
In contrast to normal tissues, cancer grows from unbalanced cell divisions, due to one or
multiple functionalmutations. As individual cancer cells may acquire additional drivermutations
over the course of tumorigenesis, it is unclear whether they share equal probabilities to divide,
die and mutate. Measuring evolutionary dynamics in cancer is therefore more challenging
than in normal tissues and predicting the full mutation frequency distribution is practically
impossible. However, insights into the evolutionary history of cancers can still be gained from
whole genome sequencing data if adjusting the research question to the explanatory power of
the data. Moreover, the predictive power increases with the size of the studied cohort and with
prior knowledge on the functional effect of individual driver mutations. We saw in Chapter 2
that the measured mutation frequency distribution in cancer reflects major subclonal branchings
and thus reveals the temporal order of driver mutations over the course of tumorigenesis. In
addition, coarse dynamical estimates, such as the extent of cell death during tumor growth or
the selective advantage provided by pervasive driver mutations are contained in deep sequencing
data from cancer samples. Future studies, combining bulk whole genome sequencing with
genomic, epigenomic and transcriptomic information on the single cell level, will help to gain
a more comprehensive picture of the evolutionary dynamics during tumor growth. In this
way, the contribution of different levels of heterogeneity to cancer progression and treatment
failure may be disentangled. Moreover, with genomic editing becoming increasingly available,
it will be interesting to recapitulate the genetic history of human tumors in mouse models more
realistically. In that regard, it may also become possible to test if an early, tumor initiating
mutation becomes dispensable at a later stage of tumorigenesis, or whether the entire tumor can
be treated by efficient therapeutic targeting of this mutation. The road to take should therefore
complement the more phenomenological insights into cancer evolution, obtained from high-
throughput sequencing studies of human cancers, with functional studies in adequate model
systems, which may support the design of novel treatment approaches.
Taken together, apart from biological insights into the evolution of glioblastomas and
normal blood cells, this thesis also provides general insights into the potential of deep whole
genome sequencing data to uncover the evolutionary dynamics underlying tumor initiation
and progression. It remains to be seen whether these insights can contribute to therapeutic
approaches or diagnostic tools in the future.
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Figure A.1: Goodness of fit of inferred phylogenetic trees. At each fit, the predicted unique variant allele
frequencies are plotted against the measured means of all variants expected at this VAF (the order of the
plots corresponds to the order of the trees in Fig. 2.13, as indicated by capital letters in brackets; red lines,
bisetrices).
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APPENDIXB
Transition probabilities in a critical birth-death process
In the following, we will derive the transition probabilities in a ‘critical’ birth-death process
(linear birth-death process with equal birth and death probabilities). To this end, we will first
derive the probability generating function following Bailey, 1964 and then derive the transition
probabilities by Taylor expansion.
We study a critical birth-death process with division and death rate λ and population size
X (t ). In an infinitesimal time interval dt the population can either increase by one (birth),
decrease by one (death) or remain constant, yielding the following transtion probabililties:
birth: λX (t )dt (B.1a)
death: λX (t )dt (B.1b)
neither birth nor death: 1 − 2λX (t )dt . (B.1c)
With this, the Master equation for the probabililty of having n individuals at time t is directly
obtained:
dPn
dt = λ(n − 1)Pn−1 − 2λnPn + λ(n + 1)Pn+1, n ≥ 1, (B.2a)
P−1 = 0. (B.2b)
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To solve the Master equation we define the generating function F (z, t ),
F (z, t ) =
∞∑
n=0
znPn (t ) (B.3a)
dF (z, t )
dt =
∞∑
n=0
zn
dPn (t )
dt (B.3b)
=
∞∑
n=0
zn [λ(n − 1)Pn−1 − 2λnPn + λ(n + 1)Pn+1] (B.3c)
= λ
⎡⎢⎢⎢⎢⎣
∞∑
n=1
zn (n − 1)Pn−1 − 2
∞∑
n=0
znnPn +
∞∑
n=0
zn (n + 1)Pn+1
⎤⎥⎥⎥⎥⎦ . (B.3d)
Rearranging the indices yields
dF (z, t )
dt = λ
⎡⎢⎢⎢⎢⎣
∞∑
n=1
zn+1nPn − 2
∞∑
n=1
znnPn +
∞∑
n=1
zn−1nPn
⎤⎥⎥⎥⎥⎦ . (B.4)
We note that ∂F∂z =
∑∞
n=1 nz
n−1Pn and obtain the partial differential equation
∂F
∂t
= λ
[
z2 − 2z + 1
] ∂F
∂z
, (B.5)
with initial condition
F (z, t = 0) = Ψ(z). (B.6)
Eqn. B.5 is a linear partial differential equation, which can be solved with the method of
characteristics. To this end, we first derive with respect to x , using the chain rule:
∂F
∂x
=
∂F
∂z
∂z
∂x
+
∂F
∂t
∂t
∂x
. (B.7)
Next, we define the characteristic curves
dz
dx = P (z, t ,x ) = −λ(z − 1)
2, (B.8a)
dt
dx = Q (z, t ,x ) = 1, (B.8b)
for
dF
dx =
∂F
∂z
∂z
∂x
+
∂F
∂t
∂t
∂x
= R (z, t ,x ) = 0. (B.9)
and thus obtain a system of ordinary differential equations. FromEqns. B.8a and B.8bwe conclude
that
dt
dx = −
1
λ(z − 1)2
dz
dx . (B.10)
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Integration with respect to x yields
− dz
λ(z − 1)2 =
dt
1 , (B.11)
and thus
−
∫ dz
λ(z − 1)2 =
∫ dt
1 (B.12a)
t =
1
λ(z − 1) + c1. (B.12b)
On the other hand, from Eqn. B.9 we conclude that
F (z, t ) = c2. (B.13)
Thus we find the general solution:
F (z, t ) = Ψ
(
λt − 1
z − 1
)
. (B.14)
If we start with a cells at t = 0, Eqn. B.3a gives the initial condition F (z, 0) = ∑∞n=0 Pn (0) = za
and thus
F (z, 0) = za = Ψ
(
− 1
z − 1
)
. (B.15)
Moreover, Eqn. B.12b yields at t = 0
c1 = − 1
z − 1 ⇔ z = 1 −
1
c1
. (B.16)
From the initial condition, we thus have
c2 = F (z, 0) = za =
(
1 − 1
c1
)a
= Ψ(c1). (B.17)
If t , 0, we recall c1 = t − 1λ (z−1) and find
1 − 1
c1
=
1 − (z − 1) (λt − 1)
1 − (z − 1)λt . (B.18)
Thus,
F (z, t ) =
(
1 − (z − 1) (λt − 1)
1 − (z − 1)λt
)a
, (B.19)
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where we used Eqn. B.17. Finally, we rearrange by Taylor expansion around 0:
F (z, t ) =
∑
i
1
i!
∂iF
∂zi
(z − 0)i , (B.20a)
∂iF
∂zi
=
i∑
k=1
(
a
k
) (
i
k
)
Aa−kBi+k (λt )n−kki!, (B.20b)
A =
1 − (λt − 1) (z − 1)
1 − λt (z − 1) , B =
1
1 − λt (x − 1) , (B.20c)
and obtain the transition probabilities from a to b:
Pa,b =
∂bF
∂zb
z=0 (B.21a)
Pa,b (λ, t ) =
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
0 a = 0
pa a , 0,b = 0∑b
k=1
k
b
(
a
k
)
pa−k (1 − p)k
(
b
k
)
pb−k (1 − p)k a , 0,b , 0
(B.21b)
p =
λt
1 + λt . (B.21c)
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Clonal dynamics in adult hematopoiesis
The stochasticity of clonal expansions in adult hematopoiesis were assessed explicitly by solving
the master equation and, additionally, with stochastic simulations using Gillespie’s algorithm
(Gillespie, 1977). Both approaches are outlined in the following.
Indexing LT-HSCs, ST-HSCs and MPPs with 0, 1, and 2, respectively, we define the state
vector n = (n0,n1,n2) for the respective cell population counts. The model in Fig.3.10A is then
described by the following transition probabilities:
division of LT-HSCs: λ0n0 (t )dt
differentiation of LT-HSCs into ST-HSCs: α0n0 (t )dt
division of ST-HSCs: λ1n1 (t )dt
differentiation of ST-HSCs into MPPs: α1n1 (t )dt
division of MPPs: λ2n2 (t )dt
differentiation of MPPs into CMPs/CLPs: α2n2 (t )dt ,
(C.1)
Derivation and solution of the Master equation for this set of stochastic processes is
provided in Section C.1, while stochastic simulations with Gillespie’s algorithm are explained
in Section C.2.
C.1 Solving the master equation
We will show the derivation of the master equation (Eqn. 3.18) and the solution for the mean
and variance of the linear differentiation model shown in Fig.3.10A. The stochastic processes
according to Eqns. C.1 translate to the following Master equation:
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dPn (t )
dt =
2∑
i=0
⎡⎢⎢⎢⎢⎢⎢⎣
Division of cell type i                                  
λi (ni − 1)Pn−ei (t ) +
Differentiation of cell type i into cell type i + 1                                              
αi (ni + 1)Pn+ei−ei+1 (t )                                                                                                                                        
Stochastic processes running into state n
−λiniPn (t ) − αiniPn (t )                                                
Sochastic processes running out of state n
⎤⎥⎥⎥⎥⎥⎥⎦ ,
Pni = 0, if any ni = −1, (C.2)
where ei is the (i + 1)-th unit vector and e3 is set to (0, 0, 0) by convenience. From the Master
equation we can derive the probability generating function, F (z0, z1, z2, t ):
F (z0, z1, z2, t ) =
∑
n
zn00 z
n1
1 z
n2
2 Pn (t ) (C.3)
and, consequently,
∂F
∂t
=
∑
n
⎡⎢⎢⎢⎢⎣zn00 zn11 zn22
2∑
i=0
λi (ni − 1)Pn−ei (t )+
+αi (ni + 1)Pn+ei−ei+1 (t )+
−λiniPn (t ) − αiniPn (t )] . (C.4)
Rearranging the indices yields
∂F
∂t
=
∑
n
2∑
i=0
[
ziz
n0
0 z
n1
1 z
n2
2 λiniPn (t )+
+
zi+1
zi
zn00 z
n1
1 z
n2
2 αiniPn (t )+
−
2∏
j=0
z
nj
j λiniPn (t ) −
2∏
j=0
z
nj
j αiniPn (t )
⎤⎥⎥⎥⎥⎥⎦ . (C.5)
Noting that
∂F
∂zi
=
∑
n
ni
1
zi
zn00 z
n1
1 z
n2
2 Pn (t ) (C.6)
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we can substitute ∑
n
ziz
n0
0 z
n1
1 z
n2
2 λiniPn (t ) = λiz
2
i
∂F
∂zi∑
n
zi+1
zi
zn00 z
n1
1 z
n2
2 αiniPn (t ) = αizi+1
∂F
∂zi∑
n
zn00 z
n1
1 z
n2
2 λiniPn (t ) = λizi
∂F
∂zi∑
n
zn00 z
n1
1 z
n2
2 αiniPn (t ) = αizi
∂F
∂zi
,
(C.7)
yielding
∂F (z, t )
∂t
=
2∑
i=0
[λizi (zi − 1) + αi (zi+1 − zi )] ∂F (z, t )
∂zi
, (C.8)
where z3 = 1. From the probability generating function we can determine the expected value of
ni by differentiation w.r.t. zi and evaluation at z = 1:
E(ni ) =
∂F
∂zi
z=1 =
∑
n
niPn (t ). (C.9)
Accordingly, we obtain the variance and covariance as:
Var(ni ) = E(n2i ) − E(ni )2
= E(ni (ni − 1)) + E(ni ) − E(ni )2
=
∂2F
∂z2i
z=1 + ∂F∂zi
z=1 −
(
∂F
∂zi
z=1
)2
Cov(ni ,nj ) = E(ninj ) − E(ni )E(nj )
=
∂2F
∂zizj
z=1 − ∂F∂zi
z=1 ∂F∂zj
z=1.
(C.10)
Defining xi = ∂F∂zi
z=1,yi = ∂2F∂z2i z=1, and ci+j = ∂F∂zi z=1 ∂F∂zj z=1 we rewrite Eqns. C.9 and
C.10 and obtain a system of linear differential equations for the temporal evolution of the mean,
variance and covariance in the linear differentiation path:
E[nLT−HSC] = E[n0] = x0 (t )
E[nST−HSC] = E[n1] = x1 (t )
E[nMPP] = E[n2] = x2 (t )
Var[nLT−HSC] = Var[n0] = x0 (t ) + y0 (t ) − x0 (t )2
Var[nST−HSC] = Var[n1] = x1 (t ) + y1 (t ) − x1 (t )2
Var[nMPP] = Var[n2] = x2 (t ) + y2 (t ) − x2 (t )2,
(C.11)
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with
dx0
dt = (λ0 − α0) x0
dx1
dt = (λ1 − α1) x1 + α0x0
dx2
dt = (λ2 − α2) x2 + α1x1
dy0
dt = 2λ0x0 + (λ0 − α0)y0
dy1
dt = 2λ1x1 + 2 (λ1 − α1)y1 + 2α0c1
dy2
dt = 2λ2x2 + 2 (λ2 − α2)y2 + 2α1c3
dc1
dt = (λ0 − α0 + λ1 − α1)c1 + α0y0
dc2
dt = α1c1 + (λ0 − α0 + λ2 − α2)c2
dc3
dt = α0c2 + (λ1 − α1 + λ2 − α2)c3 + α1y1
(C.12)
Requiring E(ni |t ) = Xi ,Var(ni |t0) = 0 and Cov(ni ,nj |t0) = 0, i = 0, 1, 2, j = i + 1 and j ≤ 2,
the initial conditions yi = Yi and ci = Ci can be determined to
E(ni |t0) = xi = Xi
Var(ni |t0) = E(n2i ) − E(ni )2 = Yi + Xi − X 2i = 0 ↔ Yi = X 2i − Xi
Cov(ni ,nj |t0) = Ci+j − XiX j = 0 ↔ Ci = XiX j ,
(C.13)
with which the system can be solved numerically.
C.2 Stochastic simulations of clone size distributions in adult
hematopoiesis
To assess the clone size distributions in adult hematopoiesis with stochastic simulations, we
initialize the simulation with the state vector n0 and t0 = 0, and at each simulated step choose
the next event based on the probabilities of cell division and differentiation according to the
reaction rates (Eqns. C.1):
Symmetric division of cell type i: PS, i =
λini∑
j λjnj + αjnj
(C.14)
Differentiation of cell type i to type i+1: PD, i =
αini∑
j λjnj + αjnj
. (C.15)
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We then sample the time step ∆t from an exponential distribution with rate ∑j λjnj + αjnj and
update the system according to
n
j+1
i =
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎪⎪⎩
n
j
i + 1, if event = ‘Symmetric division of cell type i’,
n
j
i − 1, if event = ‘Differentiation of cell type i to i+1’,
n
j
i + 1, if event = ‘Differentiation of cell type i-1 to i’,
n
j
i, else.
tj+1 = tj + ∆t .
These steps are iteratively repeated until t ≥ tmax.
C.3 Stochastic simulations of neutral drift during adult
hematopoiesis
To assess the effect of neutral drift during adult hematopoiesis on the cellular frequencies of
mutations acquired during embryonic expansion, we simulate mutation frequencies with an
agent-based model (Fig. 3.11). On the macroscopic scale, the agent-based model traces the
number of LT-HSCs, ST-HSCs and MPPs in the state vector n = (n0,n1,n2). On the microscopic
scale, the mutation frequencies within each compartment (i.e., the number of cells harboring a
specific mutation) are stored in a 3 x l mutation matrix M , whose rows correspond to the three
compartments and whose l columns correspond to distinct loci in the genome. The first locus in
the genome without a mutation is stored in the indicator variable k and is initialized to k = 1.
During tissue expansion, cells divide symmetrically at rates λS,0, λS,1, λS,2 or asymmetrically at
rates λA,0, λA,1, λA,2. Thus cellular loss due to death or direct differentiation is neglected during
the expansion phase. New mutations are acquired at a single-base-pair substitution rate µ per
cell division.
The simulation is initiated withn0 = (1, 0, 0) andM0 = 03,l , mimicking embryonic expansion
from a single LT-HSC. On the macroscopic scale, the next event — symmetric or asymmetric cell
division — is randomly sampled with probabilities determined by the number of cells and the
reaction rates, according to:
Symmetric division of cell type i: PS, i =
λS, ini∑
j λS, jnj + λA, jnj
(C.16)
Asymmetric division of cell type i: PA, i =
λA, ini∑
j λS, jnj + λA, jnj
. (C.17)
On the microscopic scale, the number of new mutations per daughter cell, nmut,1 and nmut,2,
are sampled from a binomial distribution with sample size 3 × 109 (corresponding to the size of
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the genome) and success probability µ.
At each simulation step j, the state vector is updated according to the selected event:
n
j+1
i =
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
n
j
i + 1, if event = ‘Symmetric division of cell type i’,
n
j
i + 1, if event = ‘Asymmetric division of cell type i-1’,
n
j
i, else.
Accordingly, the mutation matrix is updated by (i) modeling the inheritance of mutations during
cell divisions and (ii) modeling the acquisition of new mutations:
If event = ‘Symmetric division of cell type i’:
M
j+1
i, l =
⎧⎪⎪⎪⎨⎪⎪⎪⎩
M
j
i, l + 1, with probability
M ji,l
ni
,
M
j
i, l, with probability 1 −
M ji,l
ni .
While k ≤ nmut,1 :
M
j+1
i,k =
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
1, if event = ‘Symmetric division of cell type i’,
1, if event = ‘Asymmetric division of cell type i’,
0, else,
k = k + 1.
While k ≤ nmut,2 :
M
j+1
i,k =
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
1, if event = ‘Symmetric division of cell type i’,
1, if event = ‘Asymmetric division of cell type i-1’,
0, else,
k = k + 1.
Embryonic expansion is simulated until n0 = 10, 000, using the parameters provided in Table 3.1.
As MPPs are rapidly turned over, it is sufficient to simulate neutral drift in MPPs during the
homeostatic phase, so that λS,2 = λA,2 = 0 during embryonic expansion. Once the hematopoietic
system is established (i.e., at n0 = 10, 000), all three compartments are simulated. However, due
to the large cell number and rapid turnover of MPPs, stochastic simulations of the full system
are computationally costly. We therefore approximate the homeostatic phase by sampling the
fate of an individual mutation from the simulated clone size distribution after two years (c.f.
Fig. 3.10D and Appendix C.2). Thus mutations newly acquired during adulthood are neglected by
the simulation, in agreement with our previous argument that these mutations do not influence
the measured mutation frequency distribution.
The final mutational profile is stored in the mutation matrixM ′, which is initialized toM ′03,l =
0. To simulate the fate of mutations present in LT-HSCs during adult hematopoieisis, we sample
for each cell a mutational profilem, according to
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ml =
⎧⎪⎪⎨⎪⎪⎩
1, with probability M0,ln0 ,
0, with probability 1 − M0,ln0 .
Next, we sample from the simulated clone size distributions the instances c0, c1, c2,
corresponding to the number of LT-HSCs, ST-HSCs and MPPs grown by this single cell after
two years and updateM ′:
M
′j+1
0, · = M
′j
0, · + c0 ×m
M
′j+1
1, · = M
′j
1, · + c1 ×m
M
′j+1
2, · = M
′j
2, · + c2 ×m.
The fate of embryonic mutations present in ST-HSCs is analogously simulated.
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